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Zusammenfassung 
 I 
Zusammenfassung 	
Die Serin/Threonin Rezeptor-interagierende Protein Kinase (RIPK)1 ist ein zentrales Protein, 
welches den Ausgang von TNF Rezeptor 1 (TNFR1)- und Toll-ähnlicher Rezeptor	 (TLR)-
vermittelten Signalen durch Kinase-abhängigen und Kinase-unabhängigen Funktionen 
determiniert. Bis heute ist es unklar, in wie fern RIPK1 in der Regulierung von Leberfunktionen 
agiert. Deshalb wurde ein konditionales RIPK1-Allel erzeugt, welches die Cre-Recombinase 
vermittelte Deletion von RIPK1 in Leber-parenchymalen Zellen (LPZ) ermöglicht.  Zusätzlich 
wurden RIPK1-Mutanten verwendet, welche, aufgrund eines Aminosäureaustausches an der 
Position 138 von Asparaginsäure zu Asparagin, eine mutierte Form von RIPK1 exprimieren 
(RIPK1D138N) und deshalb keine Kinaseaktivität besitzen. Mit Hilfe dieser Mutanten sollten die 
Kinase-abhängigen und Kinase-unabhängigen Funktionen von RIPK1 in der Regulierung bzw. 
Induzierung von Leberschäden und in der Initiierung von Leberkrebs untersucht werden. Die 
LPZ-spezifische Deletion von RIPK1 beeinflusste weder die Leberentwicklung noch die Leber 
Homöostase unter normalen Konditionen, sensibilisierte RIPK1-defiziente Hepatozyten jedoch 
zu spontaner Apoptose in vitro. RIPK1LPZ-KO Mäuse zeigten eine erhöhte Sensitivität gegenüber 
einer Lipopolysaccharid (LPS)-Injektion aufgrund von erhöhter Apoptose von Hepatozyten. Die 
LPZ-spezifische Deletion von TNFR1, Fas-assoziiert via Death Domain (FADD) oder 
TNFRSF1A-assoziiert via Death Domain (TRADD) schützte RIPK1-defiziente Hepatozyten vor 
Zelltod, wodurch die hohe Sensitivität von RIPK1LPZ-KO Mäusen nach einer LPS-Injektion 
vermindert werden konnte. Die Inaktivierung der Kinase Aktivität von RIPK1 schützte Mäuse vor 
LPS/D-Galactosamin (D-GalN) induzierten Leberschäden. Die LPZ-spezifische Deletion von 
RIPK1, aber nicht die Inaktivierung der Kinase Aktivität in Mäusen reduzierte Diethylnitrosamin 
(DEN)-induzierten Leberkrebs, was auf eine Kinase-unabhängige Funktion von RIPK1 in der 
Initiierung von Leberkrebs hindeutet. Darüber hinaus reduzierte die LPZ-spezifische Deletion 
von RIPK1 zum Teil DEN-induzierte Tumorentstehung in einem Mausmodel mit induzierter 
Adipositas. Eine reduzierte Entstehung von DEN-induziertem Leberkrebs korrelierte mit einer 
erhöhten Anzahl von frühzeitiger Caspase-8-vermittelter Apoptose und reduzierten DNS 
Schäden in RIPK1LPZ-KO Mäusen. Die Inhibierung des frühzeitigen Zelltodes durch die 
zusätzliche LPZ-spezifische Deletion von TNFR1 stellte die volle Entstehung von DEN-
induziertem Leberkrebs in RIPK1LPZ-KO Mäusen wieder her. Zusammenfassend kann 
geschlussfolgert werden, dass die Resultate dieser Arbeit eine neue, wichtige Kinase-
unabhängige Funktion von RIPK1 für die Expression von Überlebenssignalen enthüllen 
wodurch das Überleben von Hepatozyten beeinflusst wird. Durch diese Funktion reduziert 
RIPK1 durch LPS Injektion induzierte akute Leberschäden und verhindert somit Leberversagen. 
Wohingegen RIPK1 durch seine Überlebensfunktion erhöhten Zelltod nach DEN Injektion 
blockiert und dadurch zu erhöhter Tumorentstehung nach einer DEN Injektion führt. 
Summary 
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Summary 
 
The serine/threonine kinase receptor-interacting protein kinase (RIPK) 1 with pro-death 
kinase-dependent and pro-survival kinase-independent functions has emerged as an 
important regulator of cell death, survival and inflammation downstream of death receptors 
(DR) and Toll-like receptors (TLR), including tumor necrosis factor receptor (TNFR) 1 and 
TLR4 respectively. The functions of RIPK1 in regulating liver homeostasis, inflammation and 
cell death are poorly understood and remain to be elucidated. In this study we aimed to 
investigate the biological significance of the kinase-dependent and -independent functions of 
RIPK1 specifically in maintaining liver homeostasis and in the regulation of acute liver injury 
and carcinogenesis using well-established murine models. Accordingly, mice lacking RIPK1 
or its kinase activity specifically in liver-parenchymal cells (LPC) were generated using the 
Cre/LoxP system. LPC-specific RIPK1 deficiency did not affect normal liver development 
and homeostasis but sensitized RIPK1-deficient hepatocytes to spontaneous apoptotic 
death in vitro. In vivo, RIPK1LPC-KO mice were highly sensitive to lipopolysaccharide (LPS)-
induced injury showing massive hepatocyte apoptosis that resulted in early death of mice. 
LPC-specific TNFR1, Fas-Associated via Death Domain (FADD) or TNFRSF1A-Associated 
via Death Domain (TRADD) ablation prevented LPS-induced liver injury in RIPK1LPC-KO mice, 
identifying TNFR1-TRADD-FADD-induced hepatocyte apoptosis as the cause of liver 
damage. Inactivation of RIPK1 kinase activity (D138N) did not phenocopy the high sensitivity 
of RIPK1LPC-KO mice to LPS-induced liver injury suggesting a RIPK1 scaffolding function in 
preventing LPS-induced toxicity. However, inactivation of RIPK1 kinase activity partially 
prevented TNFR1-induced cell death caused by LPS/D-Galactosamine (D-GalN) suggesting 
a RIPK1 kinase-dependent function in mediating LPS/D-GalN-induced death. 
LPC-specific RIPK1 knockout but not loss of its kinase activity reduced Diethylnitrosamine 
(DEN)-induced liver carcinogenesis in mice suggesting a kinase-independent function of 
RIPK1 in promoting liver tumorigenesis. Moreover, LPC-specific RIPK1 deficiency also 
reduced liver tumor formation in a model of dietary obesity-driven DEN-induced 
hepatocarcinogenesis. Reduced liver tumor development correlated with increased early 
DEN-induced Caspase-8-mediated hepatocyte apoptosis and reduced γH2AX levels in the 
liver of RIPK1LPC-KO mice. LPC-specific TNFR1 deficiency prevented increased early 
hepatocyte apoptosis and restored liver tumor development in DEN-injected RIPK1LPC-KO 
TNFR1LPC-KO mice. 
Taken together, the results presented in this work reveal a novel, important kinase-
independent scaffolding function of RIPK1 in the regulation of liver cell survival, acute liver 
damage and liver cancer development. 
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Introduction 
 1 
1. Introduction 
1.1. Receptor-interacting protein kinases (RIPKs) 
The RIPK family consists of seven known family members, which are classified as 
serine-threonine kinases due to their highly conserved kinase domain (KD) (Figure 1) 
(Zhang, Lin, and Han 2010; Festjens et al. 2007). A number of different domain 
structures such as the intermediate domain (ID) and the Caspase activation and 
recruitment domain (CARD) are found in different RIPK family members defining the 
specific function and the interaction partners of each protein (Figure 1). RIPKs 
participate in different biological processes implicated in the regulation of cell survival 
and cell death in response to a variety of stimuli (Zhang, Lin, and Han 2010; 
Pasparakis and Vandenabeele 2015).  
Figure 1. Schematic representation of the structure of the RIPK family members  
(adapted from Zhang, Lin and Han 2010) 
The RIPK family consists of seven family members with all of them sharing a conserved KD. In 
addition to the KD each RIPK displays additional domain structures which defines their 
additional function or interaction partners. RIPK1, RIPK2, RIPK4 and RIPK5 contain in addition 
to the KD an ID. Only RIPK1 has a death domain (DD). Together with RIPK3 it contains a 
receptor homotypic interacting motif (RHIM). RIPK2 has an additional CARD domain. RIPK4 
and RIPK5 contain a C-terminal ankyrin repeats (ANK) domain, which is also present in RIPK6. 
Like RIPK7, RIPK6 has a leucine-rich repeat (LRR) motif and a Ros of complex proteins/C-
terminal of Roc (Roc/COR) domain. RIPK7 further harbors a C-terminal WD40 motif. 
 
1.1.1 RIPK1 
 
RIPK1 was initially identified in 1995 as an interaction partner of the death receptor 
(DR) Fas (CD95) using a yeast-two hybrid screen and was described to be activated 
downstream of other DRs, such as tumor necrosis factor receptor 1 (TNFR1), and toll-
like receptors (TLRs) including TLR4 (Stanger et al. 1995; Zhang, Lin, and Han 2010). 
Human and murine RIPK1 proteins share 68% homology with the highest similarity in 
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the DD. Human RIPK1 is located on chromosome 6 whereas mouse Ripk1 has been 
mapped to chromosome 13 (Hsu, Huang et al. 1996; Stanger et al. 1995). RIPK1 
consists of an N-terminal KD, an ID and a C-terminal DD (Figure 2) (Festjens et al. 
2007; Stanger et al. 1995; Kelliher et al. 1998).  
Until now, the kinase-dependent cellular functions of RIPK1 are still not fully 
understood. So far, only RIPK1 is known to be a target of its kinase activity. Degterev 
et al. identified various serine, threonine and tyrosine residues as phosphorylation sites 
(Degterev et al. 2008). Accumulating evidence suggests that the KD of RIPK1 enables 
its autophosphorylation on Ser14/15, Ser20, Ser161 and Ser166 and that site-specific 
autophosphorylation of RIPK1 defines its function (Degterev et al. 2008; de Almagro et 
al. 2017; Zhang et al. 2017)  
In addition to the KD, RIPK1 consists of an ID, which harbors a Caspase-8 cleavage 
site, ubiquitination sites, and a receptor homotypic interacting motif (RHIM) domain 
(Zhang, Lin, and Han 2010). Like autophosphorylation, site-specific ubiquitination of 
RIPK1 was recently reported to promote specific functions of RIPK1 (de Almagro et al. 
2017). Moreover, the RHIM domain of RIPK1 is required for the interaction with other 
RHIM domain containing proteins, such as RIPK3, TIR domain-containing adaptor 
inducing IFN-beta (TRIF) and DNA-dependent activator of IFN-regulatory factors 
(DAI/ZBP1) (Sun et al. 2002; Kaiser and Offermann 2005; Rebsamen et al. 2009; Lin 
et al. 2016; Newton et al. 2016).  
Furthermore, the DD of RIPK1 mediates homotypic interactions with other DD-
containing proteins, including TNFR1, TNFR superfamily 1A-associated via death 
domain (TRADD) and Fas (TNFRSF6)-associated via death domain (FADD) thus 
promoting tumor necrosis factor (TNF)-induced cell death or nuclear factor kappa light 
polypeptide gene enhancer in B-cells (NF-κB) activation (Zhang, Lin, and Han 2010) 
(Figure 2).   
 
 
 
Figure 2. Schematic representation of the RIPK1 domain structure  
RIPK1 is composed of a N-terminal KD, an ID, containing a RHIM domain, and a C-terminal 
DD. RIPK1 interacts with RIPK3, TRIF and DAI/ZBP1 via its RHIM domain while its DD allows 
its interaction with TNFR1, FADD and TRADD.   
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1.2. NF-κB signaling  
NF-κB was identified as a transcription factor that binds to the intronic enhancer of the 
kappa light chain gene in B cells (Sen and Baltimore 1986a, 1986b). The NF-κB 
transcription factor family consists of p50, its precursor p105, p52, its precursor p100, 
RelA (p65), c-Rel and RelB with all of them sharing a Rel homology domain (Mitchell, 
Vargas, and Hoffmann 2016; Hayden and Ghosh 2014). The Rel domain allows NF-κB 
family members to homo- or heterodimerize and sequence-specific DNA binding. p50 
and p52 rely on dimerization with RelA, c-Rel and RelB, which contain a transactivation 
domain, to positively induce transcription (Mitchell, Vargas, and Hoffmann 2016; 
Hayden and Ghosh 2014; Rothwarf and Karin 1999; Chen and Greene 2004). In 
resting cells, NF-κB transcription factors remain in an inactive state in the cytoplasm 
through the binding to inhibitor of κB proteins (IκBs) (IκBα, IκBβ and IκBγ) and the 
precursor proteins p100 and p105 (Hayden and Ghosh 2014).  
 
NF-κB signaling can be distinguished between canonical and non-canonical pathway 
(Figure 3). TNF, interleukin (IL)-1, lipopolysaccharide (LPS) and cluster of 
differentiation (CD)40L are potent inducers of canonical NF-κB involving p50/RelA 
heterodimerization (Figure 3) (Ghosh and Hayden 2008; Hayden and Ghosh 2008). 
Binding of the ligands to their receptor induces the ubiquitination of RIPK1 which 
serves as a platform for the recruitment of the inhibitor of κB kinase (IKK) complex 
consisting of the regulatory subunit nuclear factor kappa B essential modulator 
(NEMO) and the kinases IKK1 and IKK2. The IKK complex triggers the 
phosphorylation of IκBα on Ser32 and 36 and thereby targets it for K48-ubiquitination 
and subsequently proteasomal degradation (Woronicz et al. 1997; Mercurio et al. 
1997; Wang et al. 2001). Degradation of IκBα induces rapid translocation of the 
canonical NF-κB heterodimer p65(RelA):p50 to the nucleus initiating the transcription 
of target genes such as pro-inflammatory cytokines including Tnf and Il-6 and the anti-
apoptotic/anti-necroptotic gene Cflar (Mitchell, Vargas, and Hoffmann 2016; Hayden 
and Ghosh 2014). In contrast, binding of B cell activating factor of the TNF family 
(BAFF), TNF-like weak inducer of apoptosis (Tweak) and CD40L to their respective 
receptors induces non-canonical NF-κB activation. In the non-canonical NF-κB 
pathway, NF-κB inducing kinase (NIK)-dependent activation of IKK1 mediates 
processing of p100 to p52 leading to the formation of a transcriptionally active p52-
RelB complex. In summary, RIPK1, IKK1/2 and NEMO are key drivers of the canonical 
NF-κB pathway while the non-canonical NF-κB pathway acts independently of RIPK1, 
IKK2 and NEMO but exclusively relies on NIK and IKK1 (Figure 3) (Senftleben et al. 
2001). 
Introduction 
 4 
  
Figure 3. Canonical and non-canonical pathways of NF-κB activation  
(adapted from Horie and Umezawa 2012) 
Under resting conditions, NF-κB dimers are bound to an IκB protein. Binding of a ligand to its 
receptor mediates the degradation of the inhibitor resulting in the release of the NF-κB dimer, 
which translocates to the nucleus mediating transcription of pro-inflammatory cytokines. There 
are two types of pathways that can induce	 NF-κB activation, the canonical and the non-
canonical. The canonical	 NF-κB pathway can be induced by ligation of TNF, IL-1, LPS and 
CD40L with their respective receptor triggering the degradation of the IκB protein in a 
NEMO/IKK1/2-dependent manner resulting in the nuclear translocation of the NF-κB 
heterodimer mostly consisting of p65/RelA. In contrast, the non-canonical pathway is activated 
by the binding of CD40L, BAFF and lymphotoxin-β, LPS and TWEAK to their receptors, 
involving NF-κB inducing kinase (NIK)-dependent IKK1-mediated phosphorylation of p100, 
which associates with RelB. This induces a partial degradation of p100 to p52 leading to the 
formation of the transcriptionally active p52-RelB complex. 
1.3. Death receptor signaling 
 
The TNF receptor superfamily consists of various family members important for the 
regulation of cell survival and cell death in response to inflammatory cytokines and 
infectious particles	 (Locksley, Killeen, and Lenardo 2001). DRs, which are a subgroup 
of the TNF receptor superfamily, are characterized by their DD motif (Wajant 2003; 
Wilson, Dixit, and Ashkenazi 2009). The DR family consists of 6 family members that 
are activated by distinct ligands. Tumor necrosis factor superfamily member (Tnfrs) 1a 
(TNFR1)	 is activated by ligation with TNF or lymphotoxin α (LTα), Tnfrsf6	 (Fas or 
CD95) is activated by FasL/CD95L, TNF-related apoptosis-inducing ligand receptor 1 
and 2 (TRAILR1 and TRAILR2) are activated by TRAIL while DR3 (Tnfrsf25) and DR6 
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are activated by TLA1 and amyloid precursor protein (APP) respectively (Silke and 
Hartland 2013; Wilson, Dixit, and Ashkenazi 2009). In contrast to the other DRs, DR3 
and DR6 are not efficient in inducing cell death (Wajant 2003). Activation of DRs by 
binding to their ligands induces the recruitment of DD-containing adapter proteins via 
homotypic interactions. This interaction results in the formation of a receptor 
associated signaling complex mediating downstream signaling including cell death or 
inflammatory gene expression (Wilson, Dixit and Ashkenazi 2009).  
 
1.3.1. TNF signaling pathway 
 
TNF is a cytokine produced by immune, epithelial and endothelial cells and binds to 
two plasma membrane receptors, TNFR1 and TNFR2. Unlike TNFR1, which 
recognizes soluble and membrane-bound TNF, TNFR2 binds with a much higher 
affinity to the membrane-bound TNF precursor and is likely to be restricted to T cells 
(Brockhaus et al. 1990; Dembic et al. 1990; Schall et al. 1990; Zheng et al. 1995; Kim 
and Teh 2001; Depuydt et al. 2005). Until now, TNFR1 is the most well-studied 
receptor with respect to cell death or cell survival pathways. TNF ligation to TNFR1 
induces inflammatory, cell survival and anti-microbial processes via complex-I but in 
addition also mediates apoptosis via complex-IIa/-IIb and necroptosis through the 
necrosome (Figure 4) (Micheau and Tschopp et al 2003; Li et al. 2012; Varfolomeev 
and Vucic 2016). TNF alone is not sufficient to induce cell death in most cell types 
while in combination with inhibitors of transcription (e.g. D-Galactosamine) or 
translation (e.g. cycloheximide) TNF potently triggers cell death suggesting that NF-κB-
dependent gene expression negatively regulates TNF-induced cell death (Morikawa et 
al. 1996; Wang, Du and Wang 2008).  
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Figure 4. TNFR1 signaling induces cell survival, inflammation, anti-microbial processes 
and cell death. 
TNF ligation to TNFR1 results in formation of a receptor-bound complex (complex-I) that 
activates NF-κB and mitogen-activated protein kinase (MAPK) signaling triggering inflammation, 
cell survival and anti-microbial processes. Under certain conditions, TNF causes complex-IIa or 
IIb-mediated TRADD or RIPK1-dependent apoptotic death. However, inhibition of complex-IIa 
and IIb TNF mediates necroptosis through the necrosome formation. (for details see 1.3.1.1-3) 
 
1.3.1.1. TNFR1-induced pro-inflammatory and pro-survival signaling 
 
Binding of TNF to TNFR1 induces pro-inflammatory and anti-apoptotic functions by 
inducing canonical activation of the transcription factor NF-κB and mitogen-activated 
protein kinase (MAPK) pathways	(Varfolomeev and Vucic 2016; Baud and Karin 2001).  
TNF induces the trimerization of TNFR1 resulting in a rapid formation of a receptor 
proximal complex-I consisting of RIPK1, TRADD, TNF receptor-associated factor 2 
(TRAF2), cellular Inhibitor of Apoptosis Protein 1/2 (cIAP1/2) and linear ubiquitin chain 
assembly complex (LUBAC) (Figure 4 and 5) (Legler et al. 2003; Hayden and Ghosh 
2014; Hsu, Huang, et al. 1996). RIPK1 and TRADD are recruited via their DD to the 
intracellular DD of TNFR1. TRADD in turn recruits the E3 ubiquitin ligase TRAF2 via 
interaction through their TRAF binding domain (Hsu, Huang, et al. 1996; Hsu, Shu, et 
al. 1996; Hsu, Xiong, and Goeddel 1995; Pobezinskaya et al . 2008). TRAF2 further 
binds the E3 ligases, cIAP1 and cIAP2, and recruits them to the TNFR1 complex (Shu, 
Takeuchi, and Goeddel 1996). The recruitment of the E3 ligases cIAP1/2 to complex-I 
promotes K11-, K63- and K48-linked ubiquitination of themselves and RIPK1 (Figure 5) 
(Park, Yoon and Lee 2004; Varfolomeev et al. 2008; Dynek et al. 2010; Mahoney et al. 
2008). K63-specific modification of cIAP1/2 supports the engagement of LUBAC 
consisting of haem-oxidized IRP2 ubiquitin ligase-1 (HOIL-1L), HOIL-1 interacting 
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protein (HOIP) and SHANK-associated RH domain-interacting protein (SHARPIN) 
(Ikeda et al. 2011; Tokunaga et al. 2011). K63-specific modification of RIPK1 supports 
the recruitment of transforming growth factor b activated kinase (TAK1) and TAK1 
binding protein 1 and 2 (TAB1/TAB2) (Wang et al. 2001; Kanayama et al. 2004). 
LUBAC in turn promotes linear ubiquitination (M1) of TNFR1, TRADD, RIPK1 and 
NEMO (Haas et al. 2009; Tokunaga et al. 2009). NEMO together with the IKKs are 
recruited to the TNFR1 complex through the interaction of NEMO with M1-, K11- and 
K63-linked ubiquitin chains, with the highest affinity for M1-ubiquitin chains, via its Ub 
binding in ABIN and NEMO (UBAN) domain (Wu et al. 2006; Rahighi et al. 2009; 
Dynek et al. 2010). Trans-autophosphorylation of TAK1 induces the activation of IKK2 
which mediates the activation of the NF-κB signaling pathway (for details see 1.2) 
(Wang et al. 2001). 
 
Figure 5. TNF-induced complex-I 
signaling  
Upon TNF ligation to TNFR1 a receptor-
associated complex-I is being assembled, 
which mediates NF-κB activation resulting 
in pro-inflammatory and pro-survival 
signaling. For details see text. 
 
Ub Ubiquitination (blue circles) 
P Phosphorylation 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stabilization of complex-I signaling is mediated by the modification of several complex-
I members with ubiquitin chains (O'Donnell et al. 2007; Mollah et al. 2007; Tokunaga et 
al. 2009) (Figure 6). Genetic studies in mice revealed impaired canonical NF-κB 
activation in response to TNF in absence of HOIL-1 and HOIP or after mutation of 
Sharpin (Mollah et al. 2007; Tokunaga et al. 2009). RIPK1 displays multiple 
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ubiquitination sites, however, it remains controversial whether ubiquitination of RIPK1 
is fundamental for NF-κB activation. Several studies indicated that ubiquitination of 
RIPK1 was indeed essential for NF-κB activation since mutation of the ubiquitination 
site at K377 abolished the recruitment of the TAK1- and IKK-complex to complex-I as 
well as IκBα phosphorylation after TNF stimulation (Ea et al. 2006; Hsu, Huang, et al. 
1996; Li et al. 2006). On the contrary, an independent study reported that mutated 
ubiquitin, which could not engage K63 chains, did not result in reduced IκBa 
phosphorylation upon TNF stimulation suggesting a ubiquitin-dependent, K63-
independent mechanism of TNF-induced NF-κB activation (Xu et al. 2009). In contrast 
to ubiquitination, autophosphorylation of RIPK1 is largely dispensable for TNF-induced 
NF-κB activation (Lee et al. 2004). However, unlike autophosphorylation, 
phosphorylation of RIPK1 by IKK1/IKK2 within complex-I was recently described to be 
important to restrain RIPK1 in complex-I in order to suppress its pro-death function and 
stabilize complex-I signaling (Dondelinger et al. 2015; Koppe et al. 2016).   
 
Positive and negative regulation of NF-κB by TNF is partially achieved through the 
transcription of A20 (Mevissen et al. 2013; Ritorto et al. 2014; Wertz et al. 2004). A20 
recruitment to complex-I requires the M1-chain forming function of LUBAC since 
absence of HOIP or M1-ubiquitin chains abolishes A20 recruitment to complex-I 
(Draber et al. 2015). Through its Zinc finger domains 4 and 7, A20 binds to K63- and 
M1 linkages respectively (Bosanac et al. 2010; Tokunaga et al. 2012; Verhelst et al. 
2012). A20 has been so far implicated in the hydrolysis of K11-, K63- and K48- but not 
M1-ubiquitin chains to positively and negatively regulate NF-κB activation (Figure 6). 
On the one hand, A20 stabilizes complex-I and favors signal transduction that leads to 
gene transcription by binding M1-ubiquitin chains. On the other hand, A20 negatively 
regulates TNF-induced NF-κB activation by hydrolyzing K63-ubiquitin chains via its 
OTU domain, leading to K48-ubiquitination and proteasomal degradation of RIPK1 
(Wertz et al. 2004; Zilberman-Rudenko et al. 2016). In addition, accumulation of M1-
ubiquitin-bound A20 can switch from positive to negative regulation of NF-κB activation 
by restricting NEMO/IKK complex binding to M1-ubiquitin chains (Zilberman-Rudenko 
et al. 2016). Together, A20 exhibits dual functions in NF-κB regulation by acting as an 
ubiquitin-stabilizing protein promoting NF-κB activation and as an ubiquitin hydrolyzing 
protein impairing NF-κB activation. 
In addition to A20, the deubiquitinase cylindromatosis (CYLD) is recruited to TNFR1-
associated signaling complex-I by associating with HOIP-1 induced by SPATA2 at 
which it regulates gene activator signaling and cell survival/death (Figure 6) (Takiuchi 
et al. 2014; Draber et al. 2015). Unlike A20, CYLD recruitment most probably depends 
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on its interaction with HOIP but is independent of LUBAC’s M1-chain-forming capacity. 
CYLD antagonizes and hydrolyzes K63-ubiquitin and M1 chains via its USP domain 
sensitizing cells to TNF-induced cell death (Figure 6) (Trompouki et al. 2003; Wright et 
al. 2007; Ritorto et al. 2014; Sato et al. 2015). In summary, controlled regulation of 
complex-I mediated signaling is achieved by A20 and CYLD. A20 positively regulates 
complex-I by binding to M1-ubiquitin chains but like CYLD it also negatively regulates 
complex-I signaling by hydrolyzing K63-ubiquitin chains. 
 
Figure 6. (De-)Ubiquitination events 
regulating proximal TNF signaling.  
TNF-induced NF-κB activation is 
tightly regulated by (de)ubiquitination 
events. Ubiquitination of several 
complex-I members including TNFR1, 
TRADD and RIPK1 is mediated by 
cIAP1/2 and LUBAC resulting in the 
stabilization of complex-I promoting 
NF-κB activation. A20 stabilizes 
complex-I by binding to M1-ubiquitin 
chains but together with CYLD it also 
negatively regulates complex-I 
signaling by hydrolyzing K63-ubiquitin 
chains.  
 
P Phosphorylation  
 
 
 
 
 
 
 
 
In addition to NF-κB signaling, TNF ligation to TNFR1 also activates MAPKs such as c-
Jun n-terminal kinases (JNK), extracellular signal-related kinases (ERK) and p38 via 
TAK1-mediated activation. TAK1 acts as a MAP3K and consequently starts the 
phosphorylation cascade (Sabio and Davis 2014; Sakurai et al. 2000). MAPKs are 
evolutionarily conserved serine-threonine kinases regulating cellular processes such 
as cell proliferation, differentiation, survival, death and regulation of gene expression. 
They are activated by phosphorylation cascades or by interaction with small 
guanosintriphosphate (GTP)-proteins of the Ras/Rho family in response to oxidative 
and osmotic stress, heat shock and pro-inflammatory cytokines including TNF (Figure 
7) (Pearson et al. 2001; Treisman 1996).  
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Figure 7. Various stimuli activate MAPK by inducing a 
phosphorylation cascade. 
Various stimuli such as oxidative or osmotic stress and 
cytokines activate MAP4K or GTPases. Activation of 
MAP4K and GTPases induces the activation of 
downstream kinases by a phosphorylation cascade. 
MAPK activation results consequently in cell proliferation, 
differentiation, cell death and inflammatory response. 
 
 
 
 
 
 
 
 
1.3.1.2. TNF-induced complex-IIa/-IIb-mediated apoptosis  
 
In addition to complex-I, binding of TNF to TNFR1 also results in apoptosis mediated 
by complex-IIa and IIb. Formation of complex-IIa through the association of TRADD 
and FADD via homotypic DD-DD interactions is induced e.g. after inhibition of pro-
survival protein translation caused by cycloheximide (CHX) (Hsu et al. 1996; Hsu, 
Xiong and Goeddel 1995; Wang, Du and Wang 2008; Micheau and Tschopp 2003). 
FADD then recruits the initiator Caspase, Caspase-8, via its death effector domain 
(DED) (Figure 8) (Micheau and Tschopp 2003; Wang, Du, and Wang 2008). 
Alternatively, under conditions such as TNF stimulation in the presence of an IAP 
inhibitor, knockout of IAPs, TAK1 inhibition or knockdown, and NEMO knockout, a 
cytosolic complex-IIb can be formed consisting of RIPK1, FADD and Caspase-8 to 
execute RIPK1-kinase-dependent apoptosis (Figure 8) (Dondelinger et al. 2013; 
Moulin et al. 2012; Legarda-Addison et al. 2009; Wang, Du, and Wang 2008; Wilson, 
Dixit, and Ashkenazi 2009). This complex mediates apoptosis in a RIPK1 kinase-
activity dependent manner (Kondylis et al. 2015). Accumulating evidence suggests that 
deubiquitination of RIPK1 is crucial for the execution of TNF-induced apoptosis (de 
Almagro et al. 2017; O’Donnell et al. 2007). Moreover, cleavage of RIPK1 at the 
Caspase cleavage site located in its ID by Caspase-8 is believed to prevent NF-κB 
activation and necroptosis but promotes complex IIa-dependent apoptotic death in 
response to DR signaling (Lin et al. 1999; Rajput et al. 2011). 
Introduction 
 11 
 
Figure 8. TNF-induced complex-IIa and -IIb formation   
Destabilization of complex-I results in the assembly of complex-IIa and -IIb in response to TNF. 
Assembly of complex-IIa and -IIb promotes Caspase-dependent apoptotic death. TNF-induced 
complex-IIa signaling is TRADD dependent whereas complex-IIb signaling is RIPK1-kinase 
activity dependent.  
 
In both complexes, homodimerization of pro-Caspase-8 results in a conformational 
change inducing the autocatalytic cleavage at Asp374 and the generation of multiple 
Caspase-8 fragments such as p43/p41 and p10 (Figure 8). After an additional 
cleavage at Asp216 the catalytic active p18 fragment and the inactive p26/24 
prodomain are produced (Medema, Scaffidi, et al. 1997; Medema, Toes, et al. 1997). 
The p18 fragment forms a homodimer which induces the cleavage and activation of 
the effector Caspases such as Caspase-3, -6 and -7 mediating extrinsic apoptosis. 
Moreover, activated Caspase-8 also triggers the activation of the pro-apoptotic BH3 
interacting domain death agonist (Bid) resulting in the mitochondrial-mediated 
amplification of the apoptotic signal induced by extrinsic stimuli (Figure 9) (Li et al. 
1998; Luo et al. 1998). Bid induces the release of mitochondrial proteins such as 
cytochrome C and second mitochondrial derived activator of Caspases (SMAC) 
leading to APAF-1-dependent apoptosome formation and pro-Caspase-9 activation 
(Luo et al. 1998; Gross et al. 1999). Activated Caspase-9 activates effector Caspases 
such as Caspase-3 and consequently amplifies apoptotic signaling also in cells with 
low levels of Death-Inducing Signaling Complex (DISC) components (Wilson, Dixit, and 
Ashkenazi 2009). Independent of Caspase-8, the mitochondria-mediated form of 
apoptosis is induced among others by DNA-damage and ER-stress and is classified as 
intrinsic apoptosis. 
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Figure 9. The extrinsic and intrinsic apoptotic pathways  
Apoptosis is induced via mitochondrial (intrinsic) or via DR-mediated (extrinsic) pathways. The 
extrinsic apoptotic pathway is dependent on FADD-pro-Caspase-8 interaction resulting in the 
processing of pro-Caspase-8 to catalytically active Caspase-8, which consequently activates 
Caspase-3/6/7. In contrast, intrinsic apoptosis is activated in response to DNA-damage and ER-
stress that induces p53 activation. p53 signaling activation results in the upregulation of p53 
upregulated modulator of apoptosis (PUMA) and phorbol-12-myristate-13-acetate-induced-
protein 1 (NOXA) that neutralizes the anti-apoptotic BCL-2 proteins, B-cell lymphoma (BCL)-2 
and BCL-XL resulting in the activation of Bid (tBid). tBid in turn activates Bax and Bak resulting 
in the disruption of mitochondrial integrity causing the release of cytochrome C and SMAC and 
consequently resulting in apoptosome-dependent activation of Caspase-9. This leads to the 
activation of Caspase-3/6/7 and ultimately to apoptosis. However, extrinsic apoptosis induces 
also intrinsic apoptosis via Caspase-8-dependent activation of Bid to tBid. 
 
Effector Caspases activate cytoplasmic endonucleases and proteases to induce the 
degradation of nuclear material and cytoskeletal proteins, respectively. These 
processes influence the morphological characteristics of apoptosis characterized by 
cell shrinkage and pyknosis, a result of chromatin condensation (Kerr, Wyllie, and 
Currie 1972). Moreover, extensive plasma membrane blebbing followed by 
karyorrhexis, separation of cell fragments into apoptotic bodies and nuclear 
fragmentation are characteristics of apoptosis (Kerr, Wyllie, and Currie 1972). 
Apoptotic bodies are subsequently phagocytosed by macrophages, parenchymal cells 
or neoplastic cells and degraded within phagolysosomes (Poon et al. 2014).  
Due to the immediate clearance of apoptotic bodies, apoptosis is considered to be 
non-immunogenic (Lamkanfi and Dixit 2010; Green et al. 2009). Conversely, current 
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studies also identified a pro-inflammatory role of apoptosis under cancerous conditions 
(Poon et al. 2014).  
Apoptotic death has to be tightly regulated since inappropriate apoptosis is involved in 
neurodegenerative diseases, autoimmune disorders and many types of cancer 
including hepatocellular carcinoma (HCC) (Poon et al. 2014; Kondylis et al. 2015). 
Accordingly, a study using a genetic model of HCC formation revealed that the liver-
parenchyma cell (LPC)-specific deficiency of NEMO triggered apoptotic death resulting 
in an inflammatory response inducing spontaneous HCC development in mice 
(Kondylis et al. 2015). Furthermore, IKK1/IKK2LPC-KO mice developed increased RIPK1-
dependent cholangiocyte death resulting in strong hepatocellular damage, severe 
biliary destructions and cholestasis, which are fatal at 7-9 months of age (Luedde et al. 
2008; Koppe et al. 2016). Conversely, inhibition of extrinsic apoptosis also results in a 
developmentally fatal outcome since Caspase-8 deficiency is embryonically lethal 
accompanied by embryonic vascular, cardiac and haematopoietic defects 
(Varfolomeev et al. 1998; Kaiser et al. 2011). Similarly, inhibition of intrinsic apoptosis 
by Caspase-9 deficiency resulted in embryonic/neonatal lethality showing enlarged 
and malformed cerebellum (Kuida et al. 1998; Hakem et al. 1998). Taken together, 
both extensive but also diminished apoptosis strongly affect tissue homeostasis and 
the viability of mice. Therefore, tight regulation of Caspase-dependent apoptosis is 
essential for development and tissue homeostasis.  
 
NF-κB-dependent expression of cellular FLICE-like inhibitory protein (cFLIP) is 
considered to negatively regulate extrinsic apoptotic signaling through modulation of 
Caspase-8 activity (Dillon et al. 2012; Feoktistova et al. 2011). cFLIP is a catalytically 
inactive homolog of Caspase-8 with two isoforms, cFLIPL and cFLIPS in humans and 
cFLIPL and cFLIPR in mice. Caspase-8 cFLIP heterodimerization results in primary 
Caspase-8 cleavage and the generation of a p10-fragment but lacks secondary 
cleavage inhibiting p18-fragment generation (Pop et al. 2011). Interaction between the 
p43/p41 Caspase-8 fragment and cFLIPL negatively regulates apoptosis and is thought 
to inhibit necroptosis. In detail, a Caspase-8-cFLIP heterodimer has been suggested to 
cleave CYLD, RIPK1 and RIPK3 degrading key drivers of TNF-induced necroptosis 
(see 1.3.1.3.). There is evidence suggesting that low levels of cFLIPL stabilize complex 
IIa by binding to Caspase-8 allowing its oligomerization to execute apoptosis and block 
necroptosis while high levels of cFLIPL prevent Caspase-8 oligomerization and thereby 
block apoptosis (Hughes et al. 2016; Fu et al. 2016). This hypothesis is based on data 
obtained by Fas/FasL signaling and yet needs to be confirmed in a TNFR1-dependent 
setting (Pop et al. 2011; Wachter et al. 2004; Hughes et al. 2016; Fu et al. 2016).  
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1.3.1.3. TNF-induced complex-IIc mediated necroptosis 
 
When the formation of complex-IIa and-IIb are blocked by FADD, Caspase-8 
deficiency or inhibition of Caspase-8 activity by zVAD-fmk, TNF induces the assembly 
of a third death-inducing complex, called complex-IIc/ necrosome, consisting of RIPK1, 
RIPK3 and mixed lineage kinase domain-like (MLKL) (Figure 10) (Newton et al. 2014; 
Pasparakis and Vandenabeele 2015). Accordingly, Fadd-/- or Caspase-8-/- mice 
showed embryonic lethality that was prevented by additional deletion of the 
necroptosis mediator RIPK3 or MLKL (Kaiser et al. 2011; Dillon et al. 2012; Alvarez-
Diaz et al. 2016) To date, necroptotic death is considered to occur independently of 
Caspases in cells with elevated levels of RIPK3 and MLKL. TNF-induced necroptotic 
death is dependent on RIPK1 kinase activity as several studies reported that mutation 
of the kinase activity or using the allosteric inhibitor of the kinase activity of RIPK1, 
necrostatin-1 (nec-1), prevented necroptotic death (Ni et al. 2016; Polykratis et al. 
2014; Degterev et al. 2008; Degterev et al. 2005; Kondylis et al. 2015; Vlantis et al. 
2016; Newton et al. 2014). Indeed, autophosphorylation of RIPK1 on Ser161 or Ser166 
was recently reported to be important for necroptotic death (de Almagro et al. 2017; 
Zhang et al. 2017). Autophosphorylation at the residue Ser161 was shown to be 
triggered in response to TNF-induced ROS (Zhang et al. 2017). However, it remains to 
be elucidated whether only autophosphorylation or phosphorylation by other kinases at 
one or multiple residues are crucial for RIPK1 functions particularly in the necrosome. 
It was recently identified that not only phosphorylation, but coordinated ubiquitination 
and phosphorylation of RIPK1 within complex-IIc are crucial for the induction of 
necroptosis (Figure 10) (de Almagro et al. 2017 and 2015). Mutation of the 
ubiquitination site of RIPK1 at K115 prevented K63- and linear ubiquitination of RIPK1 
and thereby reduced RIPK1 phosphorylation, necrosome formation and consequently 
necroptosis (de Almagro et al. 2017). However, the precise molecular mechanisms 
controlling RIPK1 activation in the necrosome are still unclear.  
Activation of RIPK1 results in conformational changes allowing an interaction between 
RIPK1 and RIPK3 through their RHIM domains (Chan, Luz, and Moriwaki 2015; Cho et 
al. 2009). The heterodimeric interaction between RIPK1 and RIPK3 mediates the 
recruitment of another RIPK3 molecule to form a RIPK3-RIPK3 amyloid complex 
allowing RIPK3 autophosphorylation (Cho et al. 2009; He et al. 2009; Li et al. 2012; 
Zhang et al. 2009; Sun et al. 2002). RIPK3 phosphorylation at Ser232 is crucial for the 
recruitment and activation of its downstream target MLKL (Zhao et al. 2012; Sun et al. 
2012; Murphy et al. 2013). The activation of the pseudokinase MLKL is mediated by its 
phosphorylation by RIPK3 at different phosphorylation sites including Ser345, Ser347, 
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Ser 352 and Thr 349 (Chen et al. 2013; Li et al. 2012; McQuade, Cho, and Chan 2013; 
Cai et al. 2014). This phosphorylation of MLKL results in a conformational change that 
exposes the 4-helical bundle domain allowing its oligomerization (Cai et al. 2014; Chen 
et al. 2013; Dondelinger et al. 2014; Sun et al. 2012; Wang et al. 2014; Xie et al. 
2013). It is still highly debated how MLKL executes necroptotic death. The current 
model suggests that MLKL binds to phospholipids of the cell membrane through its 4-
helical bundle domain resulting in the influx of Ca2+ and Na+ that likely contribute to cell 
death (Cai et al. 2014; Chen et al. 2013; Dondelinger et al. 2014; Su et al. 2014; Wang 
et al. 2014).  
 
Morphologically, necrotic cell death is characterized by organelle swelling and loss of 
plasma membrane integrity (Festjens et al. 2007; Krysko et al. 2008; Vanden Berghe 
et al. 2010). In contrast to apoptotic death, necroptotic death is currently believed to be 
highly immunogenic by releasing factors collectively described as damage-associated 
molecular patterns (DAMPs) (Kono and Rock 2008; Krysko et al. 2008; Lamkanfi and 
Dixit 2010). Consistently, FADD deficiency in both intestinal epithelial cells (IECs) and 
keratinocytes induces necroptotic death and tissue inflammation that was both 
prevented by RIPK3 deficiency (Welz et al. 2011; Bonnet et al. 2011).  
 
Figure 10. TNF-induced necrosome formation.   
TNF induces the assembly of a necrosome mediating Caspase-
independent necroptotic death in a RIPK1-RIPK3 kinase activity 
dependent manner. Coordinated ubiquitination and phosphorylation 
of RIPK1 was reported to induce the complex formation between 
RIPK1 and RIPK3, which interact via their RHIM domain, resulting in 
the phosphorylation and activation of MLKL. 
 
 
 
 
 
 
 
 
 
1.4. TLR signaling 
TLRs are receptors involved in the activation of innate immune cells recognizing 
specific patterns of microbial components (PAMPs) including bacteria, mycobacteria 
and viruses or altered host-derived DAMPs that under specific conditions may trigger 
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an immunological response (Akira, Takeda and Kaisho 2001; Akira, Uematsu and 
Takeuchi 2006; Janeway and Medzhitov 2002). All TLRs share a conserved 
cytoplasmic TIR domain with which they can interact with TIR domain-containing 
adaptors such as myeloid differentiation primary response gene 88 (MyD88) and TRIF. 
In addition to their TIR domain, TLRs contain a leucine-rich repeat (LRR) ectodomain 
which enables recognition of PAMPs and DAMPs (Kawai and Akira 2010). Until now, 
12 TLRs have been identified in humans and 10 in mice. Unlike MyD88, which is 
implicated in the signaling induced by all TLRs except for TLR3, TRIF is implicated 
only in TLR3 and TLR4 signaling (Kawai and Akira 2010). 
 
TLR4 induces an inflammatory response against gram-negative bacteria after 
recognizing lipopolysaccharide (LPS) on their outer-surface (Figure 11) (Hoshino et al. 
1999; Poltorak et al. 1998; Qureshi et al. 1999). TLR4 is the only TLR that mediates 
signaling via both MyD88 and TRIF adaptors. After LPS stimulation, TLR4 recruits the 
intracellular adapter MyD88 and TRIF via TIRAP/TRAM. MyD88 induces inflammatory 
cytokine production through NF-κB activation mediated by interleukin-1 receptor-
associated kinase (IRAK) and TRAF6 interaction. TRIF associates with either TANK-
binding kinase (TBK)1 or activates IFN regulatory factor 3 (IRF3) mediating type I IFN 
expression. In addition, TRIF interacts with RIPK1 via their RHIM domains to mediate 
MAPK and NF-κB activation (Figure 11). Similar to its role in TNF signaling, 
recruitment of RIPK1 to TLR4 via TRIF is followed by its polyubiquitination, which is 
possibly mediated by TRAF6. Polyubiquitination of RIPK1 mediates the recruitment of 
TAB1/2 and TAK1 resulting in MAPK activation and in the recruitment of the 
IKK1/2/NEMO complex inducing NF-κB activation (Cusson-Hermance et al. 2005). 
TLR4-mediated TRIF-dependent cell death occurs in order to eliminate infected host-
cells. Therefore, a death-inducing complex containing TRIF, RIPK1, RIPK3, FADD, 
Caspase-8 and cFLIP induces RIPK1 kinase-activity-dependent apoptosis and 
necroptosis (He et al. 2011; Kaiser et al. 2005; Polykratis et al. 2014).  
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Figure 11. LPS-mediated TLR4 signaling activation  
Binding of LPS to TLR4 induces the engagement of TIR domain-containing adaptor proteins 
TIRAP/MyD88 or TRAM/TRIF. This mediates the interaction between MyD88 with IRAKs and 
the adapter molecule TRAF6. Together they mediate NF-κB and MAPK activation. Via TRAM 
and TRIF TLR4 interacts with RIPK1 and TRAF3. Through TRAF3 TLR4 triggers IRF3/7-
mediated Type-I-Interferon response while via RIPK1 TLR4 induces either NF-κB/ MAPK 
activation or cell death (apoptosis or necroptosis). 
1.5. Anatomy and function of the liver 
The liver is an essential organ in vertebrates consisting of two main lobes in humans 
and four main lobes in mice (Abdel-Misih and Bloomston 2010). The liver is a 
heterogeneous organ that is predominantly composed of the liver parenchyma cell 
compartment consisting of 60-65% hepatocytes and 3.5% biliary epithelial cells and 
the non-parenchymal cell compartment including 15-20% endothelial cells, as well as 
8-12% liver-resident macrophages (Kupffer cells) and 3-8% lymphocytes and hepatic 
stellate cells (Racanelli and Rehermann 2006; Kmiec 2001). The liver mediates various 
functions that are implicated in fat and glucose metabolism, detoxification, protein 
synthesis, hormone production and glycogen storage (van den Berghe 1991; Dietschy, 
Turley, and Spady 1993). Deregulation of liver homeostasis can result in acute liver 
failure (ALF), in chronic liver diseases or in HCC (Dietschy, Turley, and Spady 1993; 
Kmiec 2001; van den Berghe 1991; Wullaert et al. 2007).  
The maintenance of liver homeostasis is dependent on the tight regulation of 
inflammation and cell death. Although under physiological conditions the turnover rate 
of differentiated hepatocytes is relatively low (200-400 days in mice/rats) compared to 
other epithelial or epidermal cells, liver regeneration capacity is highly increased upon 
extensive tissue loss during surgical resection or injury caused by massive alcohol 
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consumption, metabolic toxicity and viral or other microbial infections (Martins, 
Theruvath and Neuhaus 2008; Fausto 2004). Massive hepatocyte death exceeding the 
regenerative capacity of the liver mediates acute liver injury which can ultimately result 
in ALF causing high mortality rates of patients (Bantel and Schulze-Osthoff 2012). 
Moreover, massive hepatocyte death or chronic inflammation coupled with 
compensatory liver regeneration induced by hepatocyte proliferation is thought to 
greatly increase the risk of HCC (Luedde, Kaplowitz, and Schwabe 2014; Guicciardi et 
al. 2013). HCC is one of the most frequent and difficult to treat types of cancer 
constituting the second most common cause of cancer-related deaths worldwide 
(Shariff et al. 2009; El-Serag 2011). Understanding the mechanisms regulating chronic 
inflammation and cell death in the liver is essential to find new therapeutic strategies 
against liver diseases such as ALF and HCC. 
 
1.5.1. Murine models of liver inflammation and liver injury 
 
Several murine models of liver injury provide distinct approaches to elucidate the 
inflammatory response and cell death signaling in the liver upon damage. A well-
characterized murine model to study inflammatory signaling is the LPS-induced 
systemic inflammation model. A single intraperitoneal injection (i.p.) of sub-lethal doses 
of the gram-negative bacteria derived endotoxin LPS induces a TLR4-dependent acute 
inflammatory response, which resembles to a large extent those occurring during the 
early stages of septic shock (Martich, Boujoukos, and Suffredini 1993). LPS toxicity is 
associated with activation of KCs in the liver and the release of inflammatory cytokines 
such as TNF resulting in a strong inflammatory response that can ultimately lead to 
death by septic shock without inducing liver injury (Bautista et al. 1994; Luster et al. 
1994; Bradham et al. 1998). Combined injection of LPS with a hepatic transcription 
inhibitor D-galactosamine (D-GalN), which is metabolized into an active metabolite 
exclusively in hepatocytes and blocks transcription by depleting uridine nucleotides, 
sensitizes hepatocytes to death resulting in hepatic damage caused by TNF 
resembling viral hepatitis accompanied by focal cell death and periportal inflammation 
(Keppler, Pausch, and Decker 1974; Freudenberg, Keppler, and Galanos 1986; 
Morikawa et al. 1996; Xiong et al. 1999; Van Dien et al. 2001; Liu et al. 2008). Besides 
the LPS/TNF-induced murine model, ConA-induced hepatic inflammation reflects the 
overall physiopathological conditions observed in human viral-induced or autoimmune 
hepatitis. ConA is an effective activator of T-cells resulting in the activation of cytotoxic 
effectors such as TNF that trigger hepatocyte death consequently resulting in hepatitis 
development (Mizuhara et al. 1994; Tiegs et al. 1992). Moreover, α-galactosylceramide 
(α-GalCer), a potent NKT cell stimulator, causes liver injury through a pronounced 
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cytokine response, including TNF, IFNγ and IL-2/-4/-6. In addition, acetaminophen 
(APAP)-mediated toxicity is a model of induced hepatocyte death and hepatotoxicity 
(Nelson et al. 1990; Hinson et al. 1995). APAP is metabolized to NAPQI via Cyp450, 
which is highly electrophilic and covalently binds intracellular proteins inducing 
hepatocyte toxicity (Mitchell et al. 1973). APAP induces liver damage resembling 
histological characteristics of necrosis independently of TNFR1 signaling (Boess et al. 
1998). Together these murine models mimic human liver diseases and therefore 
enable the studies of disease initiation and progression in mice. 
 
1.5.2. Murine model of hepatocellular carcinoma   
 
The chemical compound diethylnitrosamine (DEN) has been widely used to mimic 
HCC in experimental animal models by causing DNA-damage (Tolba et al. 2015). 
DEN-induced HCC has histological and genetic similarities to that of human HCC, 
which allows studying the molecular mechanisms of hepatocarcinogenesis. In 1961, 
the hepatotoxic and carcinogenic effect of DEN was first reported in rats inducing high 
incidences of hepatic tumors upon a single application (Thomas 1961). Intraperitoneal 
injection of DEN results in the bioactivation of DEN by cytochrome P450 enzymes 
including CYP2E1 in the liver resulting in DNA-adducts formed through an alkylation 
mechanism further leading to the induction of carcinogenesis (Figure 12). These 
alkylated adducts activate the DNA-damage repair which is coupled to the DNA 
damage response resulting in cell cycle arrest, NF-κB activation or cell death (Rao and 
Vesselinovitch 1973; Li et al. 2001). Sensing DNA damage occurs through ataxia 
telangiectasia mutated (ATM) or Ataxia telangiectasia and Rad3-related protein (ATR) 
kinase (Teoh et al. 2010; Piret, Schoonbroodt, and Piette 1999). DNA damage sensing 
by ATM results in the formation of a cytoplasmic complex containing ATM, RIPK1, 
TAK1 and NEMO (Figure 12) (Yang et al. 2011). Within this complex RIPK1 is modified 
by ubiquitin resulting in the activation of the NF-κB pathway (Hur et al. 2003; Piret, 
Schoonbroodt, and Piette 1999). DNA-damage-induced NF-κB activation is dependent 
on RIPK1 since DNA-damage failed to activate NF-κB in Ripk1-/- fibroblasts. 
Additionally, this complex mediates cell cycle control and DNA repair via p53 and the 
checkpoint kinase (Chk) 2. Cell cycle arrest as well as NF-κB activation enables the 
cell to repair DNA lesions and avoid further damage until the DNA damaging agent is 
cleared. However, excessive damage that cannot be repaired properly leads to the 
induction of apoptotic death. It was suggested in a previous report that ATM induced 
apoptotic death via TNF feedfoward signaling (Biton and Ashkenazi 2011). 
Nevertheless, accumulation of excessive DNA-damage without proper clearance could 
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result in tumorigenesis. The majority of liver tumors, which are generated by a single 
injection of DEN, are mutated either in the Ha-ras or the B-raf gene (Jaworski et al. 
2005).  
Similar to human HCC, DEN-induced HCC is also more prominent and extensive in 
males. This gender disparity was reported and shown extensively to depend on the 
serum IL-6 level that is produced to a greater extent in males. In females the hormone 
estrogen inhibits the secretion of IL-6 from KCs and therefore reduces the risk of HCC 
in females (Naugler et al. 2007). 
 
 
Figure 12. DEN-induced DNA-damage response  
The carcinogen DEN needs to be bioactivated by cytochrome P450 in order to cause DNA 
adducts. DNA adducts are recognized by ATM resulting in either p53-dependent cell cycle 
control or in the formation of a death-inducing complex consisting of ATM, RIPK1, NEMO and 
TAK1 mediating NF-κB activation or cell death. Accumulation of DNA-damage without sufficient 
clearance results in DNA-damage-induced cancer. 
 
The mechanism of tumor initiation after DEN administration has not been fully solved. 
However, the current model implicates a combined effect of continuous hepatocyte 
death leading to high regenerative and proliferative capacity of hepatocytes induced by 
inflammation resulting in steatosis and fibrosis that can progress to cirrhosis. This is 
consistent with the mechanism involved in the onset of spontaneous HCC in mouse 
models such as NEMOLPC-KO and tumor initiations in human HCC (Bisgaard and 
Thorgeirsson 1996; Kondylis et al. 2015). In fact, TLR4-deficient, Bid liver-specific 
deficient and PUMA-deficient mice showed reduced apoptosis, proliferation and 
inflammatory markers resulting in reduced HCC development (Weber et al. 2016; Yu et 
al. 2016; Qiu et al. 2011). In independent reports, it was demonstrated that IKK2Δhep 
mice developed more HCC than control mice due to enhanced DEN-induced 
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hepatocyte death and increased hepatocyte proliferation capacity due to increased 
JNK activation (Koch et al. 2009; Sakurai et al. 2006; Maeda et al. 2005). Furthermore, 
BCL-2, an anti-apoptotic protein, was reported to delay HCC development upon DEN 
by interfering with hepatocyte proliferation induced by transforming growth factor alpha 
(TGFα) signaling (Vail, Pierce, and Fausto 2001). In contrast to these results, Atm-/- 
mice remained protected from DEN-induced HCC up to 15 months although Atm-/- 
mice revealed increased p53 expression-dependent CC3 levels (Teoh et al. 2010). 
ATM deficiency at the same time upregulated markers of senescence resulting in cell 
cycle arrest that could protect mice from tumor development (Teoh et al. 2010). 
Moreover, Gruber et al. reported elevated apoptosis and compensatory levels but 
reduced HCC formation in IL-6Rα-deficient mice (Gruber et al. 2013). The current 
model of DEN-induced HCC development highly depends on the correlation between 
increased cell death and compensatory proliferation. However, the data on DEN-
injected Atm-/- and IL-6Rα-deficient mice suggest an additional mechanism 
independent of cell death and compensatory proliferation. 
 
1.5.2.1. Diet-induced obesity and its role in DEN-induced HCC 
 
Epidemiological studies have identified obesity as a major risk factor for several cancer 
types including HCC (Bianchini, Kaaks, and Vainio 2002; Calle and Kaaks 2004). 
Under obese conditions, mice develop HCC with higher tumor numbers and tumor size 
(Calle and Kaaks 2004; Hill-Baskin et al. 2009). Obesity is known to induce a chronic 
low-grade inflammatory state resulting in immune cell infiltration in the white adipose 
tissue and the liver. The most prominent cytokines that are chronically expressed 
under obese conditions are TNF and IL-6 (Park et al. 2010). Blocking TNFR1 signaling 
reduces DEN/obesity-induced HCC development (Park et al. 2010). It was suggested 
that constant TNF production under obese conditions may promote an inflammatory 
environment inducing TNF-mediated cell death and compensatory proliferation 
resulting in higher tumor formation (Park et al. 2010). In contrast to TNF, IL-6 promotes 
DEN-induced HCC in lean mice by suppressing myeloid leukemia cell differentiation 
protein (MCL-1), a Bcl-2 family member, and consequently inhibit cell death. However, 
under obese conditions  Mcl-1 was stabilized and in turn inhibits apoptosis of damaged 
hepatocytes contributing to the induction and progression of tumors independent of IL-
6 signaling (Gruber et al. 2013).  
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1.6. The role of RIPK1 in tissue homeostasis, liver injury and HCC 
 
Ripk1-/- mice die shortly after birth showing excessive cell death and inflammation in 
various tissues including gut, skin and the liver (Kelliher et al. 1998; Dillon et al. 2014; 
Kaiser et al. 2014). Unlike Ripk1-/-, deficiency of RIPK1 kinase activity alone did not 
result in extensive cell death or obvious pathological features suggesting that a kinase-
independent function of RIPK1 regulates cell survival and tissue homeostasis 
(Polykratis et al. 2014). Moreover, RIPK1 kinase inactive mutants prevent TNF-induced 
necroptosis and apoptosis in mouse models with increased cell death implying an 
essential role for autophosphorylation-mediated activation of RIPK1 in DR-induced cell 
death (Polykratis et al. 2014; Kondylis et al. 2015; Vlantis et al. 2016). In contrast to 
RIPK1 KD deficiency, deficiency of RIPK1 RHIM domain largely resembled the 
perinatal death of Ripk1-/- mice showing epidermal hyperplasia and immune cell 
infiltrations suggesting a pro-survival function of the RHIM domain of RIPK1. Genetic 
studies revealed a pivotal role of the RHIM domain of RIPK1 in regulating skin 
inflammation and DAI/ZBP1-induced necroptotic death (Lin et al. 2016; Newton et al. 
2016).  
Similar to Ripk1-/- mice, intestinal epithelial cell (IEC)-specific or epidermis-specific 
deficiency of RIPK1 resulted in premature death of mice due to massive IEC/ 
keratinocyte death and extensive inflammation emphasizing a pro-survival scaffolding 
function of RIPK1 in the gut and the skin (Dannappel et al. 2014; Takahashi et al. 
2014). The gut or the skin resembles the most important barrier protecting from 
harmful bacteria and viruses. Disruption of either of these barriers enables the invasion 
of harmful bacteria allowing direct contact with resident immune cells triggering an 
inflammatory response and might consequently result in the pathology observed in 
RIPK1E-KO and RIPK1IEC-KO mice. Accordingly, Takahashi et al. identified a 
MyD88/microbiota-dependent mechanism of RIPK1 in mediating gut pathology using 
antibiotic treatments or by performing germ-free housing of mice (Takahashi et al. 
2014). This finding was challenged by the finding of Dannappel et al. that showed a 
MyD88/microbiota-independent mechanism of RIPK1 using similar approaches 
(Dannappel et al. 2014). However, ablation of TNFR1 signaling partially reduced cell 
death in RIPK1IEC-KO and RIPK1E-KO mice improving tissue homeostasis suggesting a 
partial role of RIPK1 in negatively regulating TNF-dependent cell death	 (Takahashi et 
al. 2014; Dannappel et al. 2014). Moreover, ablation of TNFR1 and TRIF prolonged 
the survival of Ripk1-/- mice suggesting a combined effect of TNFR1 and TRIF in 
mediating cell death, inflammation and the premature death of these mice (Dillon et al. 
2014).  
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Since complete or IEC/keratinocyte specific-deficiency of RIPK1 in mice result in 
premature death, limited data are available about the kinase-dependent or kinase-
independent functions of RIPK1 in response to LPS or in cancer development. 
Increasing evidence suggests a crucial role for RIPK1 in LPS/TLR-induced toxicity due 
to its important regulatory role in inflammation and cell death. Vivarelli et al. reported 
an involvement of RIPK1 in TLR4-mediated signaling by activating PI3K/AKT signaling 
(Vivarelli et al. 2004). Ripk1-/- mouse splenocytes failed to proliferate and show 
impaired AKT activation in response to LPS resulting in increased apoptotic death 
suggesting an essential pro-survival function of RIPK1 in TLR4 signaling (Vivarelli et al. 
2004).  
Despite increasing evidence for an involvement of RIPK1 in the DNA-damage 
response, evidences for the importance of RIPK1 in DNA-damage-induced 
carcinogenesis are limited. Recent reports revealed a pro-survival role of RIPK1 in 
melanoma cells resulting in tumorigenesis and metastasis. Consistently, knockdown of 
RIPK1 in melanoma cells was reported to sensitize cells to death and consequently in 
less tumor formation in a xenograft model (Liu et al. 2015; Luan et al. 2015).  
Nevertheless, the in vivo function of RIPK1 in regulating TLR4-dependent signaling or 
carcinogenesis remains unaddressed, mainly due to the perinatal lethality of RIPK1 
knockout mice (Kelliher et al. 1998; Dillon et al. 2014; Kaiser et al. 2014). 
1.7. Project description 
RIPK1 is a critical regulator of cell death and inflammation downstream of death 
receptors (DR)s and toll-like receptors (TLRs) with kinase-dependent and kinase-
independent functions. Deregulation of cell death and inflammation are characteristics 
in the pathogenesis of liver diseases including acute liver failure (ALF) and 
hepatocellular carcinoma (HCC). ALF and HCC are still life-threatening diseases 
without effective and efficient long-term therapeutic strategies due to their severity and 
heterogeneity, which limits the finding of effective medications (Bantel and Schulze-
Osthoff 2012; Kim et al. 2016). Therefore, with its dual-function RIPK1 might be a 
crucial regulator of liver homeostasis, ALF and HCC. 
Here we aimed at studying the biological significance of RIPK1 kinase-dependent and 
-independent functions in the liver using well-established genetic mouse models of 
ALF or HCC that would allow us to specifically decipher the initiation, promotion and 
progression of HCC and the processes resulting in ALF. 
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2. Material and Methods 
2.1. Chemicals and biological materials 
Kits and chemicals used in this work were purchased from the depicted companies. All 
solutions were prepared with double-distilled water (ddH2O).   
 
Table 1. Reagents/Chemicals used in this study 
Reagents/ Chemicals Supplier (Catalog number) 
Acrylamid/Bis solution Serva (10688.01) 
Ammonium persulphate (APS) Sigma (A3678-100G) 
β-mercaptoethanol Sigma (M7522) 
4-2-hydroxyethyl-1-piperazineethanesulfonic acid 
(HEPES) 
Invitrogen (15630-056) 
Agarose ultra-pure Biozym (840004) 
Albumine bovine fraction (BSA) Biorad (500-0006) 
Bromophenol blue KMF 
Complete (Protease EDTA-free Inhibitor Cocktail 
Tablets 
Roche (11836145001) 
 
Diethylnitrosamine (DEN) Sigma (N0766-10ml) 
D-Galactosamine (D-GalN) Sigma (G0500) 
DMEM Gibco (41965-062) 
dimethyl sulfoxide  (DMSO) AppliChem (A3672,0050) 
ECL Detection Reagents GE Healthcare (RPN2132) 
ECL Detection Reagents (femto) Thermo Scientific (34095) 
Ethylenediaminetetraacetic acid (EDTA) JT-Baker (8993-01) 
Ethanol absolute AnalR Normapur (20821-321) 
Fetal calf serum (FCS) PAA (A15-101) 
Fluoromount-G Southern Biotech (0100-01) 
Glucose 20% Fresenius Kabi 
100x L-Glutamine (200mM) Invitrogen (25030123) 
Glycerol VWR (24386-298) 
Hydrochloride acid (HCl) 37% AppliChem (A2427-2500) 
Insulin Sanofi-Aventis (08923023) 
Isopropanol (2-Propanol) AppliChem (A3928) 
Ketamin 10mg/ml Ratiopharm 
Lactate Dehydrogenase Assay Sigma (MAK066-1KT) 
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Reagents/ Chemicals Supplier (Catalog number) 
Methanol Sigma (494437) 
Nitrogen (liquid) Sigma (N4638) 
Paraformaldehyde (PFA) AppliCHem (A3813) 
PBS (without Ca2+ and Mg2+) Gibco (14190-094) 
100x Penicillin (10000U/ml)/Streptomycin 
(10000ug/ml) 
Invitrogen (15140163) 
Phosphatase inhibitor cocktail tablets, PhosSTOP Roche (04906837 001) 
Phosphate buffered saline (PBS) Gibco (14190-094) 
Pierce ThermoScientific (22660) 
Proteinase K Roche (3115852) 
Proteinmarker PeqGold Peqlab (27-2210) 
Rompun 2% Bayer (321350-RX) 
Sodium dodecyl sulfate (SDS) Millipore (817034.1000) 
100x Sodium pyruvate (100mM) Gibco (11360-039) 
Stripping buffer ThermoScientific (21059) 
N,N,N’,N’ Tetra methylenediamine (TEMED) Serva (35925) 
Tris HCL/Base VWR (443864E) 
Triton X-100 AppliChem (A4975-0500) 
Trizol reagent Invitrogen (15596-018) 
Trypsin EDTA Gibco (12603-010) 
Tween-20 Sigma (P1379-500) 
 
Table 2. Kits used in this study 
Kits Supplier (Cat. No.) 
ABC Kit Vectastain Elite Vector (PK 6100) 
Avidin/Biotin Blocking Kit Vector (no. SP-2001) 
Liquid DAB Substrate Chromogen System DakoCytomation (Code K3466) 
RNA extraction RNeasy mini Kit Qiagen (74106) 
RNase-free DNase set  Qiagen (79254) 
SuperScriptIII cDNA synthesis Kit Invitrogen (18080-044) 
TaqMan® Gene expression Master Mix Applied Biosystems (4369542) 
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Table 3. Buffers and solutions used in this study 
Buffers and solutions Composition 
Western blot blocking buffer 
 
 
 
PBS 
Tween-20                                 0,1% 
BSA (w/v)                                    5% 
Non-fat dry milk                           5% 
Cytoplasmic and nuclear protein 
Extraction buffers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endogenous peroxidase blocking buffer  
(for IHC) 
 
 
 
High salt RIPA lysis buffer 
 
 
 
 
 
 
 
 
 
5x Laemlli loading buffer 
 
 
 
 
 
Hypotonic lysis buffer 
HEPES (pH 7.6)                     10 mM 
KCl                                         10 mM 
MgCl2                                       1 mM 
EDTA                                    0.1 mM 
 
After the swelling step 0.8% (v/v) 
Nonident P-40, Protease and 
Phosphatase inhibitors were added 
prior to use. 
 
High salt nuclear lysis buffer 
HEPES (pH 7.8)                   50 mM 
KCl                                       50 mM 
NaCl                                   300 mM 
EDTA                                  0.1 mM 
Glycerol                            10% (v/v) 
Protease and Phosphatase inhibitors 
were added prior to use. 
 
NaCitrate                               0.04 M 
Na2HPO4                                              0.121 M 
NaN3                                      0.03 M 
H2O2                                                         3% (v/v) 
 
HEPES (pH 7.6)                     20 mM 
NaCl                                     350 mM 
MgCl2                                                           1 mM 
EDTA                                     0.5 mM 
EGTA                                     0.1 mM 
Glycerol                              20 %(v/v) 
1% Nonident P-40, Protease and 
Phosphatase inhibitors  
were added prior to use 
 
Tris-HCL (pH 6.8)                 250 mM 
SDS                                    10% (w/v) 
Glycerol                               50% (v/v) 
Bromphenolblue              0.01% (w/v) 
β-Mercaptoethanol              10% (v/v) 
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Buffers and solutions 
 
PBS (1x), pH 7.3 
 
 
 
 
Primary and secondary antibody dilution 
buffer for immunoblots 
 
TAE Buffer (25x) for 10l 
 
 
 
Tail lysis Buffer 
 
 
 
 
 
 
 
TE Buffer 
 
Composition 
 
NaCl                                     137 mM 
KCl                                        2.7 mM 
Na2HPO4 – 7H2O                4.3 mM 
KH2PO4                                1.4 mM 
 
PBS Tween 0.1% 
Sodium azide 
 
Tris-Base                                1210 g 
0.5 M EDTA (pH 8.0)              500 ml 
Acetic acid                           285.5 ml 
 
Tris-HCl (pH 8.5)                  100 mM 
EDTA                                        5 mM 
NaCl                                     200 mM 
SDS                                  0.2% (w/v) 
0.01mg Proteinase K (1mg/ml in 50 
mM Tris, pH 8.0) per 200 µl lysis 
buffer was added prior to use. 
 
Tris-HCl (pH 8.0)                    10 mM 
EDTA (pH 8.0)                          1 mM 
TEX Protease K buffer, pH 8.0 
 
 
Tris-base                                50 mM 
EDTA                                       1 mM 
Triton X-100                      0.5% (v/v) 
Tris-Glycine electrophoresis 
 
 
 
Tris-Base                               25 mM 
Glycine                                250 mM 
SDS                                 0.1% (w/v) 
SDS polyacrylamid gel 10% resolving gel (for 20ml) 
H2O                                        7.9 ml 
30% acrylamid mix                 6.7 ml 
1.5 M Tris (pH 8.8)                 5.0 ml 
10% (w/v) SDS                       0.2 ml 
10% (w/v) APS                       0.2 ml 
TEMED                               0.008 ml 
5% stacking gel (for 10ml) 
H2O                                        6,8 ml 
30% acrylamid mix                 1.7 ml 
1 M Tris (pH 6.8)                  1.25 ml 
10% (w/v) SDS                       0.1 ml 
10% (w/v) APS                       0.1 ml 
TEMED                                 0.01 ml 
Western blot Transfer Buffer  Tris-Base                               25 mM 
Glycine                                 192 mM 
Methanol                                    20% 
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2.2. Molecular biology 
2.2.1. Isolation of genomic DNA 	
Genotyping is a process to determine the genetic makeup of mice. For this, mouse tail 
biopsies were incubated overnight in lysis buffer (s. table 3) in a thermomixer 
(Eppendorf, Hamburg, Germany) at 56°C and 1100 rounds per minute (rpm). The 
genomic DNA was precipitated by adding 1 volume of isopropanol. After centrifugation, 
the DNA pellet was washed with 70% (v/v) ethanol, dried at room temperature (RT) for 
approximately 10 minutes (min) and subsequently resuspended in TE buffer (s. table 
3). 
 
2.2.2. PCR for genotyping 	
PCR was used to genotype mice using specific primer listed in table 4. PCR is a 
technique to amplify a piece of deoxyribonucleic acid (DNA)-fragment, generating 
million copies of this DNA sequence. To amplify this DNA sequence, a mixture 
containing amongst others water, MgCl2 and Taq was added to 2 µl of the DNA 
template that was amplified by using a thermal cycler. The first step was an 
initialization step that heated up the reaction to 95-98°C, which was held for 4 minutes, 
to activate the DNA polymerase followed by a denaturation step also around 95-98°C 
for 20-30 seconds. This step is required to melt the double stranded DNA template by 
disrupting the hydrogen bonds between complementary bases. After that an annealing 
step at 50-65°C (depending on the primers) was started for 20-40 seconds. This 
temperature allows the annealing of the primers, which are single stranded nucleic 
acids acting as a starting point for DNA synthesis, to the single-stranded DNA 
template. When stable hydrogen bonds between the primer and the DNA template 
were formed, the polymerase binds to the primer-DNA hybrid and started the DNA 
synthesis. Finally, an extension and elongation step was performed at 72-80°C 
(depends on the temperature optimum of the polymerase). At this step the DNA 
polymerase uses dNTPs that are complementary to the template and synthesizes a 
complementary DNA chain to the template DNA. To amplify the DNA template, the 
thermal cycler repeats the denaturation, annealing and extension/elongation step 35 
times. After that the final elongation step, which is usually performed at 70-74°C for 
around 4 minutes, was used to ensure that every single stranded DNA is elongated. 
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Table 4. Primer-sequences for genotyping PCRs and PCR-amplified fragment 
sizes 
Typing for Primer Sequence (5’- 3’) Band size 
Alfp-Cre TCC AGA TGG CAA ACA TAC GC Tg: 300 bp 
WT: no band GTG TAC GGT CAG TAA ATT GGA C 
Fadd floxed TCA CCG TTG CTC TTT GTC TAC WT: 208 bp 
FL: 280 bp 
DEL: 331 bp 
GTA ATC TCT GTA GGG AGC CCT 
CTA GCG CAT AGG ATG ATC AGA 
Ripk1 floxed CAT GGC TGC AAA CAC CTA AAC WT: 320 bp 
FL: 380 bp GTT ACA ACA TGC AAA TCA AC 
Ripk1 deleted GAGGAAGACATCACTGAAGA DEL: 230 bp 
 
 CAGAGGGCTGGATCTGGTGG 
Ripk1D138N/D138N TACCTTCTAACAAAGCTTTCC WT: 220 bp 
D138N: 180 bp AATGGAACCACAGCATTGGC 
CCCTCGAAGAGGTTCACTAG 
Tnfr1 floxed CAA GTG CTT GGG GTT CAG GG WT: 134 bp 
FL: 195 bp CGT CCT GGA GAA AGG GAA AG 
Tradd floxed GGC CAG ACA TCT CCA CCG TAG WT: 400 bp 
FL: 440 bp TTT GCC TTC AGC CTA AGT TCC 
R26ikk2casFL/sFL AAAGTCGCTCTGAGTTGTTATC WT: 570bp 
sFL: 450bp GATATGAAGTACTGGGCTCTT 
GCATCGCCTTCTATCGCCT 
 
Table 5. PCR-programes for genotyping PCRs 
Typing for PCR program Cycles 
Temperature Time 
 
 
Alfp-Cre 
94°C 3 min  
94°C 
60°C 
72°C 
30 sec 
30 sec 
30 min 
 
35 
72°C  10 min  
Fadd floxed 94°C 3 min  
94°C 
60°C 
72°C 
30 sec 
45 sec 
30 sec 
 
35 
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72°C 3 min  
Typing for PCR program Cycles 
Ripk1 floxed 94°C 2 min  
94°C 
58°C 
72°C 
30 sec 
30 sec 
30sec 
 
35 
72°C 5 min  
Ripk1D138N/D138N 94°C 2 min  
94°C 
60°C 
72°C 
30 sec 
30 sec 
30 sec 
 
40 
72°C 5 min  
Tnfr1 floxed 94°C 3 min  
94°C 
60°C 
72°C 
30 sec 
1 min 
2 min 
 
29 
72°C 5 min  
Tradd floxed 95°C 3 min  
95°C 
57°C 
72°C 
30 sec 
30 sec 
1.30 min 
 
35 
72°C 5 min  
R26ikk2casFL/sFL 94°C 3 min  
94°C 
56°C 
72°C 
30 sec 
30 sec 
30 sec 
35 
72°C 5 min  
 
2.2.3. Agarose gel electrophoresis 
 
Agarose gel electrophoresis is used to separate the DNA fragments according to their 
sizes. For this, products of the PCR reaction were analyzed using a 2% agarose gel 
containing 0.5 mg/ml ethidium bromide. 10 µl of the PCR product containing loading 
dye was loaded on to the gel and gels were run in 1xTAE buffer for 30 min at 120 mV. 
DNA was visualized using ultraviolet (UV) light and the size of the PCR product was 
compared to a standard DNA marker (Peqlab). 
 
2.2.4. Isolation of RNA 
 
RNA extraction from hepatocytes or liver tissues was performed using the Qiagen 
RNeasy kit following manufacturer’s guidelines. For tissue samples, livers were 
homogenized in 1ml Trizol reagent (Invitrogen). Samples were centrifuged for 10 min 
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at 13000 rpm to pellet cell debris. The supernatant was transferred into a new tube and 
in order to extract nucleic acids 200 µl chloroform per 1 ml Trizol was added. Samples 
were mixed vigorously for 15 sec and were centrifuged for 15 min at 13000 rpm to 
separate the aqueous and organic phase. The upper aqueous phase was mixed with 
an equal volume of 70% (v/v) ethanol. Samples were loaded on Qiagen RNeasy 
columns and centrifugation for 1min at 9000 rpm allows binding of nucleic acids to the 
filter of the column. Afterwards to digest genomic DNA RNase-free DNase diluted in 
RDD buffer (provided by the manufacturer) was added to the filter of the column for 20 
min. Filters of the columns were washed twice with 500 µl of washing buffer (provided 
by the manufacturer). RNA was eluted in nuclease free water by centrifugation for 1 
min at 13000 rpm. Finally, the concentration and purity of extracted RNA were 
measured by photometric analysis using a NanoDrop. 
2.2.5. cDNA synthesis 	
Synthesis of cDNA from extracted RNA was performed using the Superscript III kit 
(Invitrogen) according to manufacturer’s instructions. For 10 µl final reaction volume, 
1µg RNA was added to 1 µl of 50 ng/µL random hexamer primers and 1 µl of 10 mM 
dNTPs. The reaction mixture was first incubated at 65°C for 5 min to allow primer 
annealing and subsequently cooled down on ice for 1 min. Meanwhile, 10 µl cDNA 
reaction mix containing 2 µl 10x RT-reaction buffer, 4 µl 25 mM MgCl2, 2 µl 0.1 M 
DTT, 1µl RNase OUT (40 U/µl) and 1 µl of SuperScript III polymerase (200 U/µL) were 
prepared and added to the samples. Reverse transcription was performed for 10 min at 
25°C, 50 min at 50°C for cDNA synthesis and heat-inactivation was performed for 5 
min at 85°C in a PCR cycler. To digest the remaining RNA 1 µl RNaseH was added to 
the reaction and the samples were incubated for 20 min at 37°C. The cDNA reaction 
mix was diluted 10-fold in nuclease-free water and 2 µl of cDNA was used for an actin-
PCR, to check successful cDNA synthesis, and for quantitative real time-PCR (qRT-
PCR). 
 
2.2.6. qRT-PCR 	
Gene expression was quantified by performing probe-based Taqman qRT-PCR. qRT–
PCR was performed with TaqMan probes (Table 6) in duplicates for each sample (Life 
Technologies) with TATA-box-binding protein (Tbp) as reference gene. qRT-PCR was 
performed in a final volume of 10 µl, consisting of 2 µl cDNA, 5 µl Mastermix (Applied 
Biosystems), 0.5 µl primer-probe mix (Applied Biosystems) and 2.5 µl nuclease-free 
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water. All reactions were carried out in 384-well plates. Relative expression of gene 
transcripts was analyzed by using the 2-ΔCt method.  
Table 6. Taqman probes used for qRT-PCR 
Gene Taqman probe 
A20 Mm00437121_m1 
Bax Mm00432051_m1 
Birc2 Mm00431811_m1 
Birc3 Mm00431800_m1 
Bcl-xl Mm00437783_m1 
cflip Mm01255580_m1 
Fas Mm00433237_m1 
FasL Mm00438864_m1 
Iκbα Mm00477798_m1 
Il-1b Mm00434228_m1 
Il-6 Mm00446190_m1 
Il-10 Mm00439616_m1 
Il-18 Mm00434225_m1 
Il-27 Mm00461162_m1 
Noxa Mm00451763_m1 
p53 Mm01731290_g1 
p21 Mm00432448_m1 
Puma Mm00519268_m1 
Tbp Mm00446973_m1 
Tnf Mm00443258_m1 
Tnfr1 Mm01182929_m1 
Trail Mm01283606_m1 
Trailr Mm00457866_m1 
Xiap Mm00776505_m1 
 
2.2.7. Multiplex assay  
(Assay was performed in collaboration with the Papadopoulos lab, Cologne) 	
The expression of TNF was measured using a bead-based multiplex immunoassay. 50 
µl of serum from Ripk1FL/FL and RIPK1LPC-KO mice were analyzed using the Bio-Rad kit 
(Bio-Rad Laboratories, Hercules, CA, USA) in a multiplex analyzer (Bio-plex200, Bio-
Rad Laboratories, Hercules, CA, USA) according to the manufacturer’s instructions. 
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The concentration was calculated from the standard curve and presented as pg/ml of 
serum. 
2.3. Cellular biology 
2.3.1. Haematoxylin and Eosin staining of liver tissue sections 	
Architecture and histology were determined using 5-µm-thick paraffin-embedded liver 
sections stained with haematoxylin and eosin (H&E). To stain with haematoxylin and 
eosin paraffin sections were de-paraffinized by incubating for 20 min in xylol followed 
by rehydration in ethanol-solutions. Thereafter, sections were incubated for 3 min in 
heamatoxylin solution, differentiated in tap water for 15 min and were subsequently 
incubated for 1 min in Eosin staining solution. Afterwards sections were dehydrated 
and fixated using xylol. Slides were finally mounted with Entellan. 
 
2.3.2. Immunhistochemistry 
 
Paraffin sections were rehydrated and heat-induced antigen retrieval was performed in 
citrate, TRIS buffer, pH 6 (Table 3). Sections were incubated with primary antibodies 
listed in table 7. Biotinylated secondary antibodies were purchased from Perkin Elmer 
and Dako. Stainings were visualized with ABC Kit Vectastain Elite (Vector 
Laboratories) and DAB substrate (DAKO and Vector Laboratories). Incubation times 
with DAB substrate were equal for all samples. 
 
      Table 7. Primary antibodies used for IHC in this study 
Antibodies Company Cat. No. 
anti-B220 home made clone RA3 6B2 
anti-CD3 Abcam Ab 5690 
anti-cleaved Caspase-3 Cell Signaling 9661 
anti-cleaved Caspase-8 Cell Signaling 8592 
anti-cleaved Caspase-9 Cell Signaling 9509 
anit-Ki-67 Dako M724901 
α-SMA Sigma Aldrich A2547 
anti-F4/80 AbD Serotec clone A3-1 
anti-γH2AX Millipore 05-636 
anti-p53 Leica NCL-p53-CM5p 
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2.3.2.1. Quantification of positively stained cells  
 
IHC quantification was performed on 5-10 randomly selected fields (10x magnification) 
per liver section. Liver sections from 3-7 mice per genotype per timepoint (after LPS or 
DEN) were analyzed. Quantifications of cleaved Caspase-3+, Caspase-8+ and 
Caspase-9+ cells were performed manually. γH2AX+ cells were quantified using 
Image J software (Version 1.48;http://rsbweb.nih.gov/ij/) by applying the appropriate 
pixel threshold equally on all selected images. Graphs are indicating the average 
number of γH2AX+ cells of 5 randomly selected fields per mouse. 
2.4. Biochemistry 
2.4.1. Preparation of protein extracts 
Liver tissues of mice were collected and snap frozen at −80 °C until processing. 
Tissues were homogenized using Precellys and homogenized lysates or hepatocytes 
were lysed in protein lysis buffer supplemented with protease and phosphatase 
inhibitor tablets (Table 3). Protein concentration was assessed using the Pierce dye-
binding method kit (Bio-rad).  
 
2.4.2. Subcellular fractionation 	
Primary hepatocytes were treated with 20ng/ml murine TNF for 30,60,120, 240 min or 
left untreated. Cells were directly lysed in hypotonic buffer (Table 3) for 10 min on ice 
followed by centrifugation for 5 min, 2300g at 4°C. The supernatants were collected as 
cytoplasmic extracts. The pellets were washed twice with hypotonic buffer and lysed in 
high salt nuclear lysis buffer including phosphatase inhibitors (Roche) and complete 
protease inhibitors (Roche) (Table 3) for 30 min on ice. Cell lysates were centrifuged 
for 10 min at 16000 g at 4°C, and the supernatants were collected as nuclear extracts. 
 
2.4.3. Western blot analysis 
 
Protein lysates (50µg Protein/20µl) were separated on SDS-PAGE and transferred to 
PVDF membranes (IPVH00010, Millipore). Membranes were blocked with 5% 
milk/0.1% PBST and were probed with primary antibodies against the proteins 
indicated in table 8 for 16h at 4°C. Membranes were washed thrice with 0.1% PBST 
and were incubated with a horseradish peroxidase conjugated secondary antibody 
indicated in table 9 for 1h at RT. Proteins were detected with enhanced 
chemiluminescent detection substrate (GE Healthcare and Thermo Scientific). 
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Table 8. Primary antibodies and conditions used for immunoblot analysis  
Antibodies Company Cat. No. Source Dilution 
β-Actin Santa Cruz I19 Goat 1:1000 
cFLIP Alexis ADI-AAP-440-E Rabbit 1:1000 
cIAP1 Enzo ALX-803-335-C100 Rat 1:1000 
Cleaved Caspase-3 Cell Signaling 9661 Rabbit 1:1000 
PARP1 Cell Signaling 9542 Rabbit 1:1000 
p-ERK Cell Signaling 9101 Rabbit 1:1000 
ERK Cell Signaling 9102 Rabbit 1:1000 
FADD Upstate 05-486 Rabbit 1:1000 
p-IκBα Cell Signaling 9246 Mouse 1:1000 
IκBα Santa Cruz Sc-371 Rabbit 1:1000 
p-JNK Cell Signaling 9251 Rabbit 1:1000 
JNK Cell Signaling 9252 Rabbit 1:1000 
Lamin A/C Santa Cruz Sc-6215 Goat 1:1000 
RIPK1 BD Biosciences 610459 Mouse 1:1000 
RelA Santa Cruz Sc-372 Rabbit 1:1000 
p-p38 Cell Signaling 9211 Rabbit 1:1000 
p38 Cell Signaling 9212 Rabbit 1:1000 
p53 Cell Signaling 2524 Mouse 1:1000 
TNFR1 Cell Signaling 13377 Rabbit 1:1000 
TRADD Santa Cruz sc-7868 Rabbit 1:1000 
TRAF2 Santa Cruz Sc-876 Rabbit 1:1000 
 
Table 9. Secondary antibodies and conditions used for immunoblot analysis  
Antibodies Company Cat. No. Source Dilution 
Rabbit IgG-HRP GE healthcare NA934V Goat 1:5000 
Mouse IgG-HRP GE healthcare NA9310V Sheep 1:5000 
Goat IgG HRP Jackson Lab 705-035-003 donkey 1:10000 
Rat IgG-HRP Jackson Lab  112-035-003 Goat 1:10000 
2.5. Mouse experiments 
2.5.1. Animal care 	
All animal procedures and experiments were performed in compliance with protocols 
and licenses approved by local government authorities (Bezirksregierung Köln) and 
were performed according to the National Institutes of Health guidelines. All mice were 
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housed with 3-4 animals per cage at 22-24°C and at regular 12 hours light/dark cycle 
with the light on at 6 am. Unless otherwise stated, animals were allowed ad libitum 
access to regular chow diet (Teklad Global Rodent 2018, Harlan) and acidified drinking 
water. For obesity-induced DEN-induced HCC experiments animals were allowed ad 
libitum access to either normal chow diet (NCD) (ssniff EF acc. D12450 (l) mod.) 
containing 13kJ% fat or high-fat diet (HFD) (ssniff EF acc D12492 (l) mod.) containing 
60kJ% fat and acidified drinking water. 
For breeding, male and female mice were placed together into one cage at a minimum 
age of 8 weeks. Litters were marked with ear tags at 2 weeks of age and tail biopsies 
were taken for genotyping. At 3 weeks of age litters were weaned. 
Animals requiring medical attention after LPS, LPS/D-GalN or DEN injection were 
receiving appropriate care and were excluded from experiments described. No other 
exclusion criteria existed. 
 
2.5.2. Causes recombination (Cre)/LoxP conditional gene targeting 
 
The Cre/LoxP mediated recombination of conditional genes allows cell type-specific 
deletion of genes of interest early during embryonic development enabling cell type-
specific analysis of gene functions. To generate a conditional knockout allele, two 
LoxP sites which are specific 34 bp DNA sequences need to be inserted in the same 
orientation to flank the gene locus or exon of interest (Rajewsky et al. 1996; Sauer 
1988).  The 34bp LoxP sites consist of a 8bp spacer that is flanked by two 13bp 
inverted palindromes (Figure 13A). The spacer region is the only factor that contributes 
to the orientation of the LoxP sites. LoxP orientation is important in determine the type 
of recombination such as intra-molecular inversion or excision. Co-alignment of two 
loxP sites in the same molecule preferably induces excision of the gene of interest and 
circulation of the excised DNA (Figure 13B). Cre-recombinase also catalyzes the 
reverse reaction namely the (re-)integration of DNA into a single loxP. Nevertheless, 
integration is inefficient due to the fact that reinserted DNA is flanked by two loxP sites 
favoring re-excision (Araki et al. 1997). In addition to DNA excision, Cre-recombinase 
can induce DNA inversion in presence of inverted loxP sites (Figure 13C). 
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Figure 13. Cre/LoxP-mediated conditional gene targeting  
(A) The 34bp loxP site is the recognition site of Cre recombinases consisting of an asymmetric 
8bp sequence which is flanked by two sets of 13bp palindromic sequences. (B-C) The 
orientation of the loxP sites is of high importance for the type of recombination. Therefore, loxP 
sites in the same direction favors the excision and the circulation of the exon of interest while 
inverted loxP site induces inversion of the exon of interest. 
 
An allele carrying loxP sites is referred to as ‚floxed’ (FL) and consequently, mice 
carrying an allele with loxP sites are named floxed mice. In order to delete a loxP site 
flanked gene/exon of interest, floxed mice are crossed to mice expressing a 
bacteriophage P1-derived Cre recombinase under the control of a tissue-specific 
promoter. Only in Cre-expressing cells, loxP sites are recognized and recombined by 
Cre recombinase resulting in excision of the floxed gene fragment and consequently 
inactivation of the gene of interest. 
 
2.5.3. Generation of mice 	
Mice with LPC-specific deletion of RIPK1 were generated by crossing Ripk1FL/FL mice 
with Alfp-Cre transgenic mice (Kellendonk et al. 2000). Ripk1FL/FL mice were generated 
as previously described in (Dannappel et al. 2014). RIPK1LPC-KO mice were crossed to 
FaddFL/FL	 (Mc Guire et al. 2010), R26ikk2casFL/sFL	 (Sasaki et al. 2006), Ripk1D138N/D138N	
(Polykratis et al. 2014), Tnfr1FL/FL	 (Van Hauwermeiren et al. 2013) or TraddFL/FL	
(Ermolaeva et al. 2008) mice to generate double deficient mice. For all experiments 
littermates not carrying the Alfp-Cre transgene were used as control mice. 
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2.5.4. Serum levels of alanine (ALT), aspartate amino transferase (AST) and Low-
density-lipoprotein-cholesterol (LDL-C) 	
Blood was collected from the caval vein during sacrifice and was spun down at 
10000rpm for 15 min to collect the sera. Serum ALT, AST and LDL-C levels were 
measured in the sera of mice using standard assays in a Roche-Cobas C111 
biochemical analyzer. 
 
2.5.5. Intraperitoneal injection (i.p.) of LPS and D-GalN 	
Mice were injected i.p. at 9 weeks of age with LPS 5µg/g BW LPS (Sigma Aldrich). 
Mice were sacrificed 5.5h after LPS injection using CO2 or their survival was 
monitored. In cases of combined LPS/D-GalN injection, 1mg/g BW D-GalN was 
injected 1h prior to LPS injection. 
 
2.5.6. Isolation of hepatocytes 	
Primary hepatocytes were isolated from livers of 5-week-old mice by perfusing through 
the vena cava with EBSS supplemented with 100mM EGTA followed by a collagenase 
solution, containing EBSS, 15mg Collagenase type 2 and 2mg trypsin inhibitor, at 
37°C. Afterwards, the liver was gently scraped in DMEM medium supplemented with 
1% FCS and filtered through a 70 µm nylon filter. The flow-through was mixed with 1 
volume of a 90% Percoll/HBSS solution and spun at 450g for 7 min. Hepatocytes 
settled at the bottom were washed twice with DMEM 1% FCS medium and were plated 
on collagen-coated plates. 4h after plating medium was changed. 
 
2.5.7. Cell survival assay (Lactate Dehydrogenase assay) 	
Primary hepatocyte death in vitro was determined using a lactate dehydrogenase 
(LDH) release-based cytotoxicity assay (Promega) after incubating primary 
hepatocytes for 16h in absence or presence of 1µg/ml cycloheximide, 20 µM zVAD-
fmk (Enzo LifeSciences), 10µg/ml anti-TNF (Etanercept) or 50ng/ml anti-FasL 
(106808, Biozol). LDH ratio (released/total LDH) was determined on cell sample 
supernatants using CytoTox 96 cytotoxicity assay (Promega) according to the 
manufacturer’s protocol. The experiments were performed in triplicates (n=6 per 
genotype). 
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2.5.8. Intraperitoneal injection of DEN 
2.5.8.1. DEN-induced carcinogenesis 	
Mice were injected i.p. at 2-weeks of age with DEN 25 mg/kg BW (Sigma Aldrich) and 
were sacrificed either after 3h, 6h, 12h, 24h and 48h upon DEN injection using CO2 or 
were maintained until the age of 32 or 36 weeks fed with either regular chow diet or 
HFD. For all experiments only male mice were used. 
 
2.5.8.2. Histopathological evaluation of HCC development in DEN-injected 32- 
and 36-week-old mice (Evaluation was performed by Dr. Beate Straub) 
 
H&E stained liver sections from mice were assessed for the presence and the stage of 
HCC development in the following ascending order of severity: No pathology, clear cell 
foci, small and large cell changes (anisokaryosis), dysplastic foci, dysplastic nodules 
and early, small or well-differentiated HCC. Each liver sample was placed only based 
on the most advanced stages, despite the fact that also less advanced stages were 
observed in these liver samples. In the corresponding graphs, each bar represents the 
% of livers per genotype in which the indicated stage was identified as the most 
advanced disease stage. 
 
2.5.8.3. acute dose of DEN 	
6-week-old mice were injected i.p. with DEN 100 mg/kg BW and were sacrificed after 
3, 6, 24 and 48h after DEN injection using CO2. For all experiments only male mice 
were used. 
 
2.5.8.4. Glucose tolerance test 	
Glucose-tolerance tests (GTT) were performed on animals fasted for 16h overnight. 
Mice were injected i.p. with 10µl/g BW glucose and blood glucose levels were 
measured 15, 30, 60 and 120min after glucose injection. GTT was performed with 12 
week-old animals fed ad libitum with either NCD or HFD and was repeated at 24 
weeks of age. 
2.6. Computer analysis 
2.6.1. Software 	
Leica microscopy Software Leica application suite, Prism Graph, Microsoft Office, 
EndnoteX7
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2.6.2. Statistical analysis 	
Data shown in graphs represent the mean, except bodyweight curves and glucose 
levels that show the mean ± s.e.m., as indicated in the figure legends. To determine 
the group size necessary for adequate statistical power, power analysis was performed 
using preliminary data sets. Statistical significance for two groups of nonparametric 
data was assessed by Mann–Whitney. For multiple group comparison, one-way Anova 
test was performed with a Post-hoc Tukey test for pairwise comparison of subgroups 
(equal variance assumed). Χ2-test was performed for the distribution of tumors of two 
groups. When two independent variables were compared, the Two-way Anova was 
performed. To compare the survival curves of mice the Mantel-Cox test was used. 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.005. Statistical analysis was performed with Prism 
version 6.0 (GraphPad). 
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3. Results 
3.1. RIPK1 is not involved in normal liver homeostasis and development 
3.1.1. Generation of mice with LPC-specific RIPK1 deficiency 
 
To investigate the role of RIPK1 in LPCs, mice with specific deletion of RIPK1 in 
hepatocytes and biliary cells were generated. Therefore, mice carrying loxP-flanked 
RIPK1 alleles (Ripk1FL/FL) (Dannappel et al. 2014) were crossed with mice expressing 
Cre recombinase under the control of an ALFP promoter. In these mice, efficient Cre 
recombination results in deficiency of RIPK1 specifically in hepatocytes and biliary 
epithelial cells but not in endothelial or KCs (hereafter referred to as RIPK1LPC-KO mice). 
Successful deletion of RIPK1 was confirmed in isolated hepatocytes and in whole liver 
tissue lysates by immunoblot analysis (Figure 14).  
 
 
 
 
 
 
Figure 14. Conditional deletion of RIPK1 in LPCs 
Immunoblot analysis for RIPK1 in whole protein extracts from primary hepatocytes (A) and liver 
tissues (B) from Ripk1FL/FL and RIPK1LPC-KO mice. Actin was used as loading control. 
 
3.1.2. LPC-specific deficiency of RIPK1 does not result in spontaneous liver 
pathology 
 
RIPK1LPC-KO mice were born at the expected Mendelian frequency with similar 
bodyweight and size compared to their floxed littermates at least up to the age of 1 
year (Figure 15A). Measurement of alanine and aspartic acid aminotransferases (ALT 
and AST respectively), which are released into the bloodstream upon hepatocyte 
damage, in the sera of RIPK1LPC-KO mice showed only minor elevation of ALT and AST 
which did not considerably affect liver homeostasis (Figure 15B). Macroscopic 
evaluation of the liver and histological analysis revealed similar liver morphology 
between RIPK1LPC-KO mice and their floxed littermates even at 1 year of age (Figure 
15C). Although liver morphology was not affected by RIPK1 deficiency, focal 
accumulations of immune cells in H&E-stained liver sections of RIPK1LPC-KO mice were 
observed (Figure 15C). In these immune cell foci strong staining for Ki-67 and cleaved 
Caspase-3 (CC3) was detected indicative for high levels of immune cell proliferation 
and apoptosis respectively (Figure 15C). Immunohistological characterization of these 
B A 
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immune cell patches revealed the presence of macrophages, B- and T-cells judged by 
positive staining for F4/80, B220 and CD3 respectively (Figure 15D). Nevertheless, 
accumulation of immune cells in the liver of RIPK1LPC-KO mice did not result in 
considerable liver inflammation at least up to the age of 1 year indicated by similar Il1b 
and Tnf gene expression levels (Figure 15E).  
Despite increased Ki-67 and CC3 levels in immune cell patches, immunohistological 
analysis of the liver parenchyma revealed similar levels for Ki-67 and CC3 between 
RIPK1LPC-KO and their floxed littermates suggesting similar hepatocyte proliferation and 
apoptosis under steady state conditions (Figure 15C). Furthermore, livers of RIPK1LPC-
KO mice did not show signs of fibrosis as assessed by immunostaining for alpha-
smooth muscle actin (αSMA), a differentiation marker of smooth muscle cells and 
myofibroblasts (Figure 15C). Taken together, LPC-specific ablation of RIPK1 does not 
affect normal liver development and homeostasis. 
 
Figure 15. LPC-specific deficiency of RIPK1 did not affect normal liver homeostasis  
(A) Bodyweight and (B) ALT and AST levels of Ripk1FL/FL and RIPK1LPC-KO mice at 1 year of 
age. (C) Representative picture of the liver (Scale bar, 1cm) and of liver sections stained with 
hematoxylin and eosin and for Ki-67, CC3 and αSMA from Ripk1FL/FL and RIPK1LPC-KO mice 
(n=4 per genotype). Scale bar 100µm. (D) Representative liver sections of Ripk1FL/FL and 
RIPK1LPC-KO mice immunostained for B220, F4/80 and CD3 (n=4 per genotype). Scale bar 
100µm. Arrows indicate immune cell patches. (E) qRT-PCR analysis of Il1b and Tnf gene 
expression in livers from Ripk1FL/FL and RIPK1LPC-KO mice.	 Graphs show relative mRNA 
expression normalized to Tbp. 
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3.2. RIPK1 prevents LPS-induced liver injury by inhibiting TNF-induced 
hepatocyte apoptosis 
3.2.1. RIPK1LPC-KO mice are prone to LPS-induced liver injury  
 
To investigate the LPC-specific role of RIPK1 in LPS-induced liver injury, groups of 
Ripk1FL/FL and RIPK1LPC-KO mice were injected i.p. with a sublethal-dose of LPS (5 µg/g 
of BW LPS). In contrast to Ripk1FL/FL mice, LPC-specific loss of RIPK1 sensitized mice 
to LPS-induced liver injury resulting in death of all mice within 6h after LPS injection 
(Figure 16A). RIPK1LPC-KO mice showed strongly elevated ALT and AST levels 5.5h 
after LPS injection indicative of severe liver damage (Figure 16B). Immunostaining of 
liver sections with antibodies against CC3 (Figure 16C) and immunoblot analysis of 
liver protein lysates for CC3 and cleaved PARP1 (Figure 16D) revealed increased 
hepatocyte apoptosis in livers of LPS-injected RIPK1LPC-KO mice suggesting an anti-
apoptotic role for RIPK1 in hepatocytes in response to LPS. 
 
Figure 16. LPC-specific ablation of RIPK1 sensitized mice to LPS-induced liver injury 
Graphs depicting survival (A) and ALT and AST levels (B) of 9-week-old non-injected or LPS-
injected Ripk1FL/FL and RIPK1LPC-KO mice (***P<0.005 for A, **P < 0.01 for B). (C) 
Representative liver sections of Ripk1FL/FL and RIPK1LPC-KO mice immunostained for CC3 
untreated or 5.5h after LPS-injection (n=4-5 per genotype). Scale bar 100µm. (D) Immunoblot 
analysis for cleaved Caspase-3 and cleaved PARP-1 in liver lysates from Ripk1FL/FL and 
RIPK1LPC-KO mice. Actin was used as loading control. 
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Given the higher susceptibility of RIPK1LPC-KO mice to LPS-induced liver injury, the 
inflammatory level in the liver of RIPK1LPC-KO mice was assessed compared to 
Ripk1FL/FL mice. At 5.5h after LPS application RIPK1LPC-KO mice had slightly elevated 
gene expression levels of pro-inflammatory cytokines suggesting mild LPS-induced 
inflammation in these mice (Figure 17).  
 
Figure 17. LPS-injected RIPK1LPC-KO 
mice showed mildly elevated cytokine 
expression levels in the liver 
 qRT-PCR analysis of cytokine gene 
expression in nontreated and LPS-injected 
livers from Ripk1FL/FL and RIPK1LPC-KO 
mice.	 Graphs show relative mRNA 
expression normalized to Tbp. 
 
 
 
 
 
 
Measuring the level of TNF in the serum of RIPK1LPC-KO and Ripk1FL/FL mice at 1, 2 and 
8h after LPS injection revealed similar levels of TNF between both groups (Figure 18). 
This result suggests that the increased liver damage in LPS-injected RIPK1LPC-KO mice 
may not be due to increased TNF release in response to LPS but rather due to a 
higher sensitivity of RIPK1-deficient hepatocytes to TNF. 
 
Figure 18. LPS-treated Ripk1FL/FL and 
RIPK1LPC-KO mice showed similar serum 
TNF levels 
Graph depicting the serum TNF levels of 
LPS-treated Ripk1FL/FL (black, timepoint 0h, 
n= 4; timepoint 1h, 2h, 8h, n= 6) and 
RIPK1LPC-KO (red, timepoint 0h, 1h, 2h, n=6; 
timepoint 8h, n= 2) mice measured by 
multiplex cytokine assay (mean ± SEM). 	
3.2.2. RIPK1 scaffolding function protects mice from LPS- but RIPK1 kinase 
activity drives LPS/D-GalN induced liver injury 
 
To explore the kinase-dependent and kinase-independent functions of RIPK1 in 
response to LPS or LPS/D-GalN, knock-in mice expressing a catalytically inactive 
kinase domain introduced by an aminoacid exchange at position 138 from aspartic 
acid to asparagine (hereafter referred to as Ripk1D138N/D138N) were used (Polykratis et 
al. 2015). Ripk1FL/FL, RIPK1LPC-KO and Ripk1D138N/D138N mice were injected with LPS and 
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their survival was monitored for 72h. In contrast to RIPK1LPC-KO mice, Ripk1D138N/D138N 
mice were less prone to LPS-induced toxicity as 80% of Ripk1D138N/D138N mice survived 
for at least 72h while none of RIPK1LPC-KO mice survived longer than 6h suggesting that 
the kinase-independent scaffolding function of RIPK1 prevented liver damage in 
response to LPS (Figure 19A).  
In order to analyze the kinase-dependent functions of RIPK1 in cell death, the hepatic 
transcription inhibitor D-GalN was used in addition to LPS in order to sensitize 
hepatocytes to death. 50% of Ripk1D138N/D138N mice survived in response to LPS/D-
GalN injection opposed to none of the WT littermates emphasizing a death-inducing 
function of RIPK1 kinase activity (Figure 19B).  
 
Figure 19. Ripk1D138N/D138N mice 
were protected to LPS- and 
LPS/D-GalN mediated liver 
injury 
Kaplain-Meier survival curve of 
Ripk1FL/FL, RIPK1LPC-KO and 
Ripk1D138N/D138N mice injected 
with LPS (A) and LPS/D-GalN 
(B) (***P<0.005, *P<0.05). 
 
 
 
 
 
 
3.2.3. RIPK1 prevents TNF-dependent and -independent apoptotic death of 
primary hepatocytes  
 
To elucidate the mechanism of RIPK1 in preventing LPS-induced liver damage primary 
hepatocytes from RIPK1LPC-KO and Ripk1FL/FL mice were isolated. Although in vivo 
RIPK1 deletion did not affect basal liver homeostasis, RIPK1-deficient primary 
hepatocytes died spontaneously in culture within 24h after isolation (Figure 20). 
Spontaneous hepatocyte death of RIPK1-deficient hepatocytes was prevented by the 
pan-Caspase inhibitor zVAD-fmk suggesting that RIPK1-deficient hepatocytes died 
predominantly by apoptosis (Figure 20). Moreover, the addition of a TNF inhibitor 
reduced considerably spontaneous apoptosis of RIPK1-deficient hepatocytes, while 
the addition of a neutralizing antibody against FasL had no measurable effect even 
when given together with a TNF inhibitor. Together these results suggest that RIPK1-
deficient hepatocytes undergo TNF-dependent but also TNF-independent apoptosis 
(Figure 20).  
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Figure 20. Loss of RIPK1 sensitized 
hepatocytes to TNF-dependent and –
independent apoptosis  
Graph depicting survival of Ripk1FL/FL and 
RIPK1-deficient hepatocytes 24h after 
isolation. Hepatocytes were cultured for 
24h in the presence or absence of a TNF 
inhibitor, a neutralizing antibody for FasL 
or zVAD-fmk (***P< 0.001, **P< 0.01, ns= 
not significant). 
 
 
 
 
3.2.4. RIPK1 deficiency impairs TNF-induced NF-κB activation in primary 
hepatocytes 
 
Since impaired NF-κB activation was reported to sensitize cells to death (Kondylis et 
al. 2015), NF-κB activation in RIPK1-deficient primary hepatocytes was assessed in 
response to TNF. To prevent spontaneous hepatocyte apoptosis, hepatocytes were 
cultured in presence of zVAD-fmk allowing the analysis of TNF-induced NF-κB 
signaling. To confirm that zVAD-fmk did not affect TNF signaling, Ripk1FL/FL primary 
hepatocytes were cultured in presence or absence of zVAD-fmk and the response to 
TNF was compared. In presence of zVAD-fmk, NF-κB activation remained unaffected 
in response to TNF in Ripk1FL/FL primary hepatocytes indicated by similar IκBα 
degradation by immunoblot analysis (Figure 21A). In addition, NF-κB target gene 
expression was similar in Ripk1FL/FL hepatocytes in presence or absence of zVAD-fmk 
(Figure 21B). 
 
Figure 21. zVAD-fmk stimulation of 
hepatocytes did not affect TNF-induced 
NF-κB activation 
(A) Immunoblot of Ripk1FL/FL hepatocytes 
for IκBα after TNF stimulation for the 
depicted timeperiods in absence or 
presence of zVAD-fmk. 
Actin was used as 
loading control.  
(B) Gene expression levels of Tnfaip3 and 
Iκbα in response to TNF in absence or 
presence of zVAD-fmk. Graphs show 
relative mRNA expression normalized to 
Tbp. 
 
To elucidate whether ablation of RIPK1 affects NF-κB activation, Ripk1FL/FL and RIPK1-
deficient primary hepatocytes were isolated and cultured with zVAD-fmk over night 
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before stimulation with TNF for 5, 15, 30, 60 and 120 min. TNF stimulation caused 
rapid phosphorylation and degradation of IκBα (Figure 22A) and robust nuclear 
accumulation of the NF-κB subunit RelA in Ripk1FL/FL hepatocytes (Figure 22B) while 
RIPK1-deficient primary hepatocytes did not show RelA nuclear translocation, 
phosphorylation and degradation of IκBα. Consistently, gene expression levels of NF-
κB target genes, Tnfaip3, Birc3, Nfkbia and Tnf, were significantly reduced in absence 
of RIPK1 (Figure 22C). Therefore, deficiency of RIPK1 strongly impaired NF-κB 
activation in primary hepatocytes in vitro. 
Figure 22. Loss of RIPK1 in hepatocytes impaired TNF-induced NF-κB activation 
(A) Immunoblot analysis of p-IκBα and IκBα in total protein lysates of zVAD-fmk treated 
Ripk1FL/FL and RIPK1-deficient primary hepatocytes stimulated with TNF for the depicted time 
periods. (B) Immunoblot analysis for RelA in cytoplasmic and nuclear extracts from zVAD-fmk 
stimulated Ripk1FL/FL or RIPK1-deficient hepatocytes. Actin and Lamin A/C were used as 
loading controls. (C) qRT-PCR analysis of NF-κB target gene expression in TNF stimulated 
Ripk1FL/FL and RIPK1-deficient primary hepatocytes (mean± SEM, ***P<0.005).	 Graphs show 
relative mRNA expression normalized to Tbp. 	
3.2.5. LPC-specific deficiency of RIPK1 sensitizes hepatocytes to FADD-
dependent apoptosis in response to LPS 	
To investigate whether RIPK1 deficiency sensitizes hepatocytes to FADD-dependent 
apoptosis in response to LPS, RIPK1LPC-KO mice were crossed to FaddFL/FL mice to 
generate RIPK1LPC-KO mice that additionally lacked FADD in LPCs. Efficient deletion of 
FADD in RIPK1LPC-KO livers was confirmed by immunoblot analysis (Figure 23A). 
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LPC-specific ablation of FADD fully prevented the early death of RIPK1LPC-KO mice 
upon injection with LPS (Figure 23B). Moreover, deficiency of FADD significantly 
reduced serum ALT and AST levels (Figure 23C) and apoptotic death indicated by 
immunoblot analysis of liver protein extracts for CC3 (Figure 23D) and IHC for CC3 
(Figure 23E) in RIPK1LPC-KO FADDLPC-KO mice to the same extent like in LPS-injected 
Ripk1FL/FL mice. Taken together, these results demonstrate that the high liver damage 
in RIPK1LPC-KO mice is triggered by LPS-induced FADD-dependent apoptosis. 
 
Figure 23. LPC-specific ablation of FADD prevented LPS-induced death of RIPK1LPC-KO 
mice  
(A) Immunoblot analysis for RIPK1 and FADD in whole protein extracts from liver tissues of 
mice with depicted genotypes. Actin was used as loading control. (B) Kaplan-Meier survival 
curve for mice with indicated genotypes injected with LPS (***P< 0.005). (C) Graphs depicting 
serum ALT and AST levels in non-injected and LPS-injected mice of indicated genotypes (*P< 
0.05). (D) Immunoblot analysis for CC3 in total liver protein lysates of non-injected and LPS-
injected mice with depicted genotypes. Actin was used as loading control. (E) Representative 
liver sections of mice of indicated genotypes immunostained for CC3 untreated or 5.5h after 
LPS-injection (n=4 per genotype). Same RIPK1LPC-KO control was used in figure 16C. Scale bar 
100µm.  
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3.2.6. LPC-specific deficiency of RIPK1 sensitizes hepatocytes to TNFR1-
dependent apoptosis in response to LPS 
 
TNFR1 signaling is implicated in LPS-induced liver injury (Filliol et al. 2017) and 
moreover, was shown in this study in vitro to be involved in spontaneous death of 
RIPK1-deficient hepatocytes. Therefore, to test the significance of TNF-induced 
apoptosis in LPS-mediated death of RIPK1LPC-KO mice, mice were crossed to Tnfr1FL/FL 
mice to generate mice that lacked RIPK1 and TNFR1 in LPCs. Efficient deletion of 
TNFR1 in RIPK1LPC-KO livers was confirmed by immunoblot analysis (Figure 24A). 
Consistent with LPC-specific deletion of FADD, LPC-specific deficiency of TNFR1 fully 
protected RIPK1LPC-KO mice against LPS-mediated liver injury (Figure 24B). LPC-
specific deficiency of TNFR1 significantly reduced liver injury indicated by serum ALT 
and AST levels (Figure 24C) and apoptotic death indicated by immunoblot analysis of 
liver protein extracts for CC3 (Figure 24D) and IHC for CC3 (Figure 24E) in RIPK1LPC-
KO TNFR1LPC-KO mice to the same extent like in LPS-injected Ripk1FL/FL mice. In 
summary, these results show that LPS-induced FADD-mediated apoptosis in 
RIPK1LPC-KO mice is dependent on TNFR1 signaling.  
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Figure 24. LPC-specific ablation of TNFR1 prevented LPS-induced death of RIPK1LPC-KO 
mice  
(A) Immunoblot analysis for RIPK1 and TNFR1 in whole protein extracts from liver tissues of 
mice with depicted genotypes. Actin was used as loading control. (Same blot was used to 
analyze FADD expression shown in Figure 23A) (B) Kaplan-Meier survival curve for mice with 
indicated genotypes injected with LPS (***P< 0.005). (C) Graphs depicting serum ALT and AST 
levels in non-injected and LPS-injected mice of indicated genotypes (*P< 0.05). (D) Immunoblot 
analysis for CC3 in total liver protein lysates of non-injected and LPS-injected mice of indicated 
genotypes. Actin was used as loading control. Same protein lysates from untreated Ripk1FL/FL 
and RIPK1LPC-KO mice were used already for the immunoblot indicated in Figure 23D. (E) 
Representative liver sections mice of indicated genotypes immunostained for CC3 untreated or 
5.5h after LPS-injection (n=4 per genotype). Same RIPK1LPC-KO control was used in figure 16C. 
Scale bar 100µm.  	
3.2.7. LPC-specific deficiency of RIPK1 sensitizes hepatocytes to TNF-induced 
TRADD/FADD-dependent apoptosis in response to LPS 
 
In absence of RIPK1, cell death in response to TNFR1 is mediated by TRADD-
dependent complex-IIa, which consequently recruits FADD and Caspase-8 to execute 
apoptosis (Pasparakis and Vandenabeele 2015). To test the importance of TRADD in 
triggering FADD-dependent apoptosis in response to LPS in RIPK1LPC-KO mice, 
RIPK1LPC-KO mice were crossed to TraddFL/FL mice to generate RIPK1LPC-KO TRADDLPC-
KO mice. Efficient deletion of TRADD in RIPK1LPC-KO livers was confirmed by 
immunoblot analysis (Figure 25A). Indeed, LPC-specific ablation of TRADD fully 
prevented early death of RIPK1LPC-KO mice upon injection with LPS (Figure 25B). 
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Moreover, deficiency of TRADD significantly reduced serum ALT and AST levels 
(Figure 25C) and CC3 levels indicated by immunoblot (Figure 25D) and IHC analysis 
(Figure 25E) in RIPK1LPC-KO TRADDLPC-KO mice to the same extent like in Ripk1FL/FL 
mice. Taken together, LPS induces TNFR1-dependent TRADD/FADD-mediated 
apoptosis in RIPK1LPC-KO mice. 
 
Figure 25. LPC-specific ablation of TRADD prevented LPS-induced death of RIPK1LPC-KO 
mice  
(A) Immunoblot analysis for TRADD and RIPK1 in whole protein extracts from liver tissues of 
mice with depicted genotypes. Actin was used as loading control. (B) Kaplan-Meier survival 
curve for mice with indicated genotypes injected with LPS (***P< 0.005). (C) Graphs depicting 
serum ALT and AST levels in non-injected and LPS-injected mice of indicated genotypes (*P< 
0.05). (D) Immunoblot analysis for CC3 in total liver protein lysates of non-injected and LPS-
injected mice of indicated genotypes. Actin was used as loading control. Same protein lysates 
from untreated Ripk1FL/FL and RIPK1LPC-KO mice were used already for the immunoblot indicated 
in Figure 23/24D. (E) Representative liver sections of mice of depicted genotypes 
immunostained for CC3 untreated or 5.5h after LPS-injection (n=4 per genotype). Same 
RIPK1LPC-KO control was used in figure 16C. Scale bar 100µm.  	
3.2.8. LPC-specific deficiency of TNFR1, FADD or TRADD protects RIPK1-
deficient primary hepatocytes from spontaneous death in vitro 	
In agreement with the in vivo data indicated in figure 23 and 25, the lack of TRADD or 
FADD fully prevented spontaneous apoptosis of RIPK1-deficient hepatocytes. Ablation 
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of TNFR1 considerably reduced spontaneous apoptosis to a similar extent as the effect 
induced by the TNF inhibitor, etanercept, shown in Figure 20 (Figure 26). Collectively, 
these results demonstrated an anti-apoptotic role of RIPK1 in primary hepatocytes by 
preventing TRADD and FADD-dependent hepatocyte apoptosis that is partially 
triggered by TNFR1-dependent signaling. 
Figure 26. LPC-specific ablation of 
TNFR1, FADD or TRADD reduced 
spontaneous hepatocyte death in 
vitro 
Graph depicting the % of survival of 
primary hepatocytes isolated from 
mice with depicted genotypes 
cultured for 24h (***P< 0.005, **P< 
0.01, *P< 0.05). 
 
3.2.9. LPC-specific deletion of RIPK1 does not sensitize to RIPK3-dependent 
necroptosis 
LPC-specific FADD or TRADD deficiency fully prevented spontaneous death of RIPK1-
deficient primary hepatocytes and hepatocyte death in LPS-injected RIPK1LPC-KO mice. 
These results suggest a pivotal role for apoptosis in mediating death of RIPK1-deficient 
hepatocytes whereas necroptosis seemed to be dispensable. To analyze the impact of 
necroptosis in primary hepatocyte death, cells were cultured in the presence of TNF, 
cycloheximide (CHX) and zVAD-fmk (Figure 27A). CHX is a potent translation inhibitor 
and is widely used in vitro to sensitize cells to death. Importantly, zVAD-fmk 
significantly prevented TNF/CHX-induced hepatocyte death of Ripk1FL/FL but also of 
RIPK1-deficient hepatocytes suggesting the dispensability of Caspase-independent 
cell death in primary hepatocytes. Furthermore, immunoblot analysis for RIPK3 protein 
levels, a key driver of necroptosis, was performed in whole liver lysates compared to 
whole epidermal skin lysates, in which necroptosis was convincingly shown before to 
be present (Dannappel et al. 2014) (Figure 27B). RIPK3 was expressed at very low 
levels in the liver under basal conditions but also 5.5h after LPS-injection compared to 
skin protein lysates reinforcing RIPK3-independent death of hepatocytes in RIPK1LPC-
KO mice. 
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Figure 27. Primary hepatocytes 
underwent RIPK3-independent 
death in vitro 
(A) Graph depicting survival of primary 
hepatocytes isolated from Ripk1FL/FL or 
RIPK1LPC-KO mice cultured for 24h in 
the presence or absence of TNF, CHX 
and zVAD-fmk (n=3). # indicates when 
all cells were dead. (*P< 0.05, **P< 
0.01, ***P< 0.005) (B) Immunoblot 
analysis for RIPK3 in liver lysates from 
Ripk1FL/FL and RIPK1LPC-KO mice. Actin 
was used as loading control. WT and 
Ripk3-/- mouse skin was used as 
controls.  
 
 
 
 
3.2.10. LPC-specific deficiency of RIPK1 does not affect the expression of pro-
survival proteins 
 
Our in vitro data in figure 22 showed that impaired NF-κB signaling might cause 
hepatocyte death emphasizing a RIPK1-dependent role in regulating cell survival. To 
analyze whether impaired complex-I-dependent signaling is involved in the higher 
susceptibility of RIPK1LPC-KO mice to LPS, 9-week old Ripk1FL/FL and RIPK1LPC-KO mice 
were sacrificed 5.5h upon LPS injection and gene expression of NF-κB target genes 
and the stabilization of pro-survival proteins were analyzed. Our analysis revealed no 
considerable differences in cflip, Birc2 and Birc3 gene expression levels between 
Ripk1FL/FL and RIPK1LPC-KO mice (Figure 28A). In addition, immunoblot analysis of 
cFLIP, cIAP1 and TRAF2 protein levels revealed no major differences between 
Ripk1FL/FL and RIPK1LPC-KO mice under untreated conditions and 5.5h after LPS 
injection (Figure 28B). Together these results suggest a complex-I independent role in 
the sensitivity of RIPK1LPC-KO mice to LPS-induced liver injury. 
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Figure 28. LPC-specific deficiency of RIPK1 did not affect gene expression and the 
stability of pro-survival proteins  
(A) qRT-PCR analysis of NF-κB target gene expression in non- or LPS-injected Ripk1FL/FL and 
RIPK1LPC-KO livers.	Graphs show relative mRNA expression normalized to Tbp. (B) Immunoblot 
analysis for cIAP1, TRAF2 and cFLIPL in total liver protein lysates of non- or LPS-injected 
Ripk1FL/FL and RIPK1LPC-KO mice. Actin was used as loading control. 
 
3.2.11. Constitutive LPC-specific expression of IKK2 protects RIPK1LPC-KO mice 
from LPS-induced death  
 
To further analyze the role of NF-κB signaling in LPS-injected RIPK1LPC-KO mice, mice 
expressing a constitutively active form of IKK2 in hepatocytes were used (R26ikk2FL/FL; 
Alfp-Cre tg/wt hereafter referred to as IKK2CaLPC). Constitutive LPC-specific 
expression of IKK2 protected 80% of RIPK1LPC-KO mice from LPS-induced death but did 
not fully prevent liver injury indicated by elevated serum ALT and AST levels in LPS-
injected RIPK1LPC-KO IKK2CaLPC mice (Figure 29A, B). However, on average serum 
ALT and AST levels were lower compared to RIPK1LPC-KO mice at 5.5h after LPS 
administration (Figure 29B). Unlike RIPK1LPC-KO mice, where the majority of mice died 
within 6h after LPS injection, approximately 80% of RIPK1LPC-KO IKK2CaLPC mice 
recovered from elevated liver damage within 48h resulting in similar serum ALT and 
AST levels compared to their floxed littermates (Figure 29B). Although stabilization of 
pro-survival proteins including TRAF2 and cIAP1 was not impaired in absence of 
RIPK1 (Figure 28), these data suggest that the lack of IKK2-dependent signaling might 
be involved in the early death of RIPK1LPC-KO mice in response to LPS. 
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Figure 29. LPC-specific expression of constitutive active IKK2 protected RIPK1LPC-KO 
mice from LPS-induced death  
(A) Kaplan-Meier survival curve for mice with indicated genotypes injected with LPS (***P< 
0.005).  (B) Graphs depicting serum ALT and AST levels in mice with indicated genotypes 5.5h, 
24h and 48h after LPS-injection (*P< 0.05). 
3.3. LPC-specific deficiency of RIPK1 reduces DEN-induced carcinogenesis by 
sensitizing hepatocytes to early apoptosis 
3.3.1. LPC-specific ablation of RIPK1 reduces DEN-induced tumor initiation and 
development 
 
Controlled regulation of cell death and survival is essential to prevent tumorigenesis. 
Since RIPK1 is an important regulator of cell death and survival in response to DR 
signaling, many studies addressed the role of RIPK1 in survival and growth of tumors 
using cancer cell lines or xenograft models. Especially in xenograft models, RIPK1 
deficiency was suggested to impair tumor growth emphasizing an important role of 
RIPK1 in tumorigenesis (Liu et al. 2015; Luan et al. 2015). 
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To elucidate the in vivo role of RIPK1 in carcinogen-induced liver tumorigenesis, an 
established model of DEN-induced carcinogenesis was employed. For this, groups of 
male RIPK1LPC-KO and Ripk1FL/FL mice were injected with 25 mg/kg BW DEN at 2 weeks 
of age. RIPK1LPC-KO mice showed similar bodyweight gain and liver to bodyweight ratio 
compared to their control littermates up to the age of 32 weeks (Figure 30A,G). 
Moreover, injection of DEN did not result in elevation of serum ALT and AST levels at 
32 weeks of age indicating that RIPK1 deficiency did not compromise major liver 
functions in response to DEN injection (Figure 30B). Strikingly, 100% of Ripk1FL/FL mice 
displayed tumors while only 37% of RIPK1LPC-KO mice had macroscopically visible 
tumors at the age of 32 weeks (Figure 30D). Macroscopic examination of tumors at the 
age of 32 weeks revealed a strong reduction in the number and size of tumors in 
RIPK1LPC-KO mice (Figure 30C-E). Histopathological analysis of liver sections revealed 
that about 40% of RIPK1LPC-KO mice did not show signs of liver tumorigenesis (Figure 
30F). In addition, those RIPK1LPC-KO mice bearing dysplastic changes in their livers 
generally showed less advanced tumors with about 5% of the mice showing well-
differentiated HCC and 20% small HCC (Figure 30F). On the contrary to RIPK1LPC-KO 
mice, Ripk1FL/FL mice showed well-differentiated HCC in about 20% of the cases and 
small HCC in about 60% of the mice (Figure 30F). Chronic fatty livers and chronic 
inflammatory states are major factors involved in liver carcinogenesis. Nevertheless, 
histopathological analysis did not reveal extensive steatosis and inflammation in the 
liver of DEN-injected Ripk1FL/FL and RIPK1LPC-KO mice suggesting that a single dose of 
DEN did not induce an inflammatory response and steatosis in the liver 30 weeks after 
DEN injection (Figure 30H, I). Taken together, LPC-specific deficiency of RIPK1 
negatively affects tumor initiation and tumor growth in response to DEN. 
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Figure 30. LPC-specific deficiency of RIPK1 reduced tumor incidences and growth  
(A and B) Graphs depicting the body weight (mean	± SEM) (A) and serum ALT and AST levels 
at 32 weeks of age (B) of DEN-injected Ripk1FL/FL and RIPK1LPC-KO mice. (C) Representative 
pictures of livers (Scale bar: 1cm) and H&E stained liver sections from DEN-injected Ripk1FL/FL 
and RIPK1LPC-KO mice at the age of 32 weeks. Scale bar, 100 µm. * indicates the tumor area. 
(D) Tumor load in mice with indicated genotypes as estimated by quantification of the tumor 
size distribution (***P < 0.005) (E) Graphs depicting the number of tumors per liver (**P< 0.01) 
(F) Histopathological evaluation of HCC development in 32-week-old mice with the indicated 
genotypes. Each color bar represents the % of livers per genotype in which the indicated stage 
was identified as the most advanced disease stage. (G-I) Graphs depicting the liver/bodyweight 
ratio (G), the grade of steatosis (H), and the grade of inflammation (I) in 32-week-old mice 
injected with DEN. 
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Even at the age of 36 weeks macroscopic analysis of livers from Ripk1FL/FL and 
RIPK1LPC-KO revealed a reduction in DEN-induced tumorigenesis in RIPK1LPC-KO mice, 
as 33% of RIPK1LPC-KO mice showed no macroscopically visible tumors opposed to 8% 
of the control animals (Figure 31C, D, E). Similar to the results shown in figure 30 at 32 
weeks, Ripk1FL/FL and RIPK1LPC-KO mice did not show differences in bodyweight gain, 
serum ALT and AST levels and liver to bodyweight ratio at 36 weeks of age (Figure 
31A, B, F). In contrast to 32-week old mice, 36-week old RIPK1LPC-KO mice showed a 
similar incidence of 5-10 mm tumors (Figure 31D). Together, these results show that 
RIPK1 deficiency delays DEN-induced liver tumorigenesis by decreasing overall tumor 
incidence and tumor numbers 30 and 34 weeks after DEN-injection.  
Figure 31. RIPK1LPC-KO mice showed delayed tumor growth and reduced tumor numbers 
and incidences at 36 weeks of age 
(A) Graph depicting the bodyweight of DEN-injected Ripk1FL/FL and RIPK1LPC-KO mice starting 
from DEN injection until the age of 36 weeks (mean± SEM). (B) Graph depicting serum ALT 
and AST level of DEN-injected Ripk1FL/FL and RIPK1LPC-KO mice at 36 weeks of age. (C) 
Representative pictures of livers (Scale bar: 1cm). * indicates the tumor area.(D) Graphs 
depicting the size distribution of tumors found in livers of DEN-injected Ripk1FL/FL and RIPK1LPC-
KO mice at the age of 36 weeks (***P<0.005), (E-F) Graphs depicting the number of tumors (E) 
or liver/bodyweight ratio (F). 
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3.3.2. Loss of RIPK1 kinase activity does not affect DEN-induced carcinogenesis 
 
RIPK1 exhibits both kinase-dependent and kinase-independent functions. To elucidate 
the importance of the kinase-dependent functions of RIPK1 in DEN-induced 
carcinogenesis, Ripk1D138N/D138N knock-in mice were used (Polykratis et al. 2014). To 
investigate the LPC-specific function of RIPK1 kinase activity, we employed mice that 
carry one loxP-flanked and one RIPK1D138N mutant allele crossed to Alfp-Cre 
transgenic mice (Ripk1FL/D138N; Alfp-CreTg/WT, hereafter referred to as RIPK1LPC-KO/D138N). 
In these mice, Cre-mediated recombination deleted the loxP-flanked Ripk1 allele in 
LPCs, therefore, these cells expressed only the kinase inactive RIPK1D138N protein 
whereas cells in the rest of the body remained Ripk1FL/D138N. Groups of male RIPK1LPC-
KO/D138N mice and Ripk1FL/D138N littermates were injected with 25 mg/kg BW DEN at the 
age of 2 weeks and their livers were examined for the presence of tumors at the age of 
36 weeks. Ripk1FL/D138N and RIPK1LPC-KO/D138N mice did not show differences in 
bodyweight gain until the age of 36 weeks (Figure 32B) and did not show increased 
levels of the serum ALT and AST at the age of 36 weeks (Figure 32C). Unlike 
RIPK1LPC-KO mice, RIPK1LPC-KO/D138N mice had similar tumor incidences, tumor numbers 
and also tumor size compared to their control littermates (Figure 32D-G). Furthermore, 
RIPK1LPC-KO/D138N mice showed similar liver to bodyweight ratio, steatosis and 
inflammation 36 weeks upon DEN-injection compared to Ripk1FL/D138N littermates 
(Figure 32H-J). Taken together, loss of RIPK1 kinase activity does not affect DEN-
induced liver tumorigenesis suggesting that RIPK1 promotes liver tumor development 
via kinase-independent scaffolding functions. 
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Figure 32. RIPK1LPC-KO/D138N mice showed similar tumor development compared to 
Ripk1FL/D138N mice  
(A) Immunoblot analysis for RIPK1 in liver lysates of 9-week-old Ripk1FL/D138N and RIPK1LPC-
KO/D138N mice (n=3 per genotype). (B) Bodyweight curve of DEN-injected Ripk1FL/D138N and 
RIPK1LPC-KO/D138N mice starting from DEN injection until the age of 36 weeks (mean ± SEM). (C) 
Graph depicting serum ALT and AST levels of 36-week-old Ripk1FL/D138N and RIPK1LPC-KO/D138N 
mice upon DEN injection. (D) Representative pictures of livers (Scale bar: 1cm) and H&E 
stained liver sections from DEN-injected Ripk1FL/D138N and RIPK1LPC-KO/D138N mice at the age of 
36 weeks. Scale bar, 100 µm. Dashed lines indicate the tumor area. (E) Tumor load in 36-
week-old Ripk1FL/D138N and RIPK1LPC-KO/D138N mice as estimated by quantification of the tumor 
size distribution. (F) Graph depicting the number of tumors per liver. (G) Histopathological 
evaluation of HCC development in 36-week-old Ripk1FL/D138N and RIPK1LPC-KO/D138N mice. Each 
color bar represents the % of livers per genotype in which the indicated stage was identified as 
the most advanced disease stage (n=14-15 per genotype).  (H-J) Graphs depicting the 
liver/bodyweight ratio (H), grade of steatosis (I), and the grade of inflammation (J) in 36-week-
old mice injected with DEN.  
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3.3.3. LPC-specific deficiency of RIPK1 reduces DEN-induced γH2AX levels  	
Given the fact that RIPK1LPC-KO mice showed reduced tumor incidences 30- and 34-
weeks after DEN injection (Figure 30 and 31) these results suggested a pivotal role of 
RIPK1 in the regulation of tumor initiation and growth. To interrogate the RIPK1-
dependent mechanisms regulating initiation and growth of DEN-induced tumors the 
role of RIPK1 in the liver was analyzed in response to DEN. In order to amplify 
hepatocyte response to DEN groups of male RIPK1LPC-KO and Ripk1FL/FL mice were 
injected at 6 weeks of age with an acute dose of DEN (100mg/kg BW) and were 
analyzed after 3, 6, 24, or 48h.  
To directly assess DEN-induced DNA-damage liver sections were stained with 
antibodies recognizing phosphorylated histone H2AX (γH2AX), which is generated in 
the vicinity of DNA-damage lesions (Lukas et al. 2011). DEN administration induced 
the appearance of γH2AX in the liver already 3h after injection, which persisted up to 
24h and declined thereafter (Figure 33A). Quantification of γH2AX+ hepatocytes 
revealed slightly reduced levels at 3 and 6h but significantly reduced numbers of 
γH2AX stained hepatocytes at 24h in RIPK1LPC-KO mice compared to Ripk1FL/FL 
littermates (Figure 33B). DNA-damage induces the stabilization and activation of the 
tumor suppressor p53, which maintains genomic stability by controlling the expression 
of genes regulating cellular senescence, cell-cycle progression, cell death and DNA 
repair (Bieging et al. 2014). Immunoblot analysis of liver protein extracts revealed p53 
stabilization in the liver starting at 6h, peaked at 24h and subsided 48h after DEN 
administration in both RIPK1LPC-KO and Ripk1FL/FL littermates (Figure 33C). 
Furthermore, qRT-PCR analysis of the expression of key p53 target genes did not 
reveal considerable differences in p53-dependent gene expression between RIPK1LPC-
KO and Ripk1FL/FL mice (Figure 33D). Although γH2AX levels were reduced in DEN-
injected RIPK1LPC-KO mice RIPK1 deficiency did not considerably affect p53 signaling 
suggesting a p53-independent role of RIPK1 in reducing γH2AX levels after DEN 
injection. 
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Figure 33. RIPK1LPC-KO mice showed reduced γH2AX levels but similar p53 signaling 
compared to Ripk1FL/FL mice upon an acute dose of DEN  
(A-B) Representative images of livers of non-injected or with an acute dose of DEN-injected 6-
week old Ripk1FL/FL and RIPK1LPC-KO mice stained for γH2AX. Scale bar, 100 µm (A) and 
quantification of γH2AX+ cells (mean of 5 fields per animal, n= 3-7 mice, **P<0.01) (B). (C) 
Immunoblot analysis for p53 in Ripk1FL/FL and RIPK1LPC-KO mice after 100 mg/kg of BW DEN 
injection for depicted periods of time. Actin was used as loading control. (D) qRT-PCR analysis 
of gene expression levels of p53 and p53 target genes in Ripk1FL/FL and RIPK1LPC-KO mice after 
DEN injection for indicated timeperiods. Graphs show relative mRNA expression normalized to 
Tbp. 
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3.3.4. RIPK1LPC-KO livers display highly elevated Caspase-3 cleavage after DEN 
injection 	
Loss of RIPK1 in LPCs revealed increased sensitivity of hepatocytes to apoptosis in 
vitro (Figure 20) and in vivo in response to LPS (Figure 16) suggesting a pro-survival 
function of RIPK1 in the liver. Given this high sensitivity of cells to TNF-induced 
apoptosis in absence of RIPK1, the level of hepatocyte apoptosis was assessed in 
response to an acute dose of DEN. After acute DEN injection, analysis of ALT in the 
sera of DEN-injected mice revealed elevated levels at 6 and 24h after DEN injection in 
RIPK1LPC-KO mice indicative for increased liver damage (Figure 34A). Staining for CC3 
and subsequently the quantification of positive cells in these mice showed strongly 
elevated levels of CC3+ cells starting at 3h, peaked at 6h and declined at 48h after 
acute DEN injection in RIPK1LPC-KO mice (Figure 34B, C). In contrast to RIPK1LPC-KO 
mice, Ripk1FL/FL mice did not reveal positively stained cells at 3h or 6h but began to 
show CC3+ cells at 24h (Figure 34B, C). At 24h Ripk1FL/FL mice displayed similar CC3+ 
cells compared to RIPK1LPC-KO mice and continued at 48h with a slightly higher level of 
CC3+ cells than in RIPK1LPC-KO mice (Figure 34B, C). Similarly, immunoblot analysis 
for CC3 revealed high levels 6h after DEN injection in RIPK1LPC-KO mice but not in 
Ripk1FL/FL mice (Figure 34D). However, at 24h high levels of CC3 were detected in 
Ripk1FL/FL but not in RIPK1LPC-KO protein lysates although staining for CC3 showed 
strong staining for CC3 in both RIPK1LPC-KO and Ripk1FL/FL mice (Figure 34D). This 
discrepancy between IHC and immunoblot could be explained by the instability and the 
degradation of the CC3 fragment. Furthermore, the IHC for CC3 already showed cell 
rupture and the release of CC3 suggesting the loss of the CC3 fragment during protein 
isolation. Nevertheless, these results together reveal a high sensitivity of RIPK1-
deficient hepatocytes to DEN-induced apoptosis. 
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Figure 34. LPC-specific deficiency of RIPK1 sensitized hepatocytes to DEN-induced 
apoptosis  
(A) Graph depicting serum ALT levels of 6-week-old Ripk1FL/FL and RIPK1LPC-KO mice upon DEN 
injection for indicated timeperiods (***P<0.005). (B) Representative images of livers of non-
injected or with an acute dose of DEN injected 6-week-old Ripk1FL/FL and RIPK1LPC-KO mice 
stained for CC3. Scale bar, 100 µm. (C) Quantification of CC3+ cells in livers of Ripk1FL/FL and 
RIPK1LPC-KO mice after DEN injection (mean of 5 fields per animal, n= 3-7 mice) (***P<0.005). 
(D) Immunoblot analysis for CC3 in protein lysates of livers from Ripk1FL/FL and RIPK1LPC-KO 
mice after 100mg/kg of BW DEN injection for depicted timeperiods. Actin was used as loading 
control. 
3.3.5. Increased hepatocyte apoptosis correlates with reduced levels of γH2AX+ 
cells 
LPC-specific hepatocytes were highly prone to DEN-induced apoptosis (Figure 34) and 
IHC analysis revealed reduced γH2AX levels suggesting clearance of DNA damaged 
cells by apoptosis (Figure 33). To proof this hypothesis and to analyze whether death 
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of hepatocytes is DNA-damage-dependent in RIPK1LPC-KO mice, liver sections of 
Ripk1FL/FL and RIPK1LPC-KO mice were co-stained for CC3 and γH2AX. Co-staining for 
CC3 and γH2AX revealed the presence of CC3 not only in γH2AX+ cells but also in 
γH2AX- cells, consistently not all γH2AX+ hepatocytes showed CC3 staining at the 
indicated timepoints (Figure 35). Nontheless, death of hepatocytes also occurred in 
γH2AX+ cells suggesting that reduced number of γH2AX+ cells might be a result of 
extensive apoptosis especially 6h after DEN in RIPK1LPC-KO mice (Figure 35). Together 
these data suggest that hepatocyte apoptosis happens mostly independent of DNA-
damage and hint at the presence of another stimulus in addition to DNA-damage in 
response to DEN. 
 
Figure 35. DEN-induced apoptosis happened in a DNA-damage-independent manner  
Representative images of livers of non-injected or with an acute dose of DEN injected 6-week-
old Ripk1FL/FL and RIPK1LPC-KO mice co-stained for CC3 and γH2AX. Scale bar, 100 µm. 
 
3.3.6. LPC-specific deficiency of RIPK1 results in extensive Caspase-8- and 
Caspase-9-mediated hepatocyte apoptosis  	
To identify the mediator for DEN-induced Caspase-3 activation, the levels of Caspase-
8, the initiator Caspase of extrinsic apoptosis, and Caspase-9, the initiator Caspase of 
intrinsic apoptosis, were assessed. IHC analysis for cleaved Caspase-8 (CC8) 
revealed elevated CC8+ cells 3h and 6h after DEN injection (Figure 36A,C) resembling 
the previously shown CC3+ levels (Figure 34B,C). Unlike CC3 and CC8, cleaved 
Caspase-9 (CC9) levels were not elevated at 3h but increased 6h after DEN injection 
(Figure 36B, C). Together, these results suggest the presence of Caspase-8-
dependent extrinsic apoptosis 3h after DEN-injection. However, the apoptotic death at 
6h after DEN injection either depends on Caspase-8-BID-mediated or on DNA-
damage-induced Caspase-9 activation. 
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Figure 36. DEN-injection induced Caspase-8- and Caspase-9-dependent apoptosis in 
mice  
(A-B) Representative images of livers of non-injected or with an acute dose of DEN injected 6-
week-old Ripk1FL/FL and RIPK1LPC-KO mice stained for CC8 (A) and CC9 (B) (Scale bar, 100 µm) 
and graphs depicting the quantification of CC8+ cells and CC9+ cells (mean of 5 fields per 
animal, n= 3-7 mice) (***P<0.005) (C). 
 
3.3.7. LPC-specific deficiency of RIPK1 does not affect hepatocyte proliferation 
in response to acute DEN 
Maeda et al. reported that extensive apoptosis correlated with high compensatory 
proliferation of hepatocytes resulting in DEN-induced tumorigenesis (Maeda et al. 
2005). Unlike the report of Maeda et al., apoptotic death in the liver of RIPK1LPC-KO 
mice was not accompanied by compensatory proliferation of hepatocytes when using  
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an acute dose of DEN indicated by similar Ki-67 staining between Ripk1FL/FL and 
RIPK1LPC-KO mice (Figure 37). This result emphasizes that loss of RIPK1 did not affect 
hepatocyte proliferation which could have explained the reduced induction of DEN-
induced HCC development in RIPK1LPC-KO mice. 
Figure 37. LPC-specific ablation of RIPK1 did not affect hepatocyte proliferation  
Representative images of livers of non-injected or with an acute dose of DEN injected 6-week-
old Ripk1FL/FL and RIPK1LPC-KO mice stained for Ki-67 (Scale bar, 100 µm). Quantification of Ki-
67+ cells in Ripk1FL/FL and RIPK1LPC-KO mice after DEN injection (mean of 5 fields per animal, 
n= 3). 
 
3.3.8. LPC-specific deficiency of RIPK1 does not promote cytokine induction 
 
In a previous report, increased hepatocyte death and compensatory proliferation in 
IKK2Δhep mice was accompanied by an inflammatory response (Maeda et al. 2005). 
Gene expression analysis of Il1b levels in RIPK1LPC-KO mice compared to Ripk1FL/FL 
mice upon acute DEN did not reveal major inductions suggesting that a single injection 
of an acute dose of DEN did not induce a strong inflammatory response (Figure 38). 
 
Figure 38. LPC-specific ablation of RIPK1 did not 
increase Il1b gene expression levels upon acute DEN  
qRT-PCR analysis of gene expression levels of Il1b in 
Ripk1FL/FL and RIPK1LPC-KO mice after DEN injection for 
indicated timeperiods. Graphs show relative mRNA 
expression normalized to Tbp. 	
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3.3.9. Kinase-inactive RIPK1 mice do not show elevated DEN-induced hepatocyte 
apoptosis  	
Unlike LPC-specific full-length deficiency of RIPK1, deficiency of RIPK1 kinase activity 
did not affect DEN-induced HCC development in vivo indicating a kinase-activity-
independent function of RIPK1 in mediating DEN-induced HCC (Figure 32). To 
address the kinase-dependent function of RIPK1 in response to an acute dose of DEN, 
6-week old male Ripk1FL/D138N and RIPK1LPC-KO/D138N mice were injected with an acute 
dose of DEN. In contrast to RIPK1LPC-KO mice, RIPK1LPC-KO/D138N did not show elevated 
serum ALT levels (Figure 39A) and did not reveal increased CC3+, CC8+ and CC9+ 
levels in the liver at 3, 6 and 24h upon acute DEN injection (Figure 39B-E) suggesting 
that loss of RIPK1 scaffolding function promoted DEN-induced hepatocyte apoptosis. 
These data highlight a potential correlation between the lack of early apoptosis and the 
tumor formation at 36-weeks of age. 
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Figure 39. Deficiency of RIPK1 kinase activity prevented DEN-induced apoptosis  
(A) Graph depicting serum ALT levels in Ripk1FL/D138N and RIPK1LPC-KO/D138N mice after an acute 
dose of DEN for indicated time periods. (B-D) Representative images of livers of non-injected or 
with an acute dose of DEN injected 6-week-old Ripk1FL/D138N and RIPK1LPC-KO/D138N mice stained 
for CC3 (B), CC8 (C) and CC9 (D) (Scale bar, 100 µm). (E) Quantification of CC3+, CC8+ and 
CC9+ cells in Ripk1FL/D138N and RIPK1LPC-KO/D138N mice after DEN injection. Quantification was 
performed in 5 fields per animal (mean of 5 fields per animal, n= 3). 
	
3.3.10. Loss of RIPK1 kinase activity does not affect DEN-induced DNA-damage 	
LPC-specific deletion of RIPK1 resulted in reduced levels of γH2AX independent of 
p53 signaling presumably due to extensive apoptosis early after acute DEN (Figure 
33). In contrast to RIPK1LPC-KO mice, RIPK1LPC-KO/D138N mice did not display pronounced 
apoptosis (Figure 39). IHC analysis for γH2AX in RIPK1LPC-KO/D138N mice revealed 
similar levels of γH2AX+ cells compared to levels in Ripk1FL/D138N littermates implying a 
correlation between DNA-damage and cell death levels upon DEN (Figure 40). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. Loss of RIPK1 kinase activity did not affect γH2AX levels  
Representative images of livers of non-injected or with an acute dose of DEN injected 6-week-
old Ripk1FL/D138N and RIPK1LPC-KO/D138N mice stained for γH2AX (Scale bar, 100 µm). 
Quantification of γH2AX+ cells in Ripk1FL/D138N and RIPK1LPC-KO/D138N mice after DEN injection 
was performed in 5 fields per animal (mean of 5 fields per animal, n= 3). 
 
3.3.11. Injection with an acute dose of DEN results in the induction of Tnf and 
Trail gene expression 	
To elucidate whether DR signaling is important for RIPK1-mediated HCC, gene 
expression levels of DRs and their ligands were measured 3, 6, 24 and 48h after an 
acute dose of DEN. Gene expression analysis revealed no considerable differences 
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between RIPK1LPC-KO and Ripk1FL/FL mice (Figure 41). However, in Ripk1FL/FL and 
RIPK1LPC-KO mice an induction in Tnf and Trail gene expression level was detected 
after DEN injection (Figure 41). Since previous results presented in this study showed 
higher sensitivity of RIPK1-deficient hepatocyte to DR-induced death these results 
emphasize a TNF or TRAIL-dependent role in RIPK1-deficient hepatocyte death in 
response to acute DEN. 
 
Figure 41. LPC-specific loss of RIPK1 did not alter gene expression patterns of DRs and 
their ligands in response to DEN  
qRT-PCR analysis of gene expression levels of DRs and their ligands in Ripk1FL/FL and 
RIPK1LPC-KO mice after DEN injection for indicated timeperiods. Graphs show relative mRNA 
expression normalized to Tbp. 
 
3.3.12. TNFR1 signaling promotes apoptotic death 3h after acute DEN injection 
 
Since gene expression levels of DRs and IHC analysis for cleaved Caspase-8 
indicated an important role of DR signaling in the regulation of hepatocyte apoptosis in 
RIPK1LPC-KO mice, RIPK1LPC-KO TNFR1LPC-KO mice were generated by crossing Ripk1FL/FL 
Alfp-Cre transgenic mice with Tnfr1FL/FL mice. To investigate the role of TNFR1 
signaling in DEN-induced DNA-damage and cell death, male Ripk1FL/FL Tnfr1FL/FL and 
RIPK1LPC-KO TNFR1LPC-KO mice were injected at 6 weeks of age with an acute dose of 
DEN. In contrast to RIPK1LPC-KO mice, RIPK1LPC-KO TNFR1LPC-KO mice did not show 
considerable elevated levels of ALT and AST levels 24h after acute DEN injection 
(Figure 42A). In addition, IHC analysis for CC3 and CC8 showed similar levels 
between Ripk1FL/FL Tnfr1FL/FL and RIPK1LPC-KO TNFR1LPC-KO mice at 3h after acute DEN 
injection (Figure 42B, C, E). However, 6h after acute DEN injection serum ALT and 
AST levels as well as CC3 and CC8 levels were still elevated but slightly lower 
compared to levels in RIPK1LPC-KO mice (Figure 42A-C, E) while CC9 levels remained 
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unaffected by LPC-specific loss of TNFR1 (Figure 42D, E). Together these results 
suggest that predominantly the early onset of apoptotic death 3h after DEN injection is 
TNFR1-dependent. 
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Figure 42. Loss of TNFR1 reduced CC3 and CC8 levels 3h after DEN injection 
(A) Graph depicting serum ALT levels in Ripk1FL/FL Tnfr1FL/FL and RIPK1LPC-KO TNFR1LPC-KO 
mice after acute DEN injection for indicated timeperiods. (B-D) Representative images of livers 
of non-injected or with an acute dose of DEN injected 6-week-old Ripk1FL/FL Tnfr1FL/FL and 
RIPK1LPC-KO TNFR1LPC-KO mice stained for CC3 (B), CC8 (C) and CC9 (D) (Scale bar, 100 µm). 
(E) Quantification of CC3+, CC8+ and CC9+ cells in Ripk1FL/FL Tnfr1FL/FL and RIPK1LPC-KO 
TNFR1LPC-KO mice after DEN injection was performed in 5 fields per animal (mean of 5 fields 
per animal, n= 3). 	
3.3.13. LPC-specific deficiency of TNFR1 restores γH2AX levels in RIPK1LPC-KO 
mice upon acute DEN. 	
To analyze the correlation between DEN-induced cell death and γH2AX levels in 6-
week-old Ripk1FL/FL Tnfr1FL/FL and RIPK1LPC-KO TNFR1LPC-KO mice, mice were injected 
with an acute dose of DEN for 3, 6, 24 and 48h and subsequently IHC analysis for 
γH2AX was performed in their livers. In contrast to RIPK1LPC-KO mice, RIPK1LPC-KO 
TNFR1LPC-KO mice showed similar γH2AX+ cell levels comparable to their control 
littermates suggesting a strong correlation between TNF-induced apoptotic death at 3h 
and γH2AX levels after acute DEN injection (Figure 43).  
 
Figure 43. RIPK1LPC-KO TNFR1LPC-KO mice showed similar γH2AX+ levels compared to 
Ripk1FL/FL Tnfr1FL/FL mice upon acute DEN injection  
Representative images of livers of non-injected or with an acute dose of DEN injected 6-week-
old Ripk1FL/FL Tnfr1FL/FL and RIPK1LPC-KO TNFR1LPC-KO mice stained for γH2AX (Scale bar, 100 
µm). Quantification of γH2AX+ cells in Ripk1FL/FL Tnfr1FL/FL and RIPK1LPC-KO TNFR1LPC-KO mice 
after DEN injection was performed in 5 fields per animal (mean of 5 fields per animal, n= 3). 
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3.3.14. TNFR1 signaling mediates the protective effect in RIPK1LPC-KO mice in 
response to DEN-induced carcinogenesis 	
To assess whether early hepatocyte death is indeed the cause for reduced HCC 
development in RIPK1LPC-KO mice, groups of Ripk1FL/FLTnfr1FL/FL, RIPK1LPC-KO 
TNFR1LPC-KO/WT and RIPK1LPC-KO TNFR1LPC-KO mice were injected at 2 weeks of age 
with DEN and tumor development was evaluated at 36 weeks of age. RIPK1LPC-KO 
TNFR1LPC-KO mice showed similar bodyweight gain, serum ALT and AST levels and 
liver to bodyweight ratio compared to their control littermates at the age of 36 weeks 
(Figure 44A, B, F). Macroscopic assessment of livers revealed similar tumor 
incidences, numbers and size in RIPK1LPC-KO TNFR1LPC-KO mice compared to their 
control littermates (Figure 44C-E). Strikingly, heterozygous deletion of TNFR1 in 
RIPK1LPC-KO fully restored tumor growth in those mice as efficient as in homozygously 
deleted TNFR1 mice (Figure 44C-E). Together, these data suggest a RIPK1 pro-
survival function downstream of TNFR1 in regulating DEN-induced HCC underscoring 
an early anti-apoptosis-dependent role of RIPK1 in promoting tumor induction and 
growth. 
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Figure 44. Loss of TNFR1 signaling promoted DEN-induced liver tumorigenesis  
(A) Bodyweight curve of DEN-injected Ripk1FL/FL Tnfr1FL/FL, Ripk1LPC-KO TNFR1LPC-KO/WT and 
RIPK1LPC-KO TNFR1LPC-KO mice starting from DEN injection until the age of 36 weeks (mean	 ± 
SEM). (B) Graph depicting serum ALT and AST levels of 36-week-old Ripk1FL/FL Tnfr1FL/FL, 
Ripk1LPC-KO TNFR1LPC-KO/WT and RIPK1LPC-KO TNFR1LPC-KO mice upon DEN injection. (C) 
Representative pictures of livers (Scale bar: 1cm) and H&E stained liver sections from DEN-
injected Ripk1FL/FL Tnfr1FL/FL, Ripk1LPC-KO TNFR1LPC-KO/WT and RIPK1LPC-KO TNFR1LPC-KO mice at 
the age of 36 weeks. Scale bar, 100 µm. * indicates the tumor area. (D) Tumor load in 36-week-
old Ripk1FL/FL Tnfr1FL/FL, Ripk1LPC-KO TNFR1LPC-KO/WT and RIPK1LPC-KO TNFR1LPC-KO mice as 
estimated by quantification of the tumor size distribution. (E, F) Graphs depicting the number of 
tumors per liver (E) and the liver/bodyweight ratio (F) in 36-week-old mice injected with DEN.  		
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3.3.15. LPC-specific deficiency of RIPK1 ameliorates obesity-induced liver 
carcinogenesis 
 
Genetic or HFD-induced obesity aggravates DEN-induced liver carcinogenesis in a 
TNFR1-dependent manner (Uysal et al. 1997). To address the role of RIPK1 in 
obesity-mediated liver carcinogenesis, groups of male RIPK1LPC-KO and Ripk1FL/FL mice 
were injected with DEN at 2 weeks of age and subsequently divided in two groups, one 
receiving high-fat-diet (HFD) starting from the age of 4 weeks and a control group 
receiving normal-chow-diet (NCD). RIPK1LPC-KO showed similar bodyweight gain, serum 
ALT and LDL-C levels compared to Ripk1FL/FL mice under NCD- and HFD-fed 
conditions (Figure 45A-C). Furthermore, RIPK1LPC-KO showed similar response to 
glucose at 12 and 24 weeks compared to Ripk1FL/FL mice suggesting that LPC-specific 
RIPK1 deficiency does not affect the promotion of HFD-induced obesity and the 
maintenance of glucose metabolism (Figure 45D). Macroscopic assessment of tumor 
development at 36 weeks of age revealed reduced tumor incidences, tumor size and 
tumor numbers in HFD-fed RIPK1LPC-KO mice compared to HFD-fed Ripk1FL/FL 
littermates although the protective effect induced by RIPK1 deficiency was not as 
pronounced as in mice fed a NCD (Figure 45E-G). In summary, these results suggest 
a TNFR1-dependent role for RIPK1 in regulating DEN/obesity-induced HCC supporting 
data shown in figure 44. 
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Figure 45. LPC-specific deficiency of RIPK1 mildly reduced obesity-induced liver 
carcinogenesis  
(A) Bodyweight curve of NCD- or HFD-fed DEN-injected Ripk1FL/FL and RIPK1LPC-KO mice 
starting from DEN injection until the age of 36 weeks (mean	 ± SEM). (B, C) Graph depicting 
serum ALT (B) and serum LDL-C levels (C) of NCD- or HFD-fed 36-week-old Ripk1FL/FL and 
RIPK1LPC-KO mice upon DEN injection. (D) Graphs depicting blood glucose level after glucose 
administration in NCD- or HFD-fed Ripk1FL/FL and RIPK1LPC-KO mice at 12 and 24 weeks of age 
(mean	 ± SEM). (E) Representative pictures of livers (Scale bar: 1cm) from DEN-injected 
Ripk1FL/FL and RIPK1LPC-KO mice at the age of 36 weeks after NCD or HFD feeding. Scale bar, 
100 µm. (F) Tumor load in NCD- or HFD-fed 36-week-old Ripk1FL/FL and RIPK1LPC-KO mice as 
estimated by quantification of the tumor size distribution (***P< 0.005). (G) Graphs depicting the 
number of tumors per liver in NCD- or HFD-fed 36-week old mice injected with DEN (*P< 0.05).
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4. Discussion 
4.1. RIPK1, a crucial regulator of cell survival in vivo and in vitro 
RIPK1 has emerged as an important regulator of inflammation and cell death in 
response to TNFR1- and TLR-signaling. Therefore, tight regulation of RIPK1-signaling 
is of high importance to maintain tissue homeostasis. Indeed, full body ablation of 
RIPK1 resulted in perinatal lethality of the mice due to increased apoptotic death in 
multiple tissues including the intestine and the liver (Kelliher et al. 1998; Dillon et al. 
2014; Kaiser et al. 2014). Consistently, epithelial cell-specific ablation of RIPK1 
resulted in early postnatal death with increased apoptotic and necroptotic cell death in 
the intestine or the skin (Dannappel et al. 2014; Takahashi et al. 2014).  
In sharp contrast to RIPK1IEC-KO or RIPK1E-KO mice, RIPK1LPC-KO mice were viable, 
fertile and reached adulthood without considerable morphological liver pathology 
suggesting the existence of a RIPK1-independent mechanism in liver development and 
the regulation of liver homeostasis under basal conditions. In line with recent studies, 
our results revealed normal hepatocyte proliferation and death in RIPK1LPC-KO mice 
(Suda et al. 2016; Filliol et al. 2016; Dara et al. 2015; Schneider et al. 2017). However, 
our detailed IHC analysis revealed focal immune cell patches in RIPK1LPC-KO mice, 
which did not trigger an immune response indicated by gene expression analysis of 
Tnf and Il1b. Unlike hepatocytes in Ripk1-/- mice, which might be constantly in contact 
with DAMPs/PAMPs due to intestinal barrier rupture, hepatocytes of RIPK1LPC-KO mice 
in vivo have only minimal contact with DAMPs or PAMPs since the intestinal barrier is 
intact and prevents the translocation of large amounts of PAMPs/DAMPs to the liver. 
Taken together, RIPK1LPC-KO mice do not show spontaneous liver pathology and 
premature death due to the fact that hepatocytes might have an additional or 
redundant RIPK1-independent pro-survival mechanisms to sustain the low level of 
immune cell infiltration and liver damage. Therefore, this low amount of bacterial 
components might not reach a specific threshold that would be sufficient to trigger 
extensive hepatocyte death or an inflammatory response but only result in local 
recruitment of additional macrophages, B and T cells. Future studies using co-
depletion of RIPK1 specifically in IECs and hepatocytes would shed light on the 
importance of microbiota-dependent effects on Ripk1-/- liver pathology. Noteworthy, in 
contrast to Ripk1-/- mice, in RIPK1LPC-KO mice Alfp-Cre-dependent recombination does 
not affect RIPK1 expression in KCs. Future studies are needed to unravel the effect of 
KCs on disease onset and progression in Ripk1-/- mice.  
Although RIPK1LPC-KO mice did not display obvious abnormalities in the liver, RIPK1-
deficient primary hepatocytes isolated from RIPK1LPC-KO mice died spontaneously in 
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culture. Using a TNF inhibitor directly after isolation or additional LPC-specific 
deficiency of TNFR1 was sufficient to reduce up to 50% of the spontaneous death of 
primary RIPK1-deficient hepatocytes in culture. Consistent with recent reports, RIPK1-
deficient primary hepatocytes were highly sensitive to TNF-induced apoptosis 
suggesting either an autocrine TNF release or a small contamination with immune cells 
during the process of hepatocyte isolation that results in the production of TNF (Filliol 
et al. 2016; Schneider et al. 2017; Suda et al. 2016). Given the fact that TNFR1 
signaling inhibition did not fully prevent spontaneous hepatocyte death additional 
triggers for apoptosis are likely to be present during isolation. The result in this study 
pointed to a FasL-independent mechanism of apoptosis since culturing primary 
hepatocytes in presence of a neutralizing antibody for FasL did not prevent apoptosis. 
However, it remains to be elucidated whether signaling through other DRs such as 
TRAILR or DR3/6 or TLR-signaling could be involved in the spontaneous death of 
RIPK1-deficient primary hepatocytes. Another possibility would be that TNFR1-
independent death was caused by stress associated with the mechanical and 
enzymatic disruption of the liver architecture. 
Taken together, the data presented in this work reveal that under homeostatic 
conditions RIPK1 is largely dispensable for normal liver homeostasis while under 
stressed conditions RIPK1 displays a pro-survival function in primary hepatocytes. 
4.2. RIPK1, a regulator of NF-κB activation in hepatocytes 
Ablation of RIPK1 in various tissues sensitized cells to death in vitro and in vivo 
pointing to a crucial pro-survival role of RIPK1. However, the mechanism how RIPK1 
maintains cell survival remains still highly controversial mainly due to contradictory 
studies on its role in TNF-induced NF-κB activation. First, Kelliher et al. suggested a 
major RIPK1-dependent role in mediating NF-κB activation (Kelliher et al. 1998), which 
was challenged by a later study suggesting a dispensable role of RIPK1 in NF-κB 
activation in various cell types (Wong et al. 2010). Likewise, recent studies revealed no 
impairment of NF-κB activation in RIPK1-deficient IECs and keratinocytes (Dannappel 
et al. 2014; Takahashi et al. 2014). Nevertheless, in our study RIPK1 ablation in 
hepatocytes impaired TNF-induced NF-κB activation demonstrated by diminished IκBα 
phosphorylation and degradation. Moreover, absence of RIPK1 abrogated nuclear 
translocation of p65 and significantly reduced NF-κB target gene expression 
emphasizing a crucial role of RIPK1 in mediating NF-κB activation in primary 
hepatocytes. On the contrary, recent reports revealed high sensitivity of RIPK1 
deficient hepatocytes to death independent of NF-κB activation (Filliol et al. 2016; 
Schneider et al. 2017; Suda et al. 2016). In contrast to these studies, RIPK1-deficient 
Discussion 
 81 
primary hepatocytes used in this work were cultured over night in the presence of 
zVAD-fmk to analyze TNF-mediated NF-κB activation whereas other studies stimulated 
within 3h with TNF or injected mice with LPS. Given the fact that hepatocyte isolation is 
still a highly sensitive method using a wide variety of reagents and different isolation 
protocols, small differences in the protocol or in the culturing procedure might affect the 
outcome of the experiments. An ultimate proof for RIPK1-dependent NF-κB activation 
would be to restore NF-κB signaling in RIPK1-deficient hepatocytes by expressing e.g. 
a constitutive active form of IKK2 to elucidate whether restored NF-κB signaling is able 
to prevent spontaneous hepatocyte death.  
 
Since in our study primary RIPK1-deficient hepatocytes showed impaired NF-κB 
activation in vitro, in vivo NF-κB activation was assessed to analyze the higher 
susceptibility of RIPK1LPC-KO mice to LPS. Expressing a constitutive active form of IKK2 
in fact protected 80% of RIPK1LPC-KO mice from LPS-induced liver injury demonstrating 
a crucial role for NF-κB signaling in regulating TNF-induced cell death in the absence 
of RIPK1. However, reconstituting NF-κB signaling was not sufficient to fully prevent 
liver injury but efficiently prevented early death of RIPK1LPC-KO mice. These results 
suggest an important IKK2-dependent role in the regulation of liver damage upon LPS 
by reducing the liver injury level to a certain extent allowing hepatocyte recovery. 
Recently, a NF-κB-independent function of IKK1 and IKK2 has been identified 
(Dondelinger et al. 2015). It was reported that IKKs phosphorylate RIPK1 in order to 
restrain RIPK1 in complex-I to protect cells from RIPK1 kinase-dependent death. Given 
this fact, we hypothesize that expression of a constitutive active form of IKK2 in 
RIPK1LPC-KO mice might reduce liver injury to some extent by NF-κB-dependent 
mechanisms but might not fully prevent hepatocyte apoptosis and liver injury since in 
absence of RIPK1 IKK2 could not prevent cell death by its NF-κB-independent 
mechanisms. This might result in the destabilization of complex-I leading to complex-
IIa-dependent apoptosis. Noteworthy, in LPS-injected RIPK1LPC-KO IKK2CaLPC mice, 
ALT and AST levels were decreasing with time and it remains to be elucidated whether 
this might be due increased regenerative capacity of hepatocytes or decreased 
hepatocyte death with time. On the same token, NF-κB signaling is highly activated 
after expression of a constitutive active form of IKK2 and therefore might increase 
cFLIP levels with time resulting in the inhibition of Caspase-8 oligomerization and 
consequently apoptosis. Together, these results argue for two pathways operating in 
parallel to ensure hepatocyte survival during endotoxin-mediated liver injury, a NF-κB-
dependent and -independent pathway. 
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In addition to canonical NF-κB activation, the stabilization of cIAPs and TRAF2 proteins	
by RIPK1 was suggested to prevent hepatocyte death (Feoktistova et al. 2011). 
Accordingly, RIPK1IEC-KO and RIPK1E-KO mice revealed reduced TRAF2 and cIAP1 
protein levels and consequently higher sensitivity of cells to death (Dannappel et al. 
2014). Unlike in RIPK1IEC-KO and RIPK1E-KO mice, in RIPK1LPC-KO mice no considerable 
changes in gene and protein expression of pro-survival proteins such as TRAF2 and 
cIAP1 were detected even after LPS injection. This result suggests a cell-type specific 
role of RIPK1 in stabilizing these pro-survival proteins and it underscores the presence 
of another protein stabilizing cIAPs and TRAF2 in hepatocytes. In contrast to our study, 
it was recently reported that deficiency of RIPK1 resulted in TRAF2 downregulation, 
which did not affect canonical NF-κB activation but sensitized hepatocytes to apoptotic 
death (Schneider et al. 2017; Filliol et al. 2016; Gentle et al. 2011). The discrepancy 
between our study and the recent studies remains to be investigated, however, we 
assume that RIPK1 deficiency could be compensated by TRADD, since TRADD has 
been shown to mediate the recruitment of cIAPs and TRAF2. Moreover, TRADD 
deficiency in MEFs and macrophages abrogates NF-κB activation (Ermolaeva et al. 
2008). However, TRADD-mediated NF-κB activation was supported only to a certain 
extent since our in vitro treatment of RIPK1-deficient hepatocytes with TNF still 
resulted in reduced NF-κB activation and increased hepatocyte apoptosis.  
Moreover, assuming that TRADD could compensate the deficiency of RIPK1 in term of 
NF-κB activation and the stabilization of pro-survival proteins it remains unclear why 
TRADD might not compensate the reduction of TRAF2 and cIAP1 protein level in 
RIPK1-deficient IECs or keratinocytes. Combined, this suggests a cell-type specific 
function of TRADD probably due to different expression levels of TRADD in different 
tissues. 
 
Although RIPK1 and TRAF2 alone were not sufficient to trigger spontaneous liver 
pathology, combined deficiency in LPCs triggered spontaneous hepatocyte apoptosis, 
cholestasis and chronic hepatitis resulting in HCC development	 (Schneider et al. 
2017). Deficiency of RIPK1 and TRAF2 resulted in the instability of cIAP1/2, TRAF2 
and cFLIP and reduced NF-κB activation, which correlated with chronic hepatocyte 
TRADD-dependent apoptosis that consequently resulted in liver injury and HCC 
formation (Schneider et al. 2017). However, the link between instability of pro-survival 
proteins and cell death was challenged by the fact that cFLIPL levels remained low in 
RIPK1LPC-KO TRAF2LPC-KO Caspase-8LPC-KO mice, which was attributed to the observed 
NF-κB inhibition (Schneider et al. 2017). Conversely, Kondylis et al. reported restored 
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cFLIPL levels in NEMOLPC-KO Ripk1D138N/D138N mice independent of NF-κB activation 
(Kondylis et al. 2015). 
Together these results suggest the presence of contributing proteins that are needed 
for NF-κB activation and that RIPK1 and TRAF2 display redundant or independent pro-
survival functions. It remains to be seen how RIPK1 synergizes with other members of 
complex-I to prevent complex-II formation.  
4.3. RIPK1 as a key regulator of cell death in response to LPS-induced toxicity 
To mimic the microbiota dependent effect, we employed the LPS-mediated liver injury 
model to explore the role of TLR4- and TNFR1-dependent signaling in RIPK1LPC-KO 
mice. Indeed, RIPK1LPC-KO mice were highly susceptible to a low dose of LPS 
displaying liver injury resulting in early death of mice (Figure 46). Importantly, LPC-
specific deficiency of TNFR1 protected RIPK1LPC-KO mice from early LPS-induced 
death. Consistent with LPC-specific deficiency of TNFR1 in our study, pre-treatment 
with etanercept, a TNF decoy receptor, fully protected RIPK1LPC-KO mice from LPS-
induced liver injury (Filliol et al. 2017). Since in our study RIPK1-deficient primary 
hepatocytes showed impaired NF-κB activation it strongly suggests that TNF is 
expressed by KCs in response to LPS. Accordingly, Filliol et al. reported an 
amelioration of liver injury in RIPK1LPC-KO mice challenged with LPS after depletion of 
KCs due to reduced serum TNF levels in LPS-injected mice (Filliol et al. 2017). 
Together these results strongly suggest that LPS activates TLR4, mainly present on 
KCs, which induces the release of TNF resulting in massive apoptotic hepatocyte 
death and liver injury in the absence of RIPK1 leading to liver failure and consequently 
death of the mice due to impaired liver functions.  
 
Using the kinase-inactive mutant of RIPK1 (Ripk1D138N/D138N) we demonstrated that 
RIPK1 scaffolding function rather than its kinase activity prevents LPS-induced liver 
injury. This finding is in line with recent studies revealing similar kinase-independent 
scaffolding function of RIPK1 in preventing ConA-mediated hepatitis and αGalCer-
mediated liver injury (Suda et al. 2016; Filliol et al. 2016). Employing the LPS/D-GalN 
model, which triggers TNFR1-dependent cell death (Wroblewski et al. 2016), the 
kinase activity of RIPK1 was shown to mediate to a certain extent LPS/D-GalN-induced 
death. This partial protection seen after LPS/D-GalN injection in this study could be a 
dose-dependent effect or a compensatory effect by TRADD-mediated pro-death 
function. In summary, RIPK1 exhibits kinase-independent scaffolding function to 
prevent LPS-induced liver injury but kinase-dependent functions facilitating LPS/D-
GalN induced cell death. 
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LPC-specific deficiency of FADD or TRADD fully protected RIPK1LPC-KO mice from LPS-
induced liver injury emphasizing a crucial role of apoptosis in mediating the early death 
of RIPK1LPC-KO mice in response to low doses of LPS. In line with our data, Caspase-8 
deficiency was sufficient to prevent increased liver injury in RIPK1LPC-KO mice	
(Schneider et al. 2017). In our study, ablation of RIPK1 sensitized to LPS/TNF-induced 
TRADD-dependent apoptosis. Both RIPK1 and TRADD are able to interact with 
Caspase-8 in complex-II in response to TNF, but although complex-IIa and –IIb are 
considered as two independent complexes, this has not been fully demonstrated yet.  
 
In summary, the sensitivity of RIPK1LPC-KO mice to LPS resembles largely the high 
TRIF/TNFR1-dependent sensitivity of Ripk1-/- mice to cell death emphasizing a crucial 
role of PAMPs/DAMPs in mediating hepatocyte death in Ripk1-/- mice (Dillon et al. 
2014). Importantly, our results together with other studies demonstrate a kinase-
independent scaffolding function of RIPK1 in preventing apoptosis of hepatocytes in 
LPS/TNF-mediated liver injury. In addition, our LPS/D-GalN result emphasizes the 
importance of the kinase-dependent function of RIPK1 in mediating apoptosis, which 
supports the data of Dondelinger et al. (Dondelinger et al. 2015). 
 
Figure 46. RIPK1 prevents LPS-induced liver injury  
LPS administration induces KC dependent release of the cytokine TNF, which triggers the 
activation of TNFR1-signaling. In WT hepatocytes, LPS administration triggers TNFR1-
dependent canonical NF-κB activation which prevents high levels of TNF-mediated apoptosis 
resulting in the protection of mice against LPS-induced liver injury. On the contrary, LPC-
specific deletion of RIPK1 sensitizes hepatocytes to LPS/TNF-mediated TRADD-FADD-
Caspase-8-dependent apoptosis due to impaired NF-κB activation. Elevated levels of apoptotic 
hepatocyte death results in increased liver damage indicated by increased serum ALT/AST 
levels which consequently resulted in early death of mice in response to LPS-mediated liver 
injury 
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4.4. Apoptosis as the preferable mechanism of hepatocyte death 
LPC-specific RIPK1 deficiency sensitized primary hepatocytes to TNF-induced 
apoptosis whereas necroptosis seemed to be dispensable since culturing cells in 
presence of zVAD-fmk or LPC-specific FADD or TRADD deficiency fully protected 
hepatocytes from death in vitro and in response to LPS-induced toxicity in vivo. In line 
with our data, IECs deficient for RIPK1 undergo predominantly FADD-mediated 
apoptosis. Only under condition of apoptosis inhibition, death of IECs switched to 
RIPK3-dependent necroptosis (Dannappel et al. 2014). In RIPK1E-KO mice, 
keratinocytes died in an apoptosis- and necroptosis-dependent manner (Dannappel et 
al. 2014). Likewise, in Ripk1-/- mice neither FADD/Caspase-8 nor RIPK3/MLKL alone 
could rescue the early perinatal lethality. Only a combined deficiency of Caspase-
8/RIPK3 or FADD/RIPK3 could rescue Ripk1-/- mice until adulthood without aberrant 
pathology. How tissue-specific deletion of RIPK1 affects the mechanism of cell death 
remains unclear. One important aspect is the tissue-specific expression of RIPK3, 
which was suggested to influence the induction of necroptosis (He et al. 2009). 
Strikingly, Dannappel et al. reported slightly higher RIPK3 levels in IEC protein extracts 
compared to keratinocyte protein extracts from RIPK1IEC-KO and RIPK1E-KO mice, 
respectively (Dannappel et al. 2014). However, as mentioned already above, IECs 
deficient for RIPK1 undergo predominantly FADD-mediated apoptosis while in vivo the 
keratinocyte death was primarily RIPK3-driven suggesting a RIPK3-level independent 
role in determining the mechanism of cell death	 (Dannappel et al. 2014). Unlike in the 
gut or the skin, the occurrence of necroptosis in the liver remains highly controversial. 
Several independent studies revealed low levels of RIPK3 in whole liver lysates under 
basal conditions. This suggests that hepatocytes barely undergo necroptosis but 
preferably Caspase-dependent apoptosis which is in line with our data that RIPK1LPC-KO 
FADDLPC-KO mice were fully protected in response to LPS. Highly contradictory were 
the results from various liver injury studies using acetaminophen, αGalCer, ConA or 
from chronic liver injury models such as alcoholic steatohepatitis (ASH) and non-
alcoholic-steatohepatitis (Dara et al. 2016). Studies revealing a protection using Ripk3-
/- mice indicated a RIPK3 induction upon APAP, ConA and aGalCer (Ramachandran et 
al. 2011; Jouan-Lanhouet et al. 2012; Deutsch et al. 2015; An et al. 2013; Zhou et al. 
2013; Arshad et al. 2015; Suda et al. 2016; Zhang et al. 2014). In contrast to these 
studies, several other independent reports showed no protection in Ripk3-/- mice in liver 
injury models (Dara et al. 2015; Weinlich et al. 2013; Gunther et al. 2016, Schneider et 
al. 2017). The discrepancies between these studies could be attributed to the 
specificity problems that have been reported for the commercially available RIPK3 
antibodies. Moreover, in a well-controlled study it was shown that RIPK3 is very 
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strongly expressed in immune cells rather than in hepatocytes. Therefore, future 
studies using conditional RIPK3 knockout mice would help deciphering the hepatocyte 
specific effect of RIPK3 in these liver injury models. 
Furthermore, there are contrasting results about the implication of other necroptosis-
inducing proteins such as RIPK1 and MLKL in mediating liver injury in these different 
studies (Dara et al. 2016). It is worth mentioning that all these studies were performed 
under different experimental settings. Furthermore, studies were performed using 
different concentrations of APAP and ConA and in different animal facilities. In 
conclusion, inconsistencies in protection in these liver injury models using Ripk3-/- mice 
emphasized a minor role of necroptosis in the liver. Moreover, deficiency of RIPK3 did 
not prevent HCC development in NEMOLPC-KO mice with NEMOLPC-KO Ripk3-/- mice 
revealing increased liver damage due to increased hepatocyte apoptosis (Kondylis et 
al. 2015).   This result demonstrated that RIPK3-dependent necroptosis does not 
contribute to spontaneous HCC development in NEMOLPC-KO mice. These results 
together with our own results strongly suggest a negligible impact of RIPK3-mediated 
necroptosis in hepatocytes due to very low levels of RIPK3 in the liver.  
4.5. The pro-survival scaffolding function of RIPK1 promotes DEN-induced 
hepatocarcinogenesis 
Given the fact that RIPK1 displays dual-functions in regulating cell survival and cell 
death it could be a promising target for new therapeutic strategies against HCC. Our in 
vivo results revealed a delay in DEN-induced HCC development in RIPK1LPC-KO mice, 
which could be a consequence of extensive apoptotic death early after DEN injection 
(Figure 47). Immunohistological analysis revealed extensive hepatocyte apoptosis 
already 3 and 6h after acute DEN. Interestingly, LPC-specific TNFR1 deficiency 
strongly reduced the level of Caspase-8-dependent apoptosis 3h after acute DEN 
while at 6h Caspase-8-dependent death was only mildly affected suggesting the 
presence of an additional trigger for Caspase-8-dependent apoptosis. Since our 
analysis revealed also an induction in Trail gene expression levels it is likely that 
TRAIL is involved in mediating Caspase-8-dependent apoptosis 6h after DEN. 
However, it remains to be analyzed whether Caspase-9-dependent apoptosis is 
mediated by Caspase-8 signaling or by DNA-damage 6h after DEN. Strikingly, the 
level of DNA-damage was significantly reduced in RIPK1LPC-KO but not in RIPK1LPC-KO 
TNFR1LPC-KO mice. Accordingly, additional LPC-specific TNFR1 ablation restored tumor 
growth and tumor numbers 34 weeks after DEN injection in RIPK1LPC-KO TNFR1LPC-KO 
mice. Together these results pointed to a crucial TNFR1-dependent role in triggering 
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cell death 3h after acute DEN resulting in clearance of DNA damaged cells, less tumor 
initiation and less HCC development. 
In line with this, the loss of RIPK1 mildly reduced obesity-induced liver carcinogenesis 
which was reported to induce liver carcinogenesis in a TNFR1-dependent manner 
(Park et al. 2010). Presumably due to the clearance of DNA-damaged cells at 2 weeks 
of age, RIPK1LPC-KO mice showed less tumor initiation after DEN injection. But at 4 
weeks of age HFD feeding started and promoted a constant inflammatory basis with 
elevated TNF expression. Constant TNF production might cause constant hepatocyte 
death in RIPK1LPC-KO mice. However, at the same time constant cell death might induce 
compensatory proliferation promoting tumorigenesis and, therefore, would explain the 
lower protective effect of RIPK1 deficiency on obesity-mediated DEN-induced 
tumorigenesis compared to the effect seen in DEN-injected NCD-fed mice (Figure 47). 
 
Figure 47. RIPK1 promotes DEN-induced HCC development by preventing early TNF- 
mediated apoptotic death  
Metabolized DEN leads to DNA damage by alkylation that is recognized by ATM. ATM in turn 
induces NF-κB activation resulting in TNF expression. Subsequently TNF mediates TNFR1-
dependent NF-κB activation or apoptosis. (A) In WT hepatocytes or in hepatocytes lacking the 
kinase activity of RIPK1 DEN triggers DEN/TNF-dependent NF-κB activation which blocks TNF- 
and DNA-damage-dependent apoptosis early after DEN injection resulting in DEN-mediated 
HCC development. (B) However, the absence of RIPK1 sensitizes hepatocytes 3h after acute 
DEN injection to TNFR1 induced TRADD-FADD-Caspase-8-dependent apoptosis and to DNA-
damage-driven apoptosis 6h after DEN injection resulting in reduced HCC development. (C) 
Additional ablation of TNFR1 blocks hepatocyte death 3h after acute DEN injection and 
restores tumor formation in RIPK1LPC-KO TNFR1LPC-KO mice to similar extent as in their floxed 
Discussion 
 88 
littermates. (D) Prior to HFD feeding RIPK1LPC-KO mice, display early apoptosis as in (B) 
resulting in the reduction of DNA-damaged cells. Once fed with HFD, RIPK1-deficient 
hepatocytes expressed enhanced levels of TNF that could result in higher levels of TRADD-
FADD-Caspase-8-dependent apoptosis inducing compensatory proliferation. 
 
In previous reports, early extensive cell death is considered to increase cytokine-
induced compensatory proliferation of hepatocytes which may have sustained DNA 
damage consequently inducing tumorigenesis (Koch et al. 2009; Maeda et al. 2005; 
Sakurai et al. 2008; Sakurai et al. 2006). Accordingly, hepatocyte-specific ablation of 
IKK2 resulted in increased HCC development showing increased hepatocyte apoptosis 
correlating with significantly increased mRNA levels of cellular proliferation markers 
including cyclin D1, hepatocyte growth factor (HGF) and proliferating cell nuclear 
antigen (PCNA) early on. Furthermore, IKK2Δhep mice displayed liver inflammation 
indicated by elevated IL-1α, IL-1β, TNF and IL-6 early after acute DEN injection 
(Maeda et al. 2005). Consistently, BIDLPC-KO, Jnk1-/- and Puma-/- mice revealed 
attenuated DEN-induced HCC development and consistently showed reduced 
hepatocyte death, cyclin D1 and PCNA mRNA expression levels and no inflammatory 
response (Sakurai et al. 2006; Yu et al. 2016; Qiu et al. 2011). Our analysis of 
hepatocyte proliferation in RIPK1LPC-KO livers did not show increased proliferation 
indicated by similar Ki-67 staining early after DEN injection compared to Ripk1FL/FL 
mice although extensive apoptotic death was present early on. Moreover, inhibition of 
the kinase activity of RIPK1 resulted in reduced apoptotic death early after DEN 
injection and in similar tumor formation between RIPK1LPC-KO/D138N and Ripk1FL/FL mice. 
In contrast to partial hepatectomy or other models of severe acute liver injury (Martin, 
Theruvath and Neuhaus 2008), the overall number of apoptotic hepatocytes in the 
livers of DEN-injected RIPK1LPC-KO is relatively small and it might not be sufficient to 
trigger compensatory proliferation. The divergence between RIPK1LPC-KO and IKK2Δhep 
mice in response to DEN suggests a IKK2/ NF-κB-independent mechanism for RIPK1 
in regulating DEN-induced HCC development but future studies are needed to unravel 
the mechanism of RIPK1 and IKK2 in regulating DEN-induced HCC development. 
 
Our results implicated a key role of early apoptotic death in preventing HCC 
development regulated by RIPK1 scaffolding functions which seems to be 
contradictory to previous studies. As described above, in other models elevated levels 
of apoptosis correlated with increased HCC formation after DEN. However, the 
timepoint of apoptosis occurrence after acute DEN was reported to occur later then in 
our study. Wree et al. reported considerable TUNEL, Ki-67 and PCNA staining and 
increased cytokine expression levels in the liver of BidFL/FL mice compared to BidΔhep at 
48h after acute DEN injection. Furthermore, Qiu et al. reported reduced apoptotic 
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levels in Puma-/- mice 3-10 days after acute DEN injection. Moreover, Maeda et al. and 
Sakurai et al. showed elevated apoptosis in IKK2Δhep and Jnk1-/- mice 24-48h after 
25mg/kg BW DEN injection (Maeda et al. 2005; Sakurai et al. 2006). Taken only these 
studies into account, there are inconsistencies in term of DEN dosage and the 
timepoint of analysis. Importantly, cell death can also induce tumorigenesis by 
activating the inflammatory response as reported in a previous report (Maeda et al 
2005). Unlike IKK2Δhep mice, RIPK1LPC-KO mice did not show an elevated inflammatory 
response early after acute DEN injection indicated by low Il1b gene expression levels 
and at 32- and 36-weeks of age judged by IHC analysis consistent with Ripk1FL/FL 
littermates. The strongest discrepancy between the previous studies compared to our 
study is the fact that after 5mg/kg injection of DEN, mutant but also WT mice died 
rapidly, which was not present in our study using 25mg/kg BW of DEN suggesting 
compound differences (Maeda et al. 2005; Sakurai et al. 2006). Taken all these 
discrepancies into account, it is difficult to compare the effects on DEN-induced HCC 
seen in their studies and in our study. Importantly, under our conditions early 
hepatocyte apoptosis reduced DEN-induced HCC formation independent of any effects 
on hepatocyte proliferation. 
4.6. The role of RIPK1 in spontaneous HCC formation  
Although NEMO and RIPK1 are both involved in TNF-induced complex-I signaling, it is 
still unclear why NEMOLPC-KO and RIPK1LPC-KO mice display distinct phenotypes as 
NEMOLPC-KO mice develop spontaneously HCC whereas RIPK1LPC-KO mice do not show 
spontaneous HCC formation but even delays tumorigenesis upon DEN treatment	
(Kondylis et al. 2015). NEMOLPC-KO mice show extensive hepatocyte apoptosis 
resulting in HCC formation while early hepatocyte apoptosis in RIPK1LPC-KO mice 
results in reduction of DEN-induced HCC. One major difference between spontaneous 
HCC and DEN-induced HCC is the occurrence of cell death. Unlike spontaneous HCC, 
a single injection of DEN resulted in induction of DNA-damage and cell death during a 
short and early period after injection while LPC-specific NEMO ablation induced 
sustained cell death and constant compensatory hepatocyte proliferation throughout 
their lives. Moreover, ablation of NEMO induced an extensive inflammatory response, 
increased cell death, compensatory proliferation and strong fibrosis (Kondylis et al. 
2015). Extensive and chronic apoptosis as key factors for HCC development in 
NEMOLPC-KO mice was validated using NEMOLPC-KO FADDLPC-KO mice that displayed 
abrogated levels of apoptosis preventing HCC development (Ehlken et al. 2014). In 
contrast to LPC-specific deficiency of RIPK1, deficiency of its kinase activity alone 
strongly inhibited hepatocyte apoptosis, chronic liver disease and liver tumorigenesis in 
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NEMOLPC-KO mice suggesting that LPC-specific deficiency of NEMO predominantly 
result in RIPK1 kinase activity-dependent apoptosis. However, RIPK1 scaffolding 
function is needed to block TRADD-dependent complex IIa-mediated apoptosis. 
Accordingly, blocking key mediators of either complex IIa (TRADD) or complex IIb 
(RIPK1) dependent apoptosis was not sufficient in preventing HCC development but 
rather combined LPC-specific deficiency of NEMO, RIPK1 and TRADD	(Kondylis et al. 
2015).  
 
Impaired or inhibited NF-κB activation is thought to sensitize hepatocytes to cell death, 
therefore, inhibited or attenuated NF-κB activation and increased hepatocyte death in 
NEMOLPC-KO and RIPK1LPC-KO mice supports the current model. However, surprisingly, 
p65/RelALPC-KO mice or RelA/RelB/c-RelLPC-KO mice do not phenocopy the liver 
pathology of NEMOLPC-KO mice suggesting independent functions of NEMO and NF-κB 
in mediating HCC development (Kondylis et al. 2015). Interestingly, combined LPC-
specific deficiency of RelA and RIPK1, which independently do not show spontaneous 
HCC development, results in spontaneous HCC development similar to NEMOLPC-KO 
mice suggesting that NEMO or the IKK complex inhibits RIPK1 dependent extrinsic 
apoptosis independently of NF-κB activation (unpublished, Van et al. 2017). 
Significantly, as mentioned before combined LPC-specific ablation of RIPK1 and 
TRAF2 displayed multiple tumors at 52-weeks of age with increased apoptosis and 
proliferation consistent with TRAF2/IKK2LPC-KO mice (Schneider et al. 2017). The 
difference in the pathogenesis of these spontaneous hepatic phenotypes is indicative 
for NF-κB-independent functions of complex-I members. Interestingly, Dondelinger et 
al. reported that IKK-dependent phosphorylation of RIPK1 restrains RIPK1 in complex-I 
preventing RIPK1 kinase-dependent cell death independent of its function in NF-κB 
activation (Dondelinger et al. 2015). IKK1/2LPC-KO mice show similar liver damage as 
NEMOLPC-KO mice but on the contrary reveal a cholastatic phenotype (Luedde et al. 
2008). Supporting the finding of Dondelinger et al., LPC-specific deficiency of RIPK1 
prevented cholestasis and HCC development in IKK1/2LPC-KO mice (Koppe et al. 2016).  
Together these results suggest a combined role for NF-κB-dependent and -
independent signaling in regulating tissue homeostasis and tumorigenesis. Future 
studies will help further understanding the discrepancies between NEMO, NF-κB and 
RIPK1 in HCC development. 
4.7. RIPK1 in human cancer 
Several studies revealed a potential role of RIPK1 in human cancer. Interestingly, 
Wang et al. reported that RIPK1 was overexpressed in 80% of tested human HCC 
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(172/210 patients) which correlated with worse prognosis (Wang et al. 2016). 
Furthermore, they identified a correlation between enhanced expression of RIPK1 and 
supressed cell apoptosis which promoted cell growth in HCC. Accordingly, knockdown 
of RIPK1 restored cell apoptosis resulting in growth arrest of HCC cells (Wang et al. 
2016). Consistently, Liu et al. reported an upregulation in RIPK1 expression in human 
melanoma via DNA copy-number gain and constitutive TNF-mediated ubiquitination. 
Mechanistically, RIPK1 was shown to promote cell proliferation in a NF-κB dependent 
manner (Liu et al. 2015) and through the activation of autophagy (Luan et al. 2015). In 
addition, RIPK1 was implicated in the promotion of breast cancer metastasis through 
NF-κB activation (Bist et al. 2011) and the survival of pancreatic cancer cells against 
TRAIL-induced apoptosis (Wang et al. 2007). Together with our results, these studies 
support a crucial role of RIPK1 in promoting tumorigenesis and metastasis by 
preventing apoptotic death in mouse and most importantly in human indicating that 
RIPK1 might be a promising target for cancer therapy. However, contrary to these 
studies, Schneider et al. emphasized that loss of RIPK1 in human HCC correlated with 
worse prognosis and increasing evidence pointed towards downregulation of RIPK1 in 
many cancer cell lines including metastatic HNSCC (Schneider et al. 2017). These 
data were supported by the finding of Koppe et al. which found RIPK1 downregulation 
in a subgroup of HCC patients with undefined characteristics suggesting an anti-
carcinogenic role of RIPK1 independent of its kinase activity in the liver (Koppe et al. 
2016).  
Given these contradictory data, future studies are essential to help understanding the 
pro- and anti-carcinogenic function of RIPK1 in humans to provide more evidence for 
specific RIPK1 targeting for cancer therapy. 
4.8. Concluding Remarks 
Collectively, the data presented in this work demonstrated a pro-survival kinase-
independent scaffolding-function of RIPK1 in regulating liver cell survival, LPS-induced 
acute liver damage and DEN-induced HCC development. Thus, our data demonstrated 
a pivotal pro-survival role of RIPK1 highlighting RIPK1 on the one hand as a potent 
protector from ALF but on the other hand as a potent driver of HCC development by 
preventing massive hepatocyte apoptosis. Our data on LPS-induced liver injury are in 
agreement with recently published studies while our data on DEN-induced HCC 
revealed a novel crucial role of early short-term apoptosis in reducing HCC 
development by reducing the amount of DNA-damaged cells. Future studies will help 
to further unravel the molecular mechanism of RIPK1 in regulating TNF-mediated cell 
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survival and cell death allowing the design of specific therapeutic strategies for ALF 
and HCC by considering RIPK1 as a specific target. 
References 
 93 
5. References 
 
Abdel-Misih, S. R., and M. Bloomston. 2010. 'Liver anatomy', Surg Clin North Am, 90: 
643-53. 
Akira, S., K. Takeda, and T. Kaisho. 2001. 'Toll-like receptors: critical proteins linking 
innate and acquired immunity', Nat Immunol, 2: 675-80. 
Akira, S., S. Uematsu, and O. Takeuchi. 2006. 'Pathogen recognition and innate 
immunity', Cell, 124: 783-801. 
Alvarez-Diaz, S., C. P. Dillon, N. Lalaoui, M. C. Tanzer, D. A. Rodriguez, A. Lin, M. 
Lebois, R. Hakem, E. C. Josefsson, L. A. O'Reilly, J. Silke, W. S. Alexander, D. 
R. Green, and A. Strasser. 2016. 'The Pseudokinase MLKL and the Kinase 
RIPK3 Have Distinct Roles in Autoimmune Disease Caused by Loss of Death-
Receptor-Induced Apoptosis', Immunity, 45: 513-26. 
Bantel, H., and K. Schulze-Osthoff. 2012. 'Mechanisms of cell death in acute liver 
failure', Front Physiol, 3: 79. 
Baud, V., and M. Karin. 2001. 'Signal transduction by tumor necrosis factor and its 
relatives', Trends Cell Biol, 11: 372-7. 
Bautista, A. P., N. Skrepnik, M. R. Niesman, and G. J. Bagby. 1994. 'Elimination of 
macrophages by liposome-encapsulated dichloromethylene diphosphonate 
suppresses the endotoxin-induced priming of Kupffer cells', J Leukoc Biol, 55: 
321-7. 
Bianchini, F., R. Kaaks, and H. Vainio. 2002. 'Overweight, obesity, and cancer risk', 
Lancet Oncol, 3: 565-74. 
Bieging, K. T., S. S. Mello, and L. D. Attardi. 2014. 'Unravelling mechanisms of p53-
mediated tumour suppression', Nat Rev Cancer, 14: 359-70. 
Bisgaard, H. C., and S. S. Thorgeirsson. 1996. 'Hepatic regeneration. The role of 
regeneration in pathogenesis of chronic liver diseases', Clin Lab Med, 16: 325-
39. 
Biton, S., and A. Ashkenazi. 2011. 'NEMO and RIP1 control cell fate in response to 
extensive DNA damage via TNF-alpha feedforward signaling', Cell, 145: 92-
103. 
Boess, F., M. Bopst, R. Althaus, S. Polsky, S. D. Cohen, H. P. Eugster, and U. A. 
Boelsterli. 1998. 'Acetaminophen hepatotoxicity in tumor necrosis 
factor/lymphotoxin-alpha gene knockout mice', Hepatology, 27: 1021-9. 
Bonnet, M. C., D. Preukschat, P. S. Welz, G. van Loo, M. A. Ermolaeva, W. Bloch, I. 
Haase, and M. Pasparakis. 2011. 'The adaptor protein FADD protects 
epidermal keratinocytes from necroptosis in vivo and prevents skin 
inflammation', Immunity, 35: 572-82. 
Bosanac, I., I. E. Wertz, B. Pan, C. Yu, S. Kusam, C. Lam, L. Phu, Q. Phung, B. 
Maurer, D. Arnott, D. S. Kirkpatrick, V. M. Dixit, and S. G. Hymowitz. 2010. 
'Ubiquitin binding to A20 ZnF4 is required for modulation of NF-kappaB 
signaling', Mol Cell, 40: 548-57. 
Bradham, C. A., J. Plumpe, M. P. Manns, D. A. Brenner, and C. Trautwein. 1998. 
'Mechanisms of hepatic toxicity. I. TNF-induced liver injury', Am J Physiol, 275: 
G387-92. 
Brockhaus, M., H. J. Schoenfeld, E. J. Schlaeger, W. Hunziker, W. Lesslauer, and H. 
Loetscher. 1990. 'Identification of two types of tumor necrosis factor receptors 
on human cell lines by monoclonal antibodies', Proc Natl Acad Sci U S A, 87: 
3127-31. 
Cai, Z., S. Jitkaew, J. Zhao, H. C. Chiang, S. Choksi, J. Liu, Y. Ward, L. G. Wu, and Z. 
G. Liu. 2014. 'Plasma membrane translocation of trimerized MLKL protein is 
required for TNF-induced necroptosis', Nat Cell Biol, 16: 55-65. 
Calle, E. E., and R. Kaaks. 2004. 'Overweight, obesity and cancer: epidemiological 
evidence and proposed mechanisms', Nat Rev Cancer, 4: 579-91. 
Chan, F. K., N. F. Luz, and K. Moriwaki. 2015. 'Programmed necrosis in the cross talk 
of cell death and inflammation', Annu Rev Immunol, 33: 79-106. 
References 
 94 
Chen, L.F. and W.C. Greene. 2004. 'Shaping the nuclear action of NF-kappaB', Nat 
Rev Mol Cell Biol, 5(5):392-401. 
Chen, W., Z. Zhou, L. Li, C. Q. Zhong, X. Zheng, X. Wu, Y. Zhang, H. Ma, D. Huang, 
W. Li, Z. Xia, and J. Han. 2013. 'Diverse sequence determinants control human 
and mouse receptor interacting protein 3 (RIP3) and mixed lineage kinase 
domain-like (MLKL) interaction in necroptotic signaling', J Biol Chem, 288: 
16247-61. 
Cho, Y. S., S. Challa, D. Moquin, R. Genga, T. D. Ray, M. Guildford, and F. K. Chan. 
2009. 'Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates 
programmed necrosis and virus-induced inflammation', Cell, 137: 1112-23. 
Cusson-Hermance, N., S. Khurana, T. H. Lee, K. A. Fitzgerald, and M. A. Kelliher. 
2005. 'Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-
{kappa}B activation but does not contribute to interferon regulatory factor 3 
activation', J Biol Chem, 280: 36560-6. 
Dannappel, M., K. Vlantis, S. Kumari, A. Polykratis, C. Kim, L. Wachsmuth, C. Eftychi, 
J. Lin, T. Corona, N. Hermance, M. Zelic, P. Kirsch, M. Basic, A. Bleich, M. 
Kelliher, and M. Pasparakis. 2014. 'RIPK1 maintains epithelial homeostasis by 
inhibiting apoptosis and necroptosis', Nature, 513: 90-4. 
Dara, L., H. Johnson, J. Suda, S. Win, W. Gaarde, D. Han, and N. Kaplowitz. 2015. 
'Receptor interacting protein kinase 1 mediates murine acetaminophen toxicity 
independent of the necrosome and not through necroptosis', Hepatology, 62: 
1847-57. 
Dara, L.,Z.X., Liu, N., Kaplowitz. 2016.'Questions and controversies: The role of 
necroptosis in liver disease', Cell death Discov,5;2:16089. 
de Almagro, M. C., T. Goncharov, A. Izrael-Tomasevic, S. Duttler, M. Kist, E. 
Varfolomeev, X. Wu, W. P. Lee, J. Murray, J. D. Webster, K. Yu, D. S. 
Kirkpatrick, K. Newton, and D. Vucic. 2017. 'Coordinated ubiquitination and 
phosphorylation of RIP1 regulates necroptotic cell death', Cell Death Differ, 24: 
26-37. 
de Almagro, M. C., T. Goncharov, K. Newton, and D. Vucic. 2015. 'Cellular IAP 
proteins and LUBAC differentially regulate necrosome-associated RIP1 
ubiquitination', Cell Death Dis, 6: e1800. 
Degterev, A., J. Hitomi, M. Germscheid, I. L. Ch'en, O. Korkina, X. Teng, D. Abbott, G. 
D. Cuny, C. Yuan, G. Wagner, S. M. Hedrick, S. A. Gerber, A. Lugovskoy, and 
J. Yuan. 2008. 'Identification of RIP1 kinase as a specific cellular target of 
necrostatins', Nat Chem Biol, 4: 313-21. 
Degterev, A., Z. Huang, M. Boyce, Y. Li, P. Jagtap, N. Mizushima, G. D. Cuny, T. J. 
Mitchison, M. A. Moskowitz, and J. Yuan. 2005. 'Chemical inhibitor of 
nonapoptotic cell death with therapeutic potential for ischemic brain injury', Nat 
Chem Biol, 1: 112-9. 
Dembic, Z., H. Loetscher, U. Gubler, Y. C. Pan, H. W. Lahm, R. Gentz, M. Brockhaus, 
and W. Lesslauer. 1990. 'Two human TNF receptors have similar extracellular, 
but distinct intracellular, domain sequences', Cytokine, 2: 231-7. 
Depuydt, B., G. van Loo, P. Vandenabeele, and W. Declercq. 2005. 'Induction of 
apoptosis by TNF receptor 2 in a T-cell hybridoma is FADD dependent and 
blocked by Caspase-8 inhibitors', J Cell Sci, 118: 497-504. 
Dietschy, J. M., S. D. Turley, and D. K. Spady. 1993. 'Role of liver in the maintenance 
of cholesterol and low density lipoprotein homeostasis in different animal 
species, including humans', J Lipid Res, 34: 1637-59. 
Dillon, C. P., A. Oberst, R. Weinlich, L. J. Janke, T. B. Kang, T. Ben-Moshe, T. W. 
Mak, D. Wallach, and D. R. Green. 2012. 'Survival function of the FADD-
CASPASE-8-cFLIP(L) complex', Cell Rep, 1: 401-7. 
Dillon, C. P., R. Weinlich, D. A. Rodriguez, J. G. Cripps, G. Quarato, P. Gurung, K. C. 
Verbist, T. L. Brewer, F. Llambi, Y. N. Gong, L. J. Janke, M. A. Kelliher, T. D. 
Kanneganti, and D. R. Green. 2014. 'RIPK1 blocks early postnatal lethality 
mediated by Caspase-8 and RIPK3', Cell, 157: 1189-202. 
References 
 95 
Dondelinger, Y., M. A. Aguileta, V. Goossens, C. Dubuisson, S. Grootjans, E. Dejardin, 
P. Vandenabeele, and M. J. Bertrand. 2013. 'RIPK3 contributes to TNFR1-
mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion 
or TAK1 kinase inhibition', Cell Death Differ, 20: 1381-92. 
Dondelinger, Y., W. Declercq, S. Montessuit, R. Roelandt, A. Goncalves, I. 
Bruggeman, P. Hulpiau, K. Weber, C. A. Sehon, R. W. Marquis, J. Bertin, P. J. 
Gough, S. Savvides, J. C. Martinou, M. J. Bertrand, and P. Vandenabeele. 
2014. 'MLKL compromises plasma membrane integrity by binding to 
phosphatidylinositol phosphates', Cell Rep, 7: 971-81. 
Dondelinger, Y., S. Jouan-Lanhouet, T. Divert, E. Theatre, J. Bertin, P. J. Gough, P. 
Giansanti, A. J. Heck, E. Dejardin, P. Vandenabeele, and M. J. Bertrand. 2015. 
'NF-kappaB-Independent Role of IKKalpha/IKKbeta in Preventing RIPK1 
Kinase-Dependent Apoptotic and Necroptotic Cell Death during TNF Signaling', 
Mol Cell, 60: 63-76. 
Draber, P., S. Kupka, M. Reichert, H. Draberova, E. Lafont, D. de Miguel, L. Spilgies, 
S. Surinova, L. Taraborrelli, T. Hartwig, E. Rieser, L. Martino, K. Rittinger, and 
H. Walczak. 2015. 'LUBAC-Recruited CYLD and A20 Regulate Gene Activation 
and Cell Death by Exerting Opposing Effects on Linear Ubiquitin in Signaling 
Complexes', Cell Rep, 13: 2258-72. 
Dynek, J. N., T. Goncharov, E. C. Dueber, A. V. Fedorova, A. Izrael-Tomasevic, L. 
Phu, E. Helgason, W. J. Fairbrother, K. Deshayes, D. S. Kirkpatrick, and D. 
Vucic. 2010. 'c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 
in TNF signalling', EMBO J, 29: 4198-209. 
Ea, C. K., L. Deng, Z. P. Xia, G. Pineda, and Z. J. Chen. 2006. 'Activation of IKK by 
TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding 
by NEMO', Mol Cell, 22: 245-57. 
Ehlken, H., S. Krishna-Subramanian, L. Ochoa-Callejero, V. Kondylis, N. E. Nadi, B. K. 
Straub, P. Schirmacher, H. Walczak, G. Kollias, and M. Pasparakis. 2014. 
'Death receptor-independent FADD signalling triggers hepatitis and 
hepatocellular carcinoma in mice with liver parenchymal cell-specific NEMO 
knockout', Cell Death Differ, 21: 1721-32. 
El-Serag, H. B. 2011. 'Hepatocellular carcinoma', N Engl J Med, 365: 1118-27. 
Fausto, N. 2004. 'Liver regeneration and repair: hepatocytes, progenitor cells, and 
stem cells', Hepatology, 39: 1477-87. 
Feoktistova, M., P. Geserick, B. Kellert, D. P. Dimitrova, C. Langlais, M. Hupe, K. Cain, 
M. MacFarlane, G. Hacker, and M. Leverkus. 2011. 'cIAPs block Ripoptosome 
formation, a RIP1/Caspase-8 containing intracellular cell death complex 
differentially regulated by cFLIP isoforms', Mol Cell, 43: 449-63. 
Festjens, N., T. Vanden Berghe, S. Cornelis, and P. Vandenabeele. 2007. 'RIP1, a 
kinase on the crossroads of a cell's decision to live or die', Cell Death Differ, 14: 
400-10. 
Freudenberg, M. A., D. Keppler, and C. Galanos. 1986. 'Requirement for 
lipopolysaccharide-responsive macrophages in galactosamine-induced 
sensitization to endotoxin', Infect Immun, 51: 891-5. 
Fu, T. M., Y. Li, A. Lu, Z. Li, P. R. Vajjhala, A. C. Cruz, D. B. Srivastava, F. DiMaio, P. 
A. Penczek, R. M. Siegel, K. J. Stacey, E. H. Egelman, and H. Wu. 2016. 'Cryo-
EM Structure of Caspase-8 Tandem DED Filament Reveals Assembly and 
Regulation Mechanisms of the Death-Inducing Signaling Complex', Mol Cell, 
64: 236-50. 
Ghosh, S., and M. S. Hayden. 2008. 'New regulators of NF-kappaB in inflammation', 
Nat Rev Immunol, 8: 837-48. 
Green, D. R., T. Ferguson, L. Zitvogel, and G. Kroemer. 2009. 'Immunogenic and 
tolerogenic cell death', Nat Rev Immunol, 9: 353-63. 
Gross, A., X. M. Yin, K. Wang, M. C. Wei, J. Jockel, C. Milliman, H. Erdjument-
Bromage, P. Tempst, and S. J. Korsmeyer. 1999. 'Caspase cleaved BID 
targets mitochondria and is required for cytochrome c release, while BCL-XL 
References 
 96 
prevents this release but not tumor necrosis factor-R1/Fas death', J Biol Chem, 
274: 1156-63. 
Gruber, S., B. K. Straub, P. J. Ackermann, C. M. Wunderlich, J. Mauer, J. M. Seeger, 
H. Buning, L. Heukamp, H. Kashkar, P. Schirmacher, J. C. Bruning, and F. T. 
Wunderlich. 2013. 'Obesity promotes liver carcinogenesis via Mcl-1 stabilization 
independent of IL-6Ralpha signaling', Cell Rep, 4: 669-80. 
Guicciardi, M. E., H. Malhi, J. L. Mott, and G. J. Gores. 2013. 'Apoptosis and necrosis 
in the liver', Compr Physiol, 3: 977-1010. 
Gunther, C., G. W. He, A. E. Kremer, J. M. Murphy, E. J. Petrie, K. Amann, P. 
Vandenabeele, A. Linkermann, C. Poremba, U. Schleicher, C. Dewitz, S. 
Krautwald, M. F. Neurath, C. Becker, and S. Wirtz. 2016. 'The pseudokinase 
MLKL mediates programmed hepatocellular necrosis independently of RIPK3 
during hepatitis', J Clin Invest, 126: 4346-60. 
Hakem, R., A. Hakem, G. S. Duncan, J. T. Henderson, M. Woo, M. S. Soengas, A. 
Elia, J. L. de la Pompa, D. Kagi, W. Khoo, J. Potter, R. Yoshida, S. A. Kaufman, 
S. W. Lowe, J. M. Penninger, and T. W. Mak. 1998. 'Differential requirement for 
Caspase 9 in apoptotic pathways in vivo', Cell, 94: 339-52. 
Haas, T. L., C. H. Emmerich, B. Gerlach, A. C. Schmukle, S. M. Cordier, E. Rieser, R. 
Feltham, J. Vince, U. Warnken, T. Wenger, R. Koschny, D. Komander, J. Silke, 
and H. Walczak. 2009. 'Recruitment of the linear ubiquitin chain assembly 
complex stabilizes the TNF-R1 signaling complex and is required for TNF-
mediated gene induction', Mol Cell, 36: 831-44. 
Hayden, M. S., and S. Ghosh. 2008. 'Shared principles in NF-kappaB signaling', Cell, 
132: 344-62. 
———. 2012. 'NF-kappaB, the first quarter-century: remarkable progress and 
outstanding questions', Genes Dev, 26: 203-34. 
Hayden, M. S., and S. Ghosh. 2014. 'Regulation of NF-kappaB by TNF family 
cytokines', Semin Immunol, 26: 253-66. 
He, S., Y. Liang, F. Shao, and X. Wang. 2011. 'Toll-like receptors activate programmed 
necrosis in macrophages through a receptor-interacting kinase-3-mediated 
pathway', Proc Natl Acad Sci U S A, 108: 20054-9. 
He, S., L. Wang, L. Miao, T. Wang, F. Du, L. Zhao, and X. Wang. 2009. 'Receptor 
interacting protein kinase-3 determines cellular necrotic response to TNF-
alpha', Cell, 137: 1100-11. 
Hill-Baskin, A. E., M. M. Markiewski, D. A. Buchner, H. Shao, D. DeSantis, G. Hsiao, S. 
Subramaniam, N. A. Berger, C. Croniger, J. D. Lambris, and J. H. Nadeau. 
2009. 'Diet-induced hepatocellular carcinoma in genetically predisposed mice', 
Hum Mol Genet, 18: 2975-88. 
Hinson, J. A., N. R. Pumford, and D. W. Roberts. 1995. 'Mechanisms of 
acetaminophen toxicity: immunochemical detection of drug-protein adducts', 
Drug Metab Rev, 27: 73-92. 
Hoshino, K., O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa, Y. Takeda, K. Takeda, and S. 
Akira. 1999. 'Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are 
hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene 
product', J Immunol, 162: 3749-52. 
Hsu, H., J. Huang, H. B. Shu, V. Baichwal, and D. V. Goeddel. 1996. 'TNF-dependent 
recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex', 
Immunity, 4: 387-96. 
Hsu, H., H. B. Shu, M. G. Pan, and D. V. Goeddel. 1996. 'TRADD-TRAF2 and TRADD-
FADD interactions define two distinct TNF receptor 1 signal transduction 
pathways', Cell, 84: 299-308. 
Hsu, H., J. Xiong, and D. V. Goeddel. 1995. 'The TNF receptor 1-associated protein 
TRADD signals cell death and NF-kappa B activation', Cell, 81: 495-504. 
Hughes, M. A., I. R. Powley, R. Jukes-Jones, S. Horn, M. Feoktistova, L. Fairall, J. W. 
Schwabe, M. Leverkus, K. Cain, and M. MacFarlane. 2016. 'Co-operative and 
References 
 97 
Hierarchical Binding of c-FLIP and Caspase-8: A Unified Model Defines How c-
FLIP Isoforms Differentially Control Cell Fate', Mol Cell, 61: 834-49. 
Hur, G. M., J. Lewis, Q. Yang, Y. Lin, H. Nakano, S. Nedospasov, and Z. G. Liu. 2003. 
'The death domain kinase RIP has an essential role in DNA damage-induced 
NF-kappa B activation', Genes Dev, 17: 873-82. 
Ikeda, F., Y. L. Deribe, S. S. Skanland, B. Stieglitz, C. Grabbe, M. Franz-Wachtel, S. J. 
van Wijk, P. Goswami, V. Nagy, J. Terzic, F. Tokunaga, A. Androulidaki, T. 
Nakagawa, M. Pasparakis, K. Iwai, J. P. Sundberg, L. Schaefer, K. Rittinger, B. 
Macek, and I. Dikic. 2011. 'SHARPIN forms a linear ubiquitin ligase complex 
regulating NF-kappaB activity and apoptosis', Nature, 471: 637-41. 
Janeway, C. A., Jr., and R. Medzhitov. 2002. 'Innate immune recognition', Annu Rev 
Immunol, 20: 197-216. 
Jaworski, M., A. Buchmann, P. Bauer, O. Riess, and M. Schwarz. 2005. 'B-raf and Ha-
ras mutations in chemically induced mouse liver tumors', Oncogene, 24: 1290-
5. 
Kaiser, W. J., and M. K. Offermann. 2005. 'Apoptosis induced by the toll-like receptor 
adaptor TRIF is dependent on its receptor interacting protein homotypic 
interaction motif', J Immunol, 174: 4942-52. 
Kaiser, W. J., J. W. Upton, A. B. Long, D. Livingston-Rosanoff, L. P. Daley-Bauer, R. 
Hakem, T. Caspary, and E. S. Mocarski. 2011. 'RIP3 mediates the embryonic 
lethality of Caspase-8-deficient mice', Nature, 471: 368-72. 
Kanayama, A., R. B. Seth, L. Sun, C. K. Ea, M. Hong, A. Shaito, Y. H. Chiu, L. Deng, 
and Z. J. Chen. 2004. 'TAB2 and TAB3 activate the NF-kappaB pathway 
through binding to polyubiquitin chains', Mol Cell, 15: 535-48. 
Kawai, T., and S. Akira. 2010. 'The role of pattern-recognition receptors in innate 
immunity: update on Toll-like receptors', Nat Immunol, 11: 373-84. 
Kelliher, M. A., S. Grimm, Y. Ishida, F. Kuo, B. Z. Stanger, and P. Leder. 1998. 'The 
death domain kinase RIP mediates the TNF-induced NF-kappaB signal', 
Immunity, 8: 297-303. 
Keppler, D. O., J. Pausch, and K. Decker. 1974. 'Selective uridine triphosphate 
deficiency induced by D-galactosamine in liver and reversed by pyrimidine 
nucleotide precursors. Effect on ribonucleic acid synthesis', J Biol Chem, 249: 
211-6. 
Kerr, J. F., A. H. Wyllie, and A. R. Currie. 1972. 'Apoptosis: a basic biological 
phenomenon with wide-ranging implications in tissue kinetics', Br J Cancer, 26: 
239-57. 
Kim, E. Y., and H. S. Teh. 2001. 'TNF type 2 receptor (p75) lowers the threshold of T 
cell activation', J Immunol, 167: 6812-20. 
Kmiec, Z. 2001. 'Cooperation of liver cells in health and disease', Adv Anat Embryol 
Cell Biol, 161: III-XIII, 1-151. 
Koch, K. S., S. Maeda, G. He, M. Karin, and H. L. Leffert. 2009. 'Targeted deletion of 
hepatocyte Ikkbeta confers growth advantages', Biochem Biophys Res 
Commun, 380: 349-54. 
Kondylis, V., A. Polykratis, H. Ehlken, L. Ochoa-Callejero, B. K. Straub, S. Krishna-
Subramanian, T. M. Van, H. M. Curth, N. Heise, F. Weih, U. Klein, P. 
Schirmacher, M. Kelliher, and M. Pasparakis. 2015. 'NEMO Prevents 
Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase 
Activity-Mediated Hepatocyte Apoptosis', Cancer Cell, 28: 582-98. 
Kono, H., and K. L. Rock. 2008. 'How dying cells alert the immune system to danger', 
Nat Rev Immunol, 8: 279-89. 
Koppe, C., P. Verheugd, J. Gautheron, F. Reisinger, K. Kreggenwinkel, C. Roderburg, 
L. Quagliata, L. Terracciano, N. Gassler, R. H. Tolba, Y. Boege, A. Weber, M. 
Karin, M. Luedde, U. P. Neumann, R. Weiskirchen, F. Tacke, M. Vucur, C. 
Trautwein, B. Luscher, C. Preisinger, M. Heikenwalder, and T. Luedde. 2016. 
'IkappaB kinasealpha/beta control biliary homeostasis and 
References 
 98 
hepatocarcinogenesis in mice by phosphorylating the cell-death mediator 
receptor-interacting protein kinase 1', Hepatology, 64: 1217-31. 
Krysko, D. V., T. Vanden Berghe, K. D'Herde, and P. Vandenabeele. 2008. 'Apoptosis 
and necrosis: detection, discrimination and phagocytosis', Methods, 44: 205-21. 
Kuida, K., T. S. Zheng, S. Na, C. Kuan, D. Yang, H. Karasuyama, P. Rakic, and R. A. 
Flavell. 1996. 'Decreased apoptosis in the brain and premature lethality in 
CPP32-deficient mice', Nature, 384: 368-72. 
Lamkanfi, M., and V. M. Dixit. 2010. 'Manipulation of host cell death pathways during 
microbial infections', Cell Host Microbe, 8: 44-54. 
Lee, T. H., J. Shank, N. Cusson, and M. A. Kelliher. 2004. 'The kinase activity of Rip1 
is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 
MAP kinase activation or for the ubiquitination of Rip1 by Traf2', J Biol Chem, 
279: 33185-91. 
Legarda-Addison, D., H. Hase, M. A. O'Donnell, and A. T. Ting. 2009. 
'NEMO/IKKgamma regulates an early NF-kappaB-independent cell-death 
checkpoint during TNF signaling', Cell Death Differ, 16: 1279-88. 
Legler, D. F., O. Micheau, M. A. Doucey, J. Tschopp, and C. Bron. 2003. 'Recruitment 
of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB 
activation', Immunity, 18: 655-64. 
Li, H., M. Kobayashi, M. Blonska, Y. You, and X. Lin. 2006. 'Ubiquitination of RIP is 
required for tumor necrosis factor alpha-induced NF-kappaB activation', J Biol 
Chem, 281: 13636-43. 
Li, H., H. Zhu, C. J. Xu, and J. Yuan. 1998. 'Cleavage of BID by Caspase 8 mediates 
the mitochondrial damage in the Fas pathway of apoptosis', Cell, 94: 491-501. 
Li, J., T. McQuade, A. B. Siemer, J. Napetschnig, K. Moriwaki, Y. S. Hsiao, E. Damko, 
D. Moquin, T. Walz, A. McDermott, F. K. Chan, and H. Wu. 2012. 'The 
RIP1/RIP3 necrosome forms a functional amyloid signaling complex required 
for programmed necrosis', Cell, 150: 339-50. 
Li, N., S. Banin, H. Ouyang, G. C. Li, G. Courtois, Y. Shiloh, M. Karin, and G. Rotman. 
2001. 'ATM is required for IkappaB kinase (IKKk) activation in response to DNA 
double strand breaks', J Biol Chem, 276: 8898-903. 
Lin, J., S. Kumari, C. Kim, T. M. Van, L. Wachsmuth, A. Polykratis, and M. Pasparakis. 
2016. 'RIPK1 counteracts ZBP1-mediated necroptosis to inhibit inflammation', 
Nature, 540: 124-28. 
Lin, Y., A. Devin, Y. Rodriguez, and Z. G. Liu. 1999. 'Cleavage of the death domain 
kinase RIP by Caspase-8 prompts TNF-induced apoptosis', Genes Dev, 13: 
2514-26. 
Liu, L. M., J. X. Zhang, J. Luo, H. X. Guo, H. Deng, J. Y. Chen, and S. L. Sun. 2008. 'A 
role of cell apoptosis in lipopolysaccharide (LPS)-induced nonlethal liver injury 
in D-galactosamine (D-GalN)-sensitized rats', Dig Dis Sci, 53: 1316-24. 
Liu, X.Y., F., Lai, X. G. Yan, C.C. Jiang, S. T. Guo, C. Y. Wang, A. Croft, H.Y. Tseng, 
J. 
   S. Wilmott, R. A. Scolyer, L. Jin, X. D. Zhang. 2015.'RIP1 Kinase Is an 
Oncogenic 
           Driver in Melanoma', Cancer Res,75(8): 1736-1748. 
Locksley, R. M., N. Killeen, and M. J. Lenardo. 2001. 'The TNF and TNF receptor 
superfamilies: integrating mammalian biology', Cell, 104: 487-501. 
Luan, Q., L. Jin, C. C. Jiang, K. H. Tay, F. Lai, X. Y. Liu, Y. L. Liu, S. T. Guo, C. Y. Li, 
X. G. Yan, H. Y. Tseng, and X. D. Zhang. 2015. 'RIPK1 regulates survival of 
human melanoma cells upon endoplasmic reticulum stress through autophagy', 
Autophagy, 11: 975-94. 
Luedde, T., J. Heinrichsdorff, R. de Lorenzi, R. De Vos, T. Roskams, and M. 
Pasparakis. 2008. 'IKK1 and IKK2 cooperate to maintain bile duct integrity in 
the liver', Proc Natl Acad Sci U S A, 105: 9733-8. 
References 
 99 
Luedde, T., N. Kaplowitz, and R. F. Schwabe. 2014. 'Cell death and cell death 
responses in liver disease: mechanisms and clinical relevance', 
Gastroenterology, 147: 765-83 e4. 
Luo, X., I. Budihardjo, H. Zou, C. Slaughter, and X. Wang. 1998. 'Bid, a Bcl2 
interacting protein, mediates cytochrome c release from mitochondria in 
response to activation of cell surface death receptors', Cell, 94: 481-90. 
Lukas, J., C. Lukas, and J. Bartek. 2011. 'More than just a focus: The chromatin 
response to DNA damage and its role in genome integrity maintenance', Nat 
Cell Biol, 13: 1161-9. 
Luster, M. I., D. R. Germolec, T. Yoshida, F. Kayama, and M. Thompson. 1994. 
'Endotoxin-induced cytokine gene expression and excretion in the liver', 
Hepatology, 19: 480-8. 
Maeda, S., H. Kamata, J. L. Luo, H. Leffert, and M. Karin. 2005. 'IKKbeta couples 
hepatocyte death to cytokine-driven compensatory proliferation that promotes 
chemical hepatocarcinogenesis', Cell, 121: 977-90. 
Mahoney, D. J., H. H. Cheung, R. L. Mrad, S. Plenchette, C. Simard, E. Enwere, V. 
Arora, T. W. Mak, E. C. Lacasse, J. Waring, and R. G. Korneluk. 2008. 'Both 
cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation', Proc 
Natl Acad Sci U S A, 105: 11778-83. 
Martich, G. D., A. J. Boujoukos, and A. F. Suffredini. 1993. 'Response of man to 
endotoxin', Immunobiology, 187: 403-16. 
Martins, P. N., T. P. Theruvath, and P. Neuhaus. 2008. 'Rodent models of partial 
hepatectomies', Liver Int, 28: 3-11. 
Mc Guire, C., T. Volckaert, U. Wolke, M. Sze, R. de Rycke, A. Waisman, M. Prinz, R. 
Beyaert, M. Pasparakis, and G. van Loo. 2010. 'Oligodendrocyte-specific FADD 
deletion protects mice from autoimmune-mediated demyelination', J Immunol, 
185: 7646-53. 
McQuade, T., Y. Cho, and F. K. Chan. 2013. 'Positive and negative phosphorylation 
regulates RIP1- and RIP3-induced programmed necrosis', Biochem J, 456: 
409-15. 
Medema, J. P., C. Scaffidi, F. C. Kischkel, A. Shevchenko, M. Mann, P. H. Krammer, 
and M. E. Peter. 1997. 'FLICE is activated by association with the CD95 death-
inducing signaling complex (DISC)', EMBO J, 16: 2794-804. 
Medema, J. P., R. E. Toes, C. Scaffidi, T. S. Zheng, R. A. Flavell, C. J. Melief, M. E. 
Peter, R. Offringa, and P. H. Krammer. 1997. 'Cleavage of FLICE (Caspase-8) 
by granzyme B during cytotoxic T lymphocyte-induced apoptosis', Eur J 
Immunol, 27: 3492-8. 
Mercurio, F., H. Zhu, B. W. Murray, A. Shevchenko, B. L. Bennett, J. Li, D. B. Young, 
M. Barbosa, M. Mann, A. Manning, and A. Rao. 1997. 'IKK-1 and IKK-2: 
cytokine-activated IkappaB kinases essential for NF-kappaB activation', 
Science, 278: 860-6. 
Mevissen, T. E., M. K. Hospenthal, P. P. Geurink, P. R. Elliott, M. Akutsu, N. Arnaudo, 
R. Ekkebus, Y. Kulathu, T. Wauer, F. El Oualid, S. M. Freund, H. Ovaa, and D. 
Komander. 2013. 'OTU deubiquitinases reveal mechanisms of linkage 
specificity and enable ubiquitin chain restriction analysis', Cell, 154: 169-84. 
Micheau, O., and J. Tschopp. 2003. 'Induction of TNF receptor I-mediated apoptosis 
via two sequential signaling complexes', Cell, 114: 181-90. 
Mitchell, J. R., D. J. Jollow, W. Z. Potter, D. C. Davis, J. R. Gillette, and B. B. Brodie. 
1973. 'Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism', J 
Pha 
Mitchell, S., J. Vargas, and A. Hoffmann. 2016. 'Signaling via the NFkappaB system', 
Wiley Interdiscip Rev Syst Biol Med, 8: 227-41. 
Mizuhara, H., E. O'Neill, N. Seki, T. Ogawa, C. Kusunoki, K. Otsuka, S. Satoh, M. 
Niwa, H. Senoh, and H. Fujiwara. 1994. 'T cell activation-associated hepatic 
injury: mediation by tumor necrosis factors and protection by interleukin 6', J 
Exp Med, 179: 1529-37. 
References 
 100 
Mitchell, S., J. Vargas, and A. Hoffmann. 2016. 'Signaling via the NFkappaB system', 
Wiley Interdiscip Rev Syst Biol Med, 8: 227-41. 
Mollah, S., I. E. Wertz, Q. Phung, D. Arnott, V. M. Dixit, and J. R. Lill. 2007. 'Targeted 
mass spectrometric strategy for global mapping of ubiquitination on proteins', 
Rapid Commun Mass Spectrom, 21: 3357-64. 
Moulin, M., H. Anderton, A. K. Voss, T. Thomas, W. W. Wong, A. Bankovacki, R. 
Feltham, D. Chau, W. D. Cook, J. Silke, and D. L. Vaux. 2012. 'IAPs limit 
activation of RIP kinases by TNF receptor 1 during development', EMBO J, 31: 
1679-91. 
Moquin, D. M., T. McQuade, and F. K. Chan. 2013. 'CYLD deubiquitinates RIP1 in the 
TNFalpha-induced necrosome to facilitate kinase activation and programmed 
necrosis', PLoS One, 8: e76841. 
Morikawa, A., T. Sugiyama, Y. Kato, N. Koide, G. Z. Jiang, K. Takahashi, Y. Tamada, 
and T. Yokochi. 1996. 'Apoptotic cell death in the response of D-
galactosamine-sensitized mice to lipopolysaccharide as an experimental 
endotoxic shock model', Infect Immun, 64: 734-8. 
Murphy, J. M., P. E. Czabotar, J. M. Hildebrand, I. S. Lucet, J. G. Zhang, S. Alvarez-
Diaz, R. Lewis, N. Lalaoui, D. Metcalf, A. I. Webb, S. N. Young, L. N. Varghese, 
G. M. Tannahill, E. C. Hatchell, I. J. Majewski, T. Okamoto, R. C. Dobson, D. J. 
Hilton, J. J. Babon, N. A. Nicola, A. Strasser, J. Silke, and W. S. Alexander. 
2013. 'The pseudokinase MLKL mediates necroptosis via a molecular switch 
mechanism', Immunity, 39: 443-53. 
Naugler, W. E., T. Sakurai, S. Kim, S. Maeda, K. Kim, A. M. Elsharkawy, and M. Karin. 
2007. 'Gender disparity in liver cancer due to sex differences in MyD88-
dependent IL-6 production', Science, 317: 121-4. 
Nelson, S. D. 1990. 'Molecular mechanisms of the hepatotoxicity caused by 
acetaminophen', Semin Liver Dis, 10: 267-78. 
Newton, K., D. L. Dugger, K. E. Wickliffe, N. Kapoor, M. C. de Almagro, D. Vucic, L. 
Komuves, R. E. Ferrando, D. M. French, J. Webster, M. Roose-Girma, S. 
Warming, and V. M. Dixit. 2014. 'Activity of protein kinase RIPK3 determines 
whether cells die by necroptosis or apoptosis', Science, 343: 1357-60. 
Newton, K., K. E. Wickliffe, A. Maltzman, D. L. Dugger, A. Strasser, V. C. Pham, J. R. 
Lill, M. Roose-Girma, S. Warming, M. Solon, H. Ngu, J. D. Webster, and V. M. 
Dixit. 2016. 'RIPK1 inhibits ZBP1-driven necroptosis during development', 
Nature, 540: 129-33. 
Ni, H. M., M. R. McGill, X. Chao, B. L. Woolbright, H. Jaeschke, and W. X. Ding. 2016. 
'Caspase Inhibition Prevents Tumor Necrosis Factor-alpha-Induced Apoptosis 
and Promotes Necrotic Cell Death in Mouse Hepatocytes in Vivo and in Vitro', 
Am J Pathol, 186: 2623-36. 
O'Donnell, M. A., D. Legarda-Addison, P. Skountzos, W. C. Yeh, and A. T. Ting. 2007. 
'Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch 
in TNF signaling', Curr Biol, 17: 418-24. 
Onizawa, M., S. Oshima, U. Schulze-Topphoff, J. A. Oses-Prieto, T. Lu, R. Tavares, T. 
Prodhomme, B. Duong, M. I. Whang, R. Advincula, A. Agelidis, J. Barrera, H. 
Wu, A. Burlingame, B. A. Malynn, S. S. Zamvil, and A. Ma. 2015. 'The ubiquitin-
modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects 
cells from necroptosis', Nat Immunol, 16: 618-27. 
Park, E. J., J. H. Lee, G. Y. Yu, G. He, S. R. Ali, R. G. Holzer, C. H. Osterreicher, H. 
Takahashi, and M. Karin. 2010. 'Dietary and genetic obesity promote liver 
inflammation and tumorigenesis by enhancing IL-6 and TNF expression', Cell, 
140: 197-208. 
Park, S. M., J. B. Yoon, and T. H. Lee. 2004. 'Receptor interacting protein is 
ubiquitinated by cellular inhibitor of apoptosis proteins (c-IAP1 and c-IAP2) in 
vitro', FEBS Lett, 566: 151-6. 
Pasparakis, M., and P. Vandenabeele. 2015. 'Necroptosis and its role in inflammation', 
Nature, 517: 311-20. 
References 
 101 
Pearson, G., F. Robinson, T. Beers Gibson, B. E. Xu, M. Karandikar, K. Berman, and 
M. H. Cobb. 2001. 'Mitogen-activated protein (MAP) kinase pathways: 
regulation and physiological functions', Endocr Rev, 22: 153-83. 
Piret, B., S. Schoonbroodt, and J. Piette. 1999. 'The ATM protein is required for 
sustained activation of NF-kappaB following DNA damage', Oncogene, 18: 
2261-71. 
Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, 
M. Silva, C. Galanos, M. Freudenberg, P. Ricciardi-Castagnoli, B. Layton, and 
B. Beutler. 1998. 'Defective LPS signaling in C3H/HeJ and C57BL/10ScCr 
mice: mutations in Tlr4 gene', Science, 282: 2085-8. 
Polykratis, A., N. Hermance, M. Zelic, J. Roderick, C. Kim, T. M. Van, T. H. Lee, F. K. 
Chan, M. Pasparakis, and M. A. Kelliher. 2014. 'Cutting edge: RIPK1 Kinase 
inactive mice are viable and protected from TNF-induced necroptosis in vivo', J 
Immunol, 193: 1539-43. 
Poon, I. K., C. D. Lucas, A. G. Rossi, and K. S. Ravichandran. 2014. 'Apoptotic cell 
clearance: basic biology and therapeutic potential', Nat Rev Immunol, 14: 166-
80. 
Pop, C., A. Oberst, M. Drag, B. J. Van Raam, S. J. Riedl, D. R. Green, and G. S. 
Salvesen. 2011. 'FLIP(L) induces Caspase 8 activity in the absence of 
interdomain Caspase 8 cleavage and alters substrate specificity', Biochem J, 
433: 447-57. 
Pobezinskaya, Y. L., Y. S. Kim, S. Choksi, M. J. Morgan, T. Li, C. Liu, and Z. Liu. 2008. 
'The function of TRADD in signaling through tumor necrosis factor receptor 1 
and TRIF-dependent Toll-like receptors', Nat Immunol, 9: 1047-54. 
Qiu, W., X. Wang, B. Leibowitz, W. Yang, L. Zhang, and J. Yu. 2011. 'PUMA-mediated 
apoptosis drives chemical hepatocarcinogenesis in mice', Hepatology, 54: 
1249-58. 
Qureshi, S. T., L. Lariviere, G. Leveque, S. Clermont, K. J. Moore, P. Gros, and D. 
Malo. 1999. 'Endotoxin-tolerant mice have mutations in Toll-like receptor 4 
(Tlr4)', J Exp Med, 189: 615-25. 
Racanelli, V., and B. Rehermann. 2006. 'The liver as an immunological organ', 
Hepatology, 43: S54-62. 
Rahighi, S., F. Ikeda, M. Kawasaki, M. Akutsu, N. Suzuki, R. Kato, T. Kensche, T. 
Uejima, S. Bloor, D. Komander, F. Randow, S. Wakatsuki, and I. Dikic. 2009. 
'Specific recognition of linear ubiquitin chains by NEMO is important for NF-
kappaB activation', Cell, 136: 1098-109. 
Rajewsky, K., H. Gu, R. Kuhn, U. A. Betz, W. Muller, J. Roes, and F. Schwenk. 1996. 
'Conditional gene targeting', J Clin Invest, 98: 600-3. 
Rajput, A., A. Kovalenko, K. Bogdanov, S. H. Yang, T. B. Kang, J. C. Kim, J. Du, and 
D. Wallach. 2011. 'RIG-I RNA helicase activation of IRF3 transcription factor is 
negatively regulated by Caspase-8-mediated cleavage of the RIP1 protein', 
Immunity, 34: 340-51. 
Rao, K. V., and S. D. Vesselinovitch. 1973. 'Age- and sex-associated 
diethylnitrosamine dealkylation activity of the mouse liver and 
hepatocarcinogenesis', Cancer Res, 33: 1625-7. 
Rebsamen, M., L. X. Heinz, E. Meylan, M. C. Michallet, K. Schroder, K. Hofmann, J. 
Vazquez, C. A. Benedict, and J. Tschopp. 2009. 'DAI/ZBP1 recruits RIP1 and 
RIP3 through RIP homotypic interaction motifs to activate NF-kappaB', EMBO 
Rep, 10: 916-22. 
Ritorto, M. S., R. Ewan, A. B. Perez-Oliva, A. Knebel, S. J. Buhrlage, M. Wightman, S. 
M. Kelly, N. T. Wood, S. Virdee, N. S. Gray, N. A. Morrice, D. R. Alessi, and M. 
Trost. 2014. 'Screening of DUB activity and specificity by MALDI-TOF mass 
spectrometry', Nat Commun, 5: 4763. 
Rothwarf, D. M., and M. Karin. 1999. 'The NF-kappa B activation pathway: a paradigm 
in information transfer from membrane to nucleus', Sci STKE, 1999: RE1. 
References 
 102 
Sabio, G., and R. J. Davis. 2014. 'TNF and MAP kinase signalling pathways', Semin 
Immunol, 26: 237-45. 
Sakurai, H., H. Miyoshi, J. Mizukami, and T. Sugita. 2000. 'Phosphorylation-dependent 
activation of TAK1 mitogen-activated protein kinase kinase kinase by TAB1', 
FEBS Lett, 474: 141-5. 
Sakurai, T., S. Maeda, L. Chang, and M. Karin. 2006. 'Loss of hepatic NF-kappa B 
activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-
terminal kinase 1 activation', Proc Natl Acad Sci U S A, 103: 10544-51. 
Sakurai, T., G. He, A. Matsuzawa, G. Y. Yu, S. Maeda, G. Hardiman, and M. Karin. 
2008. 'Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release 
mediate carcinogen-induced compensatory proliferation and liver 
tumorigenesis', Cancer Cell, 14: 156-65. 
Sasaki, Y., E. Derudder, E. Hobeika, R. Pelanda, M. Reth, K. Rajewsky, and M. 
Schmidt-Supprian. 2006. 'Canonical NF-kappaB activity, dispensable for B cell 
development, replaces BAFF-receptor signals and promotes B cell proliferation 
upon activation', Immunity, 24: 729-39. 
Sato, Y., E. Goto, Y. Shibata, Y. Kubota, A. Yamagata, S. Goto-Ito, K. Kubota, J. 
Inoue, M. Takekawa, F. Tokunaga, and S. Fukai. 2015. 'Structures of CYLD 
USP with Met1- or Lys63-linked diubiquitin reveal mechanisms for dual 
specificity', Nat Struct Mol Biol, 22: 222-9. 
Sauer, B., and N. Henderson. 1988. 'Site-specific DNA recombination in mammalian 
cells by the Cre recombinase of bacteriophage P1', Proc Natl Acad Sci U S A, 
85: 5166-70. 
Schall, T. J., M. Lewis, K. J. Koller, A. Lee, G. C. Rice, G. H. Wong, T. Gatanaga, G. A. 
Granger, R. Lentz, H. Raab, and et al. 1990. 'Molecular cloning and expression 
of a receptor for human tumor necrosis factor', Cell, 61: 361-70. 
Sen, R., and D. Baltimore. 1986a. 'Inducibility of kappa immunoglobulin enhancer-
binding protein Nf-kappa B by a posttranslational mechanism', Cell, 47: 921-8. 
———. 1986b. 'Multiple nuclear factors interact with the immunoglobulin enhancer 
sequences', Cell, 46: 705-16. 
Senftleben, U., Y. Cao, G. Xiao, F. R. Greten, G. Krahn, G. Bonizzi, Y. Chen, Y. Hu, A. 
Fong, S. C. Sun, and M. Karin. 2001. 'Activation by IKKalpha of a second, 
evolutionary conserved, NF-kappa B signaling pathway', Science, 293: 1495-9. 
Shariff, M. I., I. J. Cox, A. I. Gomaa, S. A. Khan, W. Gedroyc, and S. D. Taylor-
Robinson. 2009. 'Hepatocellular carcinoma: current trends in worldwide 
epidemiology, risk factors, diagnosis and therapeutics', Expert Rev 
Gastroenterol Hepatol, 3: 353-67. 
Shu, H. B., M. Takeuchi, and D. V. Goeddel. 1996. 'The tumor necrosis factor receptor 
2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis 
factor receptor 1 signaling complex', Proc Natl Acad Sci U S A, 93: 13973-8. 
Silke, J., and E. L. Hartland. 2013. 'Masters, marionettes and modulators: intersection 
of pathogen virulence factors and mammalian death receptor signaling', Curr 
Opin Immunol, 25: 436-40. 
Stanger, B. Z., P. Leder, T. H. Lee, E. Kim, and B. Seed. 1995. 'RIP: a novel protein 
containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and 
causes cell death', Cell, 81: 513-23. 
Su, L., B. Quade, H. Wang, L. Sun, X. Wang, and J. Rizo. 2014. 'A plug release 
mechanism for membrane permeation by MLKL', Structure, 22: 1489-500. 
Sun, L., H. Wang, Z. Wang, S. He, S. Chen, D. Liao, L. Wang, J. Yan, W. Liu, X. Lei, 
and X. Wang. 2012. 'Mixed lineage kinase domain-like protein mediates 
necrosis signaling downstream of RIP3 kinase', Cell, 148: 213-27. 
Sun, X., J. Yin, M. A. Starovasnik, W. J. Fairbrother, and V. M. Dixit. 2002. 
'Identification of a novel homotypic interaction motif required for the 
phosphorylation of receptor-interacting protein (RIP) by RIP3', J Biol Chem, 
277: 9505-11. 
References 
 103 
Takahashi, N., L. Vereecke, M. J. Bertrand, L. Duprez, S. B. Berger, T. Divert, A. 
Goncalves, M. Sze, B. Gilbert, S. Kourula, V. Goossens, S. Lefebvre, C. 
Gunther, C. Becker, J. Bertin, P. J. Gough, W. Declercq, G. van Loo, and P. 
Vandenabeele. 2014. 'RIPK1 ensures intestinal homeostasis by protecting the 
epithelium against apoptosis', Nature, 513: 95-9. 
Takiuchi, T., T. Nakagawa, H. Tamiya, H. Fujita, Y. Sasaki, Y. Saeki, H. Takeda, T. 
Sawasaki, A. Buchberger, T. Kimura, and K. Iwai. 2014. 'Suppression of 
LUBAC-mediated linear ubiquitination by a specific interaction between LUBAC 
and the deubiquitinases CYLD and OTULIN', Genes Cells, 19: 254-72. 
Teoh, N., P. Pyakurel, Y. Y. Dan, K. Swisshelm, J. Hou, C. Mitchell, N. Fausto, Y. Gu, 
and G. Farrell. 2010. 'Induction of p53 renders ATM-deficient mice refractory to 
hepatocarcinogenesis', Gastroenterology, 138: 1155-65 e1-2. 
Thomas, C. 1961. '[On the morphology of diethylnitrosamine induced liver changes 
and tumors in rats]', Z Krebsforsch, 64: 224-33. 
Tiegs, G., J. Hentschel, and A. Wendel. 1992. 'A T cell-dependent experimental liver 
injury in mice inducible by concanavalin A', J Clin Invest, 90: 196-203. 
Togano, T., M. Nakashima, M. Watanabe, K. Umezawa, T. Watanabe, M. Higashihara, 
and R. Horie. 2012. 'Synergistic effect of 5-azacytidine and NF-kappaB inhibitor 
DHMEQ on apoptosis induction in myeloid leukemia cells', Oncol Res, 20: 571-
7. 
Tokunaga, F., T. Nakagawa, M. Nakahara, Y. Saeki, M. Taniguchi, S. Sakata, K. 
Tanaka, H. Nakano, and K. Iwai. 2011. 'SHARPIN is a component of the NF-
kappaB-activating linear ubiquitin chain assembly complex', Nature, 471: 633-6. 
Tokunaga, F., H. Nishimasu, R. Ishitani, E. Goto, T. Noguchi, K. Mio, K. Kamei, A. Ma, 
K. Iwai, and O. Nureki. 2012. 'Specific recognition of linear polyubiquitin by A20 
zinc finger 7 is involved in NF-kappaB regulation', EMBO J, 31: 3856-70. 
Tokunaga, F., S. Sakata, Y. Saeki, Y. Satomi, T. Kirisako, K. Kamei, T. Nakagawa, M. 
Kato, S. Murata, S. Yamaoka, M. Yamamoto, S. Akira, T. Takao, K. Tanaka, 
and K. Iwai. 2009. 'Involvement of linear polyubiquitylation of NEMO in NF-
kappaB activation', Nat Cell Biol, 11: 123-32. 
Tolba, R., T. Kraus, C. Liedtke, M. Schwarz, and R. Weiskirchen. 2015. 
'Diethylnitrosamine (DEN)-induced carcinogenic liver injury in mice', Lab Anim, 
49: 59-69. 
Treisman, R. 1996. 'Regulation of transcription by MAP kinase cascades', Curr Opin 
Cell Biol, 8: 205-15. 
Trompouki, E., E. Hatzivassiliou, T. Tsichritzis, H. Farmer, A. Ashworth, and G. 
Mosialos. 2003. 'CYLD is a deubiquitinating enzyme that negatively regulates 
NF-kappaB activation by TNFR family members', Nature, 424: 793-6. 
Uysal, K. T., S. M. Wiesbrock, M. W. Marino, and G. S. Hotamisligil. 1997. 'Protection 
from obesity-induced insulin resistance in mice lacking TNF-alpha function', 
Nature, 389: 610-4. 
Vail, M. E., R. H. Pierce, and N. Fausto. 2001. 'Bcl-2 delays and alters hepatic 
carcinogenesis induced by transforming growth factor alpha', Cancer Res, 61: 
594-601. 
van den Berghe, G. 1991. 'The role of the liver in metabolic homeostasis: implications 
for inborn errors of metabolism', J Inherit Metab Dis, 14: 407-20. 
Van Dien, M., K. Takahashi, M. M. Mu, N. Koide, T. Sugiyama, I. Mori, T. Yoshida, and 
T. Yokochi. 2001. 'Protective effect of wogonin on endotoxin-induced lethal 
shock in D-galactosamine-sensitized mice', Microbiol Immunol, 45: 751-6. 
Vanden Berghe, T., N. Vanlangenakker, E. Parthoens, W. Deckers, M. Devos, N. 
Festjens, C. J. Guerin, U. T. Brunk, W. Declercq, and P. Vandenabeele. 2010. 
'Necroptosis, necrosis and secondary necrosis converge on similar cellular 
disintegration features', Cell Death Differ, 17: 922-30. 
Van Hauwermeiren, F., M. Armaka, N. Karagianni, K. Kranidioti, R. E. Vandenbroucke, 
S. Loges, M. Van Roy, J. Staelens, L. Puimege, A. Palagani, W. V. Berghe, P. 
Victoratos, P. Carmeliet, C. Libert, and G. Kollias. 2013. 'Safe TNF-based 
References 
 104 
antitumor therapy following p55TNFR reduction in intestinal epithelium', J Clin 
Invest, 123: 2590-603. 
Varfolomeev, E., T. Goncharov, A. V. Fedorova, J. N. Dynek, K. Zobel, K. Deshayes, 
W. J. Fairbrother, and D. Vucic. 2008. 'c-IAP1 and c-IAP2 are critical mediators 
of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation', J 
Biol Chem, 283: 24295-9. 
Varfolomeev, E. E., M. Schuchmann, V. Luria, N. Chiannilkulchai, J. S. Beckmann, I. L. 
Mett, D. Rebrikov, V. M. Brodianski, O. C. Kemper, O. Kollet, T. Lapidot, D. 
Soffer, T. Sobe, K. B. Avraham, T. Goncharov, H. Holtmann, P. Lonai, and D. 
Wallach. 1998. 'Targeted disruption of the mouse Caspase 8 gene ablates cell 
death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal 
prenatally', Immunity, 9: 267-76. 
Varfolomeev, E., and D. Vucic. 2016. 'Intracellular regulation of TNF activity in health 
and disease', Cytokine. 
Verhelst, K., I. Carpentier, M. Kreike, L. Meloni, L. Verstrepen, T. Kensche, I. Dikic, 
and R. Beyaert. 2012. 'A20 inhibits LUBAC-mediated NF-kappaB activation by 
binding linear polyubiquitin chains via its zinc finger 7', EMBO J, 31: 3845-55. 
Vivarelli, M. S., D. McDonald, M. Miller, N. Cusson, M. Kelliher, and R. S. Geha. 2004. 
'RIP links TLR4 to Akt and is essential for cell survival in response to LPS 
stimulation', J Exp Med, 200: 399-404. 
Vlantis, K., A. Wullaert, A. Polykratis, V. Kondylis, M. Dannappel, R. Schwarzer, P. 
Welz, T. Corona, H. Walczak, F. Weih, U. Klein, M. Kelliher, and M. 
Pasparakis. 2016. 'NEMO Prevents RIP Kinase 1-Mediated Epithelial Cell 
Death and Chronic Intestinal Inflammation by NF-kappaB-Dependent and -
Independent Functions', Immunity, 44: 553-67. 
Wachter, T., M. Sprick, D. Hausmann, A. Kerstan, K. McPherson, G. Stassi, E. B. 
Brocker, H. Walczak, and M. Leverkus. 2004. 'cFLIPL inhibits tumor necrosis 
factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the 
death-inducing signaling complex in human keratinocytes', J Biol Chem, 279: 
52824-34. 
Wajant, H. 2003. 'Death receptors', Essays Biochem, 39: 53-71. 
Wang, C., L. Deng, M. Hong, G. R. Akkaraju, J. Inoue, and Z. J. Chen. 2001. 'TAK1 is 
a ubiquitin-dependent kinase of MKK and IKK', Nature, 412: 346-51. 
Wang, C., B. Yao, M. Xu, and X. Zheng. 2016. 'RIP1 upregulation promoted tumor 
progression by activating AKT/Bcl-2/BAX signaling and predicted poor 
postsurgical prognosis in HCC', Tumour Biol, 37: 15305-13. 
Wang, H., L. Sun, L. Su, J. Rizo, L. Liu, L. F. Wang, F. S. Wang, and X. Wang. 2014. 
'Mixed lineage kinase domain-like protein MLKL causes necrotic membrane 
disruption upon phosphorylation by RIP3', Mol Cell, 54: 133-46. 
Wang, L., F. Du, and X. Wang. 2008. 'TNF-alpha induces two distinct Caspase-8 
activation pathways', Cell, 133: 693-703. 
Wang, P., J. Zhang, A. Bellail, W. Jiang, J. Hugh, N. M. Kneteman, and C. Hao. 2007. 
'Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic 
cancer cells', Cell Signal, 19: 2237-46. 
Weber, S. N., A. Bohner, D. H. Dapito, R. F. Schwabe, and F. Lammert. 2016. 'TLR4 
Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced 
Pre-Carcinogenic Liver Injury in Fibrotic Liver', PLoS One, 11: e0158819. 
Welz, P. S., A. Wullaert, K. Vlantis, V. Kondylis, V. Fernandez-Majada, M. Ermolaeva, 
P. Kirsch, A. Sterner-Kock, G. van Loo, and M. Pasparakis. 2011. 'FADD 
prevents RIP3-mediated epithelial cell necrosis and chronic intestinal 
inflammation', Nature, 477: 330-4. 
Wertz, I. E., K. M. O'Rourke, H. Zhou, M. Eby, L. Aravind, S. Seshagiri, P. Wu, C. 
Wiesmann, R. Baker, D. L. Boone, A. Ma, E. V. Koonin, and V. M. Dixit. 2004. 
'De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-
kappaB signalling', Nature, 430: 694-9. 
References 
 105 
Wilson, N. S., V. Dixit, and A. Ashkenazi. 2009. 'Death receptor signal transducers: 
nodes of coordination in immune signaling networks', Nat Immunol, 10: 348-55. 
Woronicz, J. D., X. Gao, Z. Cao, M. Rothe, and D. V. Goeddel. 1997. 'IkappaB kinase-
beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha 
and NIK', Science, 278: 866-9. 
Wright, A., W. W. Reiley, M. Chang, W. Jin, A. J. Lee, M. Zhang, and S. C. Sun. 2007. 
'Regulation of early wave of germ cell apoptosis and spermatogenesis by 
deubiquitinating enzyme CYLD', Dev Cell, 13: 705-16. 
Wroblewski, R., M. Armaka, V. Kondylis, M. Pasparakis, H. Walczak, H.W. Mittruecker, 
C. Schramm, A.W. Lohse, G. Kollias, H. Ehlken. 2016.'Opposing role of tumor 
necrosis factor receptor 1 signaling in T-cell-mediated hepatitis and bacterial 
infection in mice', Hepatology, 10.1002/hep.28551. 
Wu, C. J., D. B. Conze, T. Li, S. M. Srinivasula, and J. D. Ashwell. 2006. 'Sensing of 
Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB 
activation [corrected]', Nat Cell Biol, 8: 398-406. 
Wullaert, A., G. van Loo, K. Heyninck, and R. Beyaert. 2007. 'Hepatic tumor necrosis 
factor signaling and nuclear factor-kappaB: effects on liver homeostasis and 
beyond', Endocr Rev, 28: 365-86. 
Xie, T., W. Peng, C. Yan, J. Wu, X. Gong, and Y. Shi. 2013. 'Structural insights into 
RIP3-mediated necroptotic signaling', Cell Rep, 5: 70-8. 
Xiong, Q., K. Hase, Y. Tezuka, T. Namba, and S. Kadota. 1999. 'Acteoside inhibits 
apoptosis in D-galactosamine and lipopolysaccharide-induced liver injury', Life 
Sci, 65: 421-30. 
Xu, M., B. Skaug, W. Zeng, and Z. J. Chen. 2009. 'A ubiquitin replacement strategy in 
human cells reveals distinct mechanisms of IKK activation by TNFalpha and IL-
1beta', Mol Cell, 36: 302-14. 
Yang, Y., F. Xia, N. Hermance, A. Mabb, S. Simonson, S. Morrissey, P. Gandhi, M. 
Munson, S. Miyamoto, and M. A. Kelliher. 2011. 'A cytosolic ATM/NEMO/RIP1 
complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated 
protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage', 
Mol Cell Biol, 31: 2774-86. 
Yu, C., S. Yan, B. Khambu, X. Chen, Z. Dong, J. Luo, G. K. Michalopoulos, S. Wu, and 
X. M. Yin. 2016. 'Gene Expression Analysis Indicates Divergent Mechanisms in 
DEN-Induced Carcinogenesis in Wild Type and Bid-Deficient Livers', PLoS 
One, 11: e0155211. 
Zhang, D., J. Lin, and J. Han. 2010. 'Receptor-interacting protein (RIP) kinase family', 
Cell Mol Immunol, 7: 243-9. 
Zhang, D. W., J. Shao, J. Lin, N. Zhang, B. J. Lu, S. C. Lin, M. Q. Dong, and J. Han. 
2009. 'RIP3, an energy metabolism regulator that switches TNF-induced cell 
death from apoptosis to necrosis', Science, 325: 332-6. 
Zhang, Y. F., W. He, C. Zhang, X. J. Liu, Y. Lu, H. Wang, Z. H. Zhang, X. Chen, and D. 
X. Xu. 2014. 'Role of receptor interacting protein (RIP)1 on apoptosis-inducing 
factor-mediated necroptosis during acetaminophen-evoked acute liver failure in 
mice', Toxicol Lett, 225: 445-53. 
Zhang, Y., S. S. Su, S. Zhao, Z. Yang, C. Q. Zhong, X. Chen, Q. Cai, Z. H. Yang, D. 
Huang, R. Wu, and J. Han. 2017. 'RIP1 autophosphorylation is promoted by 
mitochondrial ROS and is essential for RIP3 recruitment into necrosome', Nat 
Commun, 8: 14329. 
Zhao, J., S. Jitkaew, Z. Cai, S. Choksi, Q. Li, J. Luo, and Z. G. Liu. 2012. 'Mixed 
lineage kinase domain-like is a key receptor interacting protein 3 downstream 
component of TNF-induced necrosis', Proc Natl Acad Sci U S A, 109: 5322-7. 
Zheng, L., G. Fisher, R. E. Miller, J. Peschon, D. H. Lynch, and M. J. Lenardo. 1995. 
'Induction of apoptosis in mature T cells by tumour necrosis factor', Nature, 
377: 348-51. 
Zhou, W., and J. Yuan. 2014. 'Necroptosis in health and diseases', Semin Cell Dev 
Biol, 35: 14-23. 
References 
 106 
Zilberman-Rudenko, J., L. M. Shawver, A. W. Wessel, Y. Luo, M. Pelletier, W. L. Tsai, 
Y. Lee, S. Vonortas, L. Cheng, J. D. Ashwell, J. S. Orange, R. M. Siegel, and E. 
P. Hanson. 2016. 'Recruitment of A20 by the C-terminal domain of NEMO 
suppresses NF-kappaB activation and autoinflammatory disease', Proc Natl 
Acad Sci U S A, 113: 1612-7. 
Acknowledgement 
 107 
6. Acknowledgement 
 
Prof. Dr. Manolis Pasparakis: Thank you for giving me the opportunity to do my Master 
thesis and my PhD work in your lab and for trusting me with this very interesting 
project. I am very thankful for your endless support, your constant scientific guidance 
and the sustained interest in the progress of this work during all these years.  
 
Apostolis Polykratis and Vangelis Kondylis: Thank you for your constant support, for 
guiding me and helping me throughout these years. Thank you for listening to all the 
problems that I encountered during my PhD and thank you for your contribution and 
exceptional commitment during the preparation and revision of our publication. 
 
“The Girls”: I am very thankful for all your help during the last few years. Thank you for 
the countless genotypings and sections. But especially thank you for all the fun and 
long discussions in the histolab that helped me to stay positive during all these years.  
 
Martin Hafner, Johannes Winkler and Silke Röpke: A special thanks to you for helping 
me with the animal licenses, administrative, bureaucratic and many other issues.  
 
Katerina Vlantis: Thank you for believing in me since my very first internship in this lab. 
Thank you for supporting me throughout all these years. 
 
Pasparakis lab: My grateful thanks to all former and current Lab-members for all the 
help, the expertise and the fun in- and outside the Lab. It was awesome working with 
any of you! I am sorry that I had to annoy some of you a little bit more by asking the 
same question throughout these years. But now I know which antibody dilutions I 
should use for my future WBs.:) 
 
CGA members and thesis committee members: Thank you for supporting me all these 
years. A special thanks to Prof. Dr. Schumacher and Prof. Dr. Reinhardt for the 
scientific discussions that helped during the finalization of this work. 
 
To all the collaborators: Thank you for contributing to this work with special thanks to 
Dr. Beate Straub for putting so much effort to this project. 
 
Meine Familie und Freunde: Einen riesengrossen Dank an euch alle für eure 
kompromisslose Unterstützung. Danke, dass ihr mir immer das Gefühl gegeben habt 
das alles zu schaffen. Ohne Euren Rückhalt und die zahlreichen Ablenkungen wäre 
ich jetzt nicht mit so guter Laune an meiner Arbeit dran. 
 
Last but not least, Robin Schwarzer: DANKE!!! Das kann ich gar nicht oft genug sagen. 
Danke für deine grenzenlose Unterstützung und besonders für dein Vertrauen in mich. 
Danke, dass du mich immer zum Lachen bringen konntest egal wie schlimm der WB 
aussah. Danke, dass du mich immer weiter motiviert hast. Ohne dich und deine 
Unterstützung wär das alles nicht möglich gewesen. Danke, dass ich mich immer 
vollkommen auf dich verlassen konnte. Danke! 
 
 
Erklärung zur Dissertation 
 108 
7. Erklärung zur Dissertation 
Ich versichere, dass ich die von mir vorgelegte Dissertation selbstständig angefertigt, 
die benutzten Quellen und Hilfsmittel vollständig angegeben und die Stellen der Arbeit- 
einschließlich Tabellen, Karten und Abbildungen-, die anderen Werken im Wortlaut 
oder dem Sinn nach entnommen sind, in jedem Einzelfall als Entlehnung kenntlich 
gemacht habe; dass diese Dissertation noch keiner anderen Fakultät oder Universität 
zur Prüfung vorgelegen hat; dass sie-abgesehen von unten angegebenen 
Teilpublikationen- noch nicht veröffentlich worden ist sowie, dass ich eine solche 
Veröffentlichung vor Abschluss des Promotionsverfahrens nicht vornehmen werde. 
Die Bestimmungen dieser Promotionsordnung sind mir bekannt. Die von mir 
vorgelegte Dissertation ist von Prof. Dr. Manolis Pasparakis betreut worden. 
23. Juni 2017       Trieu My Van 
   
Teilpublikation  
Teile dieser Doktorarbeit wurden in folgender Publikation veröffentlicht: 
 
Van TM, Polykratis A, Straub BK, Kondylis V, Papadopoulou N, Pasparakis M, Kinase-
independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis. 
J Clin Invest. 2017 Jun 19. pii: 92508. doi: 10.1172/JCI92508.
  109 
  
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1jci.org
Introduction
Liver injury in response to immune deregulation and/or infection 
can result in acute liver failure or chronic liver disease. Chronic 
hepatocyte death coupled with compensatory hepatocyte prolifer-
ation greatly increases the risk of tumorigenesis. Indeed, hepato-
cellular carcinoma (HCC), the most frequent primary liver cancer, 
usually develops in the context of chronic liver injury and inflam-
mation caused by hepatitis B virus (HBV) or HCV infections, alco-
holic and nonalcoholic steatohepatitis, and aflatoxin-mediated 
toxicity (1). HCC is one of the most frequent and difficult to treat 
types of cancer, constituting the third most common cause of 
cancer-related death worldwide (1, 2).
Death receptors activate distinct signaling pathways con-
trolling inflammation and cell death and are implicated in liver 
disease and cancer (3, 4). Receptor-interacting protein kinase 1 
(RIPK1) is a key regulator of TNF receptor 1 (TNFR1) signaling 
(5). The kinase activity of RIPK1 triggers cell death by activating 
either caspase-8–mediated apoptosis or RIPK3-MLKL–depen-
dent (where MLKL indicates mixed lineage kinase domain-like 
protein) necroptosis. In addition, RIPK1 induces prosurvival and 
proinflammatory responses via kinase-independent scaffolding 
functions (5). RIPK1 is recruited to the TNFR1 signaling complex 
together with TNFR1-associated death domain protein (TRADD), 
the E3 ubiquitin ligases TNF receptor–associated factor 2 (TRAF2) 
and cellular inhibitors of apoptosis 1 (cIAP1) and cIAP2, and the 
linear ubiquitin chain assembly complex (LUBAC) (6, 7). RIPK1 
contributes to the activation of NF-țB, but this function seems 
to be dependent on the cell types and experimental conditions 
studied (8–11). NF-țB signaling regulates immune and inflamma-
tory responses and cell survival (12, 13) and is implicated in the 
pathogenesis of hepatitis and HCC (14, 15). Mice with liver paren-
chymal cell–specific (LPC-specific) ablation of NF-țB essential 
modulator (NEMO)/IțB kinase Ȗ (IKKȖ), the regulatory subunit of 
the IKK complex that is required for canonical NF-țB activation, 
developed spontaneously chronic hepatitis and HCC due to RIPK1 
kinase activity–driven, FAS-associated death domain (FADD)/
caspase-8–mediated hepatocyte apoptosis (16–19). In contrast, 
LPC-specific NF-țB deficiency did not cause spontaneous devel-
opment of severe chronic liver disease and cancer, suggesting 
that NEMO regulates liver homeostasis by NF-țB–dependent and 
–independent functions (16).
Mice lacking RIPK1 specifically in LPCs (Ripk1fl/fl Alfp-Cre 
mice, hereafter referred to as RIPK1LPC-KO mice) did not develop 
spontaneous liver disease, showing that RIPK1 is not required for 
normal liver homeostasis under steady-state conditions (16, 20–
24). However, RIPK1LPC-KO mice were highly sensitive to concana-
valin A–mediated (ConA-mediated) liver damage, which was part-
ly induced by TNF-mediated hepatocyte apoptosis (24). Moreover, 
administration of LPS caused severe liver injury in RIPK1LPC-KO 
mice by inducing TNF-dependent hepatocyte apoptosis (20, 21). 
Interestingly, although LPC-specific deficiency of either RIPK1 
The mechanisms that regulate cell death and inflammation play an important role in liver disease and cancer. Receptor-
interacting protein kinase 1 (RIPK1) induces apoptosis and necroptosis via kinase-dependent mechanisms and exhibits 
kinase-independent prosurvival and proinflammatory functions. Here, we have used genetic mouse models to study the role 
of RIPK1 in liver homeostasis, injury, and cancer. While ablating either RIPK1 or RelA in liver parenchymal cells (LPCs) did not 
cause spontaneous liver pathology, mice with combined deficiency of RIPK1 and RelA in LPCs showed increased hepatocyte 
apoptosis and developed spontaneous chronic liver disease and cancer that were independent of TNF receptor 1 (TNFR1) 
signaling. In contrast, mice with LPC-specific knockout of Ripk1 showed reduced diethylnitrosamine-induced (DEN-induced) 
liver tumorigenesis that correlated with increased DEN-induced hepatocyte apoptosis. Lack of RIPK1 kinase activity did not 
inhibit DEN-induced liver tumor formation, showing that kinase-independent functions of RIPK1 promote DEN-induced 
hepatocarcinogenesis. Moreover, mice lacking both RIPK1 and TNFR1 in LPCs displayed normal tumor formation in response 
to DEN, demonstrating that RIPK1 deficiency decreases DEN-induced liver tumor formation in a TNFR1-dependent manner. 
Therefore, these findings indicate that RIPK1 cooperates with NF-țB signaling to prevent TNFR1-independent hepatocyte 
apoptosis and the development of chronic liver disease and cancer, but acts downstream of TNFR1 signaling to promote DEN-
induced liver tumorigenesis.
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Academic Fellowship 
 
2013-2016 Full Ph.D. scholarship of the ‘Cologne Graduate School of 
Ageing Research’ (12 out of 400 applicants) 
 
Scientific Conferences 
 
Oral Presentations - CECAD’s 5th annual PhD/Post Doc Retreat, January 2016, 
Trier, Germany 
- CECAD’s 4th annual PhD/Post Doc Retreat, March 2015, 
Maastricht, Netherlands 
 
Poster presentation  - Keystone Symposia, Cell Death and Inflammation, April 
2017, Dublin, Ireland 
- Cell Death, Inflammation and Immunity, May 2016, Crete, 
Greece 
- Cell Symposia: Cell death and immunity, November 2015, 
Berkeley, USA 
 
Certified Courses and Soft Skill Courses 
 
Science-related training 
2016 - Short course on “Managing R&D Projects” 
- Short Course on “Entrepreneurial Introductory Translational  
 Research (EITR) 
2014    - Microbiology and Forensic Science, Open2Study 
- Biostatistics, Brain4hire, Cologne 
2013 - Felasa B course, Cologne 
 
Soft skill training 
2015    - Negotiation and Conflict Resolution, Open2study 
   - Figure making, Brain4hire, Cologne 
    - Scientific writing, Dr. Ruth Willmott, Cologne 
- Principles of Project Management, Open2study 
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2014    - Carrier development training I-III, Dr. Ruth Willmott, Cologne  
    - Scientific presentation, Dr. Ruth Willmott, Cologne  
    - Poster presentation, Dr. Ruth Willmott, Vienna   
  - PowerPoint presentation, Dr. Ruth Willmott, Cologne 
 
Standard Methods and specialized techniques 
 
Microbiological methods - Competent cell preparation and transformation  
 
DNA-specific   - DNA Isolation from cells and tissues 
    - PCR 
    - DNA cloning techniques  
   
RNA-specific   - RNA isolation from cells and tissues 
    - qRT-PCR 
 
Protein-specific  - Protein isolation from cells and tissues 
    - Western Blot 
 
Cell/tissue-specific  - Isolation and culturing of primary hepatocytes  
    - Isolation and culturing of keratinocytes  
    - Isolation and differentiation of BMDMs 
    - Isolation and culturing of primary MEFs 
    - Cell cytotoxity tests (Neutral red, WST, LDH, PI staining) 
- Histopathological analysis (cutting and various stainings of 
liver, skin, lung and gut) 
 
In vivo-specific  - DEN-induced carcinogenesis 
    - Glucose and Insulin-Tolerance test 
    - Cheek Bleeding 
    - Organ preparation (liver, skin, gut) 
 
Microscopy   - confocal microscopy 
 
Work-related Responsibilities 
     
Supervision  Medical Student between March- May 2016 
Master Student between March- May 2016 
Medical Student between June - August 2014 
Bachelor Student between May- September 2013 
 
Teaching  Master practical course titled ‘Mouse genetics’, 20 Students for 
one week, July 2015 and 2016                    
 
Professional Membership 
 
Since October 2015   First of board of Management of btS Cologne e.V. 
Since March 2014  Biotechnological student initiative (btS) Cologne e.V. 
       
Organizing Skills 
 
March- November 2015 -‘Cologne graduate school of ageing research' Symposium,  
fund raiser  
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March 2015- present - Lecture Series for multiple biotech presentations in 
collaboration with btS Cologne 
 
Languages 
 
German     native speaker, bilingual 
Vietnamese     native speaker, bilingual 
English     fluent, written and oral 
Latin      basic (‘Großes Latinum’) 
 
 
Computer Skills 
 
Operating systems  Windows XP/7, MAC OS 
Software    MS office, Endnote, 
Data analysis   Prism, Fiji 
 
 
 
  
Trieu My Van       Cologne, June 2017 
 
 
 
 
 
 
 
 
 
